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Abstract 
 
Inclusion of synthetic poly-(ethylene glycol) (PEG)-grafted phospholipids into self-assembled 
phospholipid matrices is an exceptional method to engineering optimized bio-non-fouling 
membrane mimetic surfaces. The success of many PEGylated membranes applications, however, 
depends on the ability to develop a bio-mimetic surface with highly optimized and controllable 
properties. This study, hence, focused on assessing different aspects of PEGylated 
phosphocholine membrane models, DPPC/DPPE-PEG2000 (C16/C16) and DSPC/DSPE-
PEG2000 (C18/C18). The membrane models include unilamellar vesicles and monolayers. 
Monolayer as a membrane model was used to examine the phase behavior, morphology, 
composition, and aliphatic chain length in aqueous media of physiological relevance (PBS). The 
effect of lateral PEG distribution and its conformations on the phase behavior of monolayers was 
also studied. The results obtained for both binary mixtures have been summarized in terms of 
phase diagrams. The effect of non-specific interactions of insulin on the stability and biophysical 
properties of monolayers for both binary mixtures was studied using monolayer area expansion 
approach. The data obtained has been analyzed to calculate the insulin penetration area, Ains, and 
binding degree, χins. Unilamellar vesicles were used as a membrane model to examine the 
morphology and phase behavior of binary mixtures. A comparative analysis has been performed 
to understand the correlation between PEGylated phosphocholine vesicle membranes and 
monolayers. Moreover, the changes in insulin conformation upon interactions with unilamellar 
vesicles with varying PEG content have also been examined. These findings thus imply that the 
phase behavior of PEGylated phosphocholine membranes may significantly change in response 
to slight changes in composition which can be used for rational design of PEGylated membranes 
for various biomedical applications. 
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Chapter 1: Introduction. 
 
Phospholipid membrane-mimetic surfaces have gained tremendous interest over 
the past few decades for use as exclusion filters for microfluidic devices, biosensors, 
carriers for RNA in the form of lipoplexes, nanosensor templates as well as vesicles, 
nanoparticles and microbubbles for the delivery of therapeutics and diagnostic agents 
[Chen 2013; Chordeiro 2015; Immordino 2006; Karatekin 2012; Liu 2014; Lozano 
2009a; Lozano 2009b; Peterca 2011; Popovska 2013; Reulen 2009; Seth 2013; Shi 2010; 
Silpe 2013; Suga 2013; Sung 2011; Wisniewski 2000; Zhai 2014]. Phospholipid 
membrane-mimetic surfaces are proven to be physiologically compatible and biologically 
inert with low intrinsic toxicity [Immordino 2006; Karatekin 2012; Mfuh 2011; Savva 
1998;Wade 2001]. However, a major hurdle these surfaces encounter in vivo is the 
undesirable recognition and resistance from various serum components including 
reticuloendothelial cells, macrophages, serum proteins, and platelets. The former 
description is referred as a biofouling phenomenon [Immordino 2006; Liu 2014; Savva 
1998; Vermette 2003; Wisniewski 2000]. Biofouling has the potential to significantly 
impair and reduce the in vivo efficiency of the biomedical devices coated with 
membrane-mimetic surfaces [Chordeiro 2015; Savva 1998; Vermette 2003; Wisniewski 
2000; Yen 2010]. Several innovative approaches are being explored to enhance the 
efficiency of biomedical devices by suppressing the non-specific interactions of 
biomolecules and bypassing the mononuclear phagocyte system (MPS). This also 
includes the incorporation of grafted PEG chains in the host phospholipid matrix to 
   
2 
 
engineer bio-non-fouling membrane-mimetic surfaces [Chen 2010; Chen 2013; Gref 
2000; Immordino 2006; Karatekin 2012; Liu 2014; Vermette 2003].  
 
1.1. PEGylation of Membrane-Mimetic Surfaces. 
 
Incorporation of a poly (ethylene glycol) (PEG) graft has been considered to be a 
milestone in the field of novel biomedical applications [Allen 1997; Luna 2011; 
Popovska 2013; Takemoto 2011; Vermette 2003; Vukovic 2011; Wattendorf 2008]. 
Figure 1.1 illustrates the chemical structure of PEG monomer with repeating units of 
ethylene oxide units (EO) connected via oxygen atoms. Inclusion of PEG in numerous 
biomedical formulations has shown a tremendous success in applied research to develop 
bio-non-fouling surfaces with controlled properties [Allen 1997; Luna 2011; Popovska 
2013; Takemoto 2011; Vukovic 2011; Wattendorf 2008]. PEGylated drug carriers such 
as Doxil, Lipodox and etc. have been widely used as a favorable choice for the delivery 
of various therapeutic agents [Bozzuto 2015; Vukovic 2011]. Highly hydrated PEG 
chains are commonly used in numerous biomedical applications due to their distinctive 
properties including chemical inertness, lack of toxicity, low antigenicity, 
biocompatibility, and good solubility [Antonietti 2003; Bianco-Peled 2001; Luna 2011; 
Naumann 2001; Savva 1998; Shahid 2011; Vukovic 2011; Wattendorf 2008]. PEG chains 
are believed to repel protein adhesion and improve the efficiency/performance of these 
membrane-mimetic surfaces. Two mechanisms are usually associated with PEG chains 
protecting the surface against protein or other biomolecule adhesion. These are (i) steric 
repulsion and/or (ii) formation of a hydration shell (solvent-mediated structuring) [Gref 
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2012; Immordino 2006; Kenworthy 1995; Keratekin 2012; Liu 2014; Luna 2011; 
Hristova 1995; Stepniewski 2011; Vermette 2003; Wattendorf 2008]. PEG steric 
repulsion is believed to occur when a protein or other biomolecule makes contact with the 
polymer layer and the PEG chains resist this compression by increasing their local 
concentration as well as the free energy [Taylor 2012; Vermette 2003]. Formation of 
hydration shell refers to the structuring of water molecules around PEG chain through 
hydrogen bonding [Buzzuto 2015; Naumann 1999; Vermette 2003; Wattendorf 2008]. It 
is believed that each EO (ether oxygen) unit in the PEG chain is bound to two or three 
water molecules [Buzzuto 2015; Naumann 1999]. This creates a hydration shell around 
PEG chains in a gauche conformation as can be seen in Figure 1.2 [Buzzuto 2015; Castro 
2014; Gref 2012; Savva 1998; Vermette 2003; Wattendorf 2008]. This gauche 
conformation (as opposed to a trans conformation) further aids in resistance against 
proteins and other serum components and subsequently provide escape from the MPS 
[Buzzuto 2015; Castro 2014; Gref 2012; Savva 1998; Vermette 2003; Wattendorf 2008]. 
Recently, polymer chain flexibility along with hydrophilicity has been proposed as 
another major contributing factor to protect the surfaces against biomolecules adsorption 
[Gref 2012; Wattendorf 2008]. Reports suggested that polymers (e.g. maltopentaose and 
dextran) more hydrophilic in nature than PEG molecules had a shorter circulation time 
and were not sufficient enough to protect the surfaces against opsonization [Blume 1993; 
Gref 2012]. It is believed that the flexible, mobile, and rapidly changing conformations of 
PEG chains form a dense “conformational cloud” making it challenging for the immune 
system to generate an antibody for it [Gref 2012; Torchilin 1995]. Hence, PEG possesses 
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both features, hydrophilicity and flexibility, to make it an excellent candidate for 
protecting surfaces against non-specific protein binding [Gref 2012].  
 
Surfaces modifications with PEG are applied in several ways including (i) 
covalent grafting, (ii) physical adsorption and (iii) incorporation of PEG-phospholipid 
conjugates [Damodaran 2010; Das Santos 2007; Immordino 2006; Moghimi 2001; Pallua 
2011; Wattendorf 2008]. The latter method will be used in our study due to its promising 
results in suppressing the protein adsorption onto membrane-mimetic surfaces [Baekmark 
1995; Immordino 2006; Stepniewski 2011; Takemoto 2011]. Most importantly, the non-
fouling property of PEG molecules essentially relies on the surface chain density and the 
molecular weight (MW) or chain length being incorporated in the membranes [Castro 
2014; Damodaran 2010; Efremova 2001; Gref 2000; Hristova 1995; Karatekin 2012; Liu 
2014; Luna 2011; Taylor 2012; Vermette 2003; Wattendorf 2008]. Hence, a development 
of dense and thick layers of PEG chains with appropriate molecular weight is of great 
potential interest in the biomedical field to efficiently protect the membrane-mimetic 
surfaces against dissolved biomolecules adsorption. 
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Figure 1.1. Illustration of poly(ethylene glycol) PEG monomer chemical structure with 
“n” representing the repeating unit.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Chemical drawing demonstrating the gauche conformation of poly(ethylene 
glycol) PEG and its hydrogen bonding with water molecule. Structure is drawn based on 
Bjorling 1991, Naumann 1999 and Wattendorf et al. 2008. 
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1.2. Types of PEG Chain Length Grafted onto Membrane-Mimetic Surfaces.  
 
There is a wide range of PEG molecules available commercially in terms of 
molecular weight or chain length to be incorporated into membrane-mimetic surfaces. 
However, the success of these PEGylated membranes is highly dependent on the type of 
application and type of PEG chain being employed [Efremova 2001; Gref 2000; Hristova 
1995; Liu 2014; Luna 2011; Vermette 2003; Wattendorf 2008; Xu 2000]. For example, 
PEGylation of membrane-mimetic surfaces with low molecular weight PEG (less than 
1000 Da) have been reported to reduce the biomolecule interaction only at a very high 
PEG surface density (in a range of 20 – 50 mol%) [Needham 2000; Pappalardo 2005]. 
PEG molecules with short chain length tend to form mushroom conformations, which is 
not always effective against dissolved biomolecules adsorption [Hasan 2015; Luna 2011]. 
Intermediate PEG chain length ranging from 1000 – 5000 Da is more frequently used in 
order to achieve optimum dissolved biomolecule repellence [Gref 2000; Hasan 2015; 
Hashizaki 2003; Hristova 1995; Liu 2014; Moghimi 2001; Morille 2008; Vermette 2003; 
Wattendorf 2008]. This range has also been identified as suitable for its use as a 
copolymer to suppress opsonization and subsequently low phagocytic uptake [Gref 2000; 
Moghimi 2001; Wattendorf 2008]. Long PEG chain lengths over 5000 Da have been used 
in membrane models but these studies do not show further reduction in protein adsorption 
as that from intermediate PEG chain length [Gref 2000; Vermette 2003]. Furthermore, it 
has also been suggested that incorporation of long PEG chain length results in a phase 
separation in membrane models [Bedu-Addo 1996; Pappalardo 2005], which might be a 
disadvantage for biomedical applications including nanosensor templates, microfluidic 
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devices and therapeutic/diagnostic agents carriers. Overall, a PEG chain length of 2000 
Da has shown tremendous success for optimum repellency against non-specific protein 
interactions and avoidance from mononuclear phagocytic system (MPS) and hence, has 
been used in our studies [Gref 2000; Liu 2014; Luna 2011; Moghimi 2001]. 
 
1.3. PEG Grafting Density on the Membrane-Mimetic Surfaces. 
 
 PEG surface grafting density refers to the amount of PEG-phospholipid 
conjugates being incorporated in the membrane-mimetic surfaces with the optimum bio-
non-fouling properties. Numerous reports have associated the performance of PEGylated 
membrane models with the optimum grafting density of PEG-phospholipid conjugates 
[Bedu-Addo 1996; Belsito 2000; Edwards 1997; Gref 2000; Lasic 1991; Montesano 
2001; Pappalardo 2005; Szleifer 1998; Taylor 2012]. Based on several reported data, 
liposomes and vesicles usually have a PEG grafting density between 4 – 10 mol% with 
MW of 2000 – 5000 g/mol for optimum performance [Baekmark 1995; Bedu-Addo 1996; 
Dos Santos 2007; Gref 2000; Hashizaki 2003; Lasic 1991; Lasic 1995; Liu 2014; 
Papplardo 2005]. Liposomes are known to become unstable with higher PEG grafting 
density due to increased lateral pressure among PEG chains [Lasic 1995]. Bilayers can 
normally incorporate up to 10 mol% of PEG, with MW of 2000 g/mol, without 
compromising the structural stability [Barenholz 2001; Belsito 2000; Hristova 1995; 
Ickenstein 2003; Stepniewski 2011]. Based on these studies, it can be surmised that 
grafting density along with the polymeric chain length (Molecular weight) are critical for 
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selecting the mixture composition in order to develop PEGylated membrane-mimetic 
surfaces with highly controllable properties.  
 
 As discussed above, it is really important to select an appropriate mixture 
composition in terms of PEG grafting density to optimize the performance of PEGylated 
membrane-mimetic surfaces. Many reports have suggested the optimal PEG grafting 
density in the phospholipid mixtures to be somewhere in the range of 1 – 9 mol% [Allen 
2002; Barenholz 2001; Bedu-Addo 1996; Belsito 2000; Dos Santos 2007; Lasic 1991; 
Lasic 1995; Luna 2011; Stepniewski 2011; Vermette 2003]. However, the specific PEG 
content in terms of mol% PEG has not been identified yet. Previous studies suggest that 
optimum performance of PEGylated membrane-mimetic surface can be achieved with a 
minimum PEG concentration of 2 mol% to a maximum concentration of 20 mol% [Lasic 
1995; Luna 2011; Dos Santos 2007]. Hence, this study was also motivated to determine 
the most efficient PEG content in terms of mol% that can be incorporated in the 
membrane for optimum performance, an aspect which has not gained much attention yet, 
to the best of our knowledge.   
 
In addition, the type of PEG chain and its grafting density may not be the only 
factors contributing towards the effectiveness of membrane-mimetic surfaces. Analysis of 
the data available in the literature suggests that lateral distribution of PEG can also 
influence the efficiency of PEGylated membrane-mimetic surfaces. In this study, we have 
attempted, for the first time, to assess the effect of PEG lateral distribution on the bio-
non-fouling properties of membrane-mimetic surfaces. Detailed analyses of lateral 
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distribution of PEG as well as its effect on the membrane-mimetic surfaces can also help 
elucidating the mechanistic nature of proteins and membrane-mimetic surfaces 
interactions.  
 
1.4. Non-Specific Interactions of Proteins with Membrane-Mimetic Surfaces. 
 
 Membrane-mimetic surfaces in vivo are prone to non-specific interactions with 
numerous types of dissolved molecules (e.g. proteins), which subsequently leads to 
disintegration, reduced efficiency, and rapid clearance by MPS [Allen 1991; Dhruv 2009; 
Kim 1999; Moghimi 2001; Popovska 2013; Savva 1998; Vermette 2003]. Non-specific 
interaction refers to a non-covalent interaction between membrane-mimetic surfaces and 
proteins. Non-specific interactions of proteins usually occur as accumulation, penetration 
and/or adsorption mechanism onto the surfaces [Dhruv 2009; Moghimi 2001; Popovska 
2013; Shahid 2013]. Various types of protein/membrane interactions can be associated to 
non-specific interactions. Among these electrostatic interactions, hydrophobic 
interactions, and hydrogen bonding are considered as the key players for non-specific 
interactions between protein and membrane-mimetic surfaces [Dhruv 2009; Grudzielanek 
2007; Moghimi 2001; Vermette 2003]. Types of non-specific interactions are in fact 
based on two important factors: (i) physicochemical properties of membrane and (ii) 
physicochemical properties of protein that binds to it [Immordino 2006]. Physiochemical 
characteristics of membrane-mimetic surfaces include phase state, hydrophobicity, net 
surface charge, morphology, headgroup size, acyl chain length, packing and fluidity of 
the membrane [Immordino 2006; Moghimi 2001; Shahid 2013; Vermette 2003]. On the 
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other hand, physiochemical properties of dissolved biomolecules include size, net charge, 
hydrophobicity/hydrophilicity, and flexibility of structural domains [Dhruv 2009; 
Immordino 2006; Moghimi 2001; Torchilin 1995; Vermette 2003]. It is of great interest 
to understand the mechanistic nature of non-specific protein/membrane interactions for 
the rational design of bio-non-fouling membrane-mimetic surfaces with controlled and 
predictable characteristics.  
 
 
 
1.5. Effect of Phase State on the Interactions of Dissolved Biomolecules and 
Membrane-Mimetic Surfaces. 
 
  
 Phase state, among other factors, plays a key role in the localization of dissolved 
biomolecules onto the membrane-mimetic surfaces. For instance, some proteins have a 
greater tendency towards the liquid disordered (Ld) phase than the gel phase (Lβ’) of the 
membrane. In monolayer models, Ld and Lβ’ phases are referred to as liquid expanded 
(LE) and liquid condensed (LC) phase, respectively. A few proteins have been reported to 
partition into the liquid condensed phase of the membrane models. Hence, investigating 
the nature of these preferential interactions can yield significant insights to reduce non-
specific protein binding onto membrane-mimetic surfaces.  
 
1.6. Phase Behavior of PEGylated Membrane-Mimetic Surfaces. 
 
 Incorporation of PEG-phospholipid may have a great impact on the phase 
behavior of membrane-mimetic surfaces. Several studies have reported the coexistence of 
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LC and LE phase in PEGylated phospholipid membranes [Hashizaki 2003; Lozano 
2009a; Shahid 2011]. A few studies have suggested that high concentrations of PEG may 
induce the LE phase, phase separation or formation of open bilayer discs phase in a 
typical condensed type membrane model [Baekmark 19995; Ickenstein 2003; Kneidl 
2014], which can subsequently lead to increased dissolved biomolecule interactions with 
the membrane. Hence, understanding the effect of PEG-phospholipid on the membrane 
phase behavior could allow for better tuning the PEGylated membrane-mimetic surfaces 
for numerous biomedical applications. 
  
1.7. Role of Proteins’ Physicochemical Properties on the Non-Specific Interactions 
with PEGylated Membrane-Mimetic Surfaces. 
 
 As described above, physicochemical properties of dissolved biomolecules, for 
example hydrophobicity, size, shape, charge, and flexibility of structural domains, are 
considered key parameters in the non-specific interactions with PEGylated membrane-
mimetic surfaces [Dhruv 2009; Immordino 2006; Moghimi 2001; Torchilin 1995; 
Vermette 2003]. When it comes to non-specific interactions, hydrophobic interactions 
play a prominent role in the protein/ PEGylated membrane interactions [Mollmann 2006; 
Sezgin 2012; Vermette 2003; Yang 2011]. It is believed that hydrophobic residues of 
proteins insert into the hydrophobic aliphatic chains of phospholipid molecules in order 
to minimize their unfavorable energetic exposure to the aqueous environment [Birdi 
1976; Mollmann 2006; Sezgin 2012; Vermette 2003]. It has also been suggested that 
lipids in the membrane adapt to match various lengths of peptide domains in order to ease 
the access with the phenomenon described as hydrophobic matching [Sezgin 2012]. 
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Hence, it can be deduced that non-specific interactions of proteins with PEG-grafted 
membrane-mimetic surfaces can be primarily driven by hydrophobic interactions.  
 
 The net charge of a protein can also be of great importance in the non-specific 
interactions with PEGylated membrane-mimetic surfaces. Several studies have suggested 
that proteins with an overall positive charge at the physiological pH may be more 
attracted to PEG surfaces bearing a negative charge [Vermette 2003]. On the other hand, 
the negative charge on the proteins may introduce a negative electrostatic barrier between 
the protein and PEG-grafted surfaces [Farias 1989; Vermette 2003]. However, it should 
also be noted that proteins with an overall negative charge may expose their positively 
charged amino acid residues at a certain conformation, which might result in attractive 
electrostatic interactions with the PEG-grated membrane-mimetic surfaces as opposed to 
repulsive interactions. [Nylander 1994; Vermette 2003]. Previous studies have suggested 
that PEG chains in the membrane-mimetic surfaces might attract some dissolved 
biomolecules rather than repel them [Efremova 2001; Taylor 2012; Xu 2000]. Moreover, 
PEG chains on the membrane models have shown significant steric repulsion towards 
large proteins such as human serum albumin (HSA) [Lee 2016; Rahamati 2008; Vermette 
2003]. However, PEG chains might not experience the compression and do not efficiently 
reduce the penetration of small proteins. Therefore, understanding the intricate 
interactions of PEG-grafted membranes with small proteins is crucial to designing 
controlled membrane-mimetic surfaces for various biomedical applications.  
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1.8. Objectives. 
 
 The objectives of this study include: 
• to investigate the phase behavior of different types of PEG-grafted phosphocholine 
membrane under physiological conditions 
• to study the effect of aliphatic chain length and PEG content on the phase behavior of 
PEGylated phosphocholine membrane models 
• to elucidate the effect of non-specific interactions of small protein, insulin, on the 
phase behavior of PEGylated membrane models 
• to investigate the effect of insulin/membrane interactions on the conformational 
changes and folding/unfolding states of insulin 
• and, most importantly, to determine the optimal mixture composition, in terms of 
aliphatic chain length and PEG content, that can stabilize the LC/gel phase in the 
membrane, enhance the homogeneous distribution of PEG chains as well as reduce the 
non-specific adsorption of small proteins e.g. insulin on the membrane models.  
The outcome of this study can be used to further fill the gap to improve the efficiency of 
bio-non-fouling membrane-mimetic surfaces in many biomedical applications including 
nanosensors templates, microbubbles, nanoscale size exclusion filters for microfluidic 
devices as well as therapeutic carriers. 
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1.8.1. The Membrane Models for Membrane-Mimetic Surfaces. 
 
 Monolayers and unilamellar vesicles have been selected as models for PEG-
grafted membrane-mimetic surfaces. Both types of models offer distinct information and 
are prepared by incorporating PEG-phospholipid conjugates in the host matrix 
phospholipids, as will be elaborated below in detail. 
 
1.8.1.1. Langmuir Monolayer as a Membrane Model. 
 
 Langmuir phospholipid monolayers have been extensively used as two 
dimensional controlled experimental models for biological membranes as well as 
precursors of membrane-mimetic surfaces [Collier 2001; Li 2014; Lozano 2009a; Luna 
2011; Stefaniu 2014a; Stefaniu 2014b; Stepniewski 2011; Ziblat 2011]. A Langmuir 
monolayer represents half of a biological membrane (c.f. Figure 1.3 A and B). 
Monolayers are usually constructed on a Langmuir trough by spreading amphiphilic 
molecules onto the aqueous phase (Figure 1.3). The Langmuir trough is made of Teflon 
with two moveable Teflon coated barriers that are used to control the area available to 
amphiphilic molecules Figure 1.3 C [Gaines 1966]. Upon spreading, the hydrophobic 
aliphatic chains of phospholipids orient towards the air whereas the hydrophilic region 
submerge in the aqueous phase [Gaines 1966; Dhruv 2009; Li 2014]. At this point, 
molecules are disordered, which means that they are spread over a large area and do not 
experience much interactions from each other [Shahid 2013; Dhruv 2009]. When the 
barriers begin to compress, amphiphilic molecules come in contact with each other and 
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form a tightly packed monolayer. This facilitates investigating different aspects including 
packing and phase state of a monolayer at the air/aqueous interface [Dhruv 2009; Li 
2014]. This system can be represented using a surface pressure plot with respect to 
molecular area available to each molecule. This plot is known as the surface pressure – 
area, π – A, isotherm [Dhruv 2009; Gaines 1966] and will be described in more detail 
below. The technical specifications of Langmuir trough as well as equations used to 
calculate area per phospholipid molecule and molecular area have been explained in 
detail elsewhere and hence, will not be discussed herein [Shahid 2013; Jebrail 2007; 
Nosrati 2010 
 
 Being a model system prepared on a smooth aqueous surface, monolayers can 
offer direct control over a wide range of parameters to examine the intermolecular 
interactions, membrane dynamics as well as generic phase behaviour [Collier 2001; 
Gaines 1966; Li 2014]. These parameters include surface (lateral) pressure, area per 
amphiphilic molecule, temperature, surface potential, pH, phospholipid compositions, 
PEG content, aliphatic chain length, packing conditions, viscosity, molecules mobility, 
subphase components as well as monolayer/protein interactions [Li 2014; Dhruv 2009; 
Mohwald 1990; Nunes 2011; Shahid 2011; Shahid 2013; Stefaniu 2014a; Stepniewski 
2011; Tanwir 2012; Ziblat 2011]. A major advantage of Langmuir monolayer technique 
lies in the possibility of interfacing it with various other techniques to acquire extensive 
knowledge about the physical dimensions of monolayers. Some of the advanced 
techniques include epifluorescence microscopy (EFM), Brewster angle microscopy 
(BAM), infrared reflection – absorption spectroscopy (IRRAS), grazing incidence X-ray 
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diffraction (GIXD), UV-vis absorption, and surface potential [DeWolf 1999; Jebrail 
2008; Li 2014; Shahid 2013; Stefaniu 2014a, Stefaniu 2014b; Tsoukanova 2008]. 
Phospholipid monolayers have been used as one of the key membrane models in this 
study. 
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Figure 1.3: Schematics illustrating (A) a sketch of a typical biological membrane bilayer 
with lipids and different types of proteins embedded in the membrane, (B) a single layer 
of the membrane (monolayer) and (C) a lipid monolayer at the air/aqueous interface on 
the Langmuir trough mimicking the membrane. Sketches made are based on Li 2014 and 
Avanti Polar. 
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1.8.1.2. Unilamellar Vesicle as a Membrane Model. 
 
 Unilamellar phospholipid vesicle has been widely studied as a membrane model 
to elucidate various properties of membranes including lateral structure, phase behavior, 
packing order, as well as mechanical properties [Akashi 1996; Bagatolli 2000; Bagatolli 
2006; Juhasz 2012; Mathievet 1996; Peterca 2011; Wesolowska 2009]. A schematic 
diagram of a unilamellar vesicle is illustrated in Figure 1.4. The formation of a 
phospholipid vesicle is considered to be a two-step self-assembly process [Antonietti 
2003]. In the first step, phospholipids form a bilayer, which subsequently closes up to 
form a vesicle in order to avoid its hydrophobic regions exposed to aqueous media at its 
edges [Antonietti 2003; Collier 2011; Walde 2001]. However, vesicles do not form 
spontaneously as they are not usually thermodynamically stable. The formation of stable 
and monodisperse vesicles greatly depends on the physical properties of the amphiphiles 
as well as the experimental conditions [Peterca 2011; Walde 2001]. Several 
methodologies are utilized in order to generate vesicles with high stability and properties 
of interest such as size, polydispersity, morphology and etc. This includes 
electroformation, solvent evaporation, and gentle hydration method [Akashi 1996; 
Bagatolli 2000; Bagatolli 2006; Bozzuto 2015; Korlach 1999; Manley 2008; Moscho 
1996; Wesolowska 2009]. Although electroformation is considered by far to be the most 
successful method used to obtain high yield of giant unilamellar vesicles (GUVs); we 
have utilized the latter two protocols to produce PEGylated GUVs, as discussed in detail 
in Chapter 6. This is due to the buffer, salts and other constituents used in the 
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experiments that may potentially interfere with the electric field and produce artifacts in 
the vesicle membrane [Manley 2008].   
 
The terms liposome (from the Greek, the body of lipids) and vesicle (from the 
Latin, small bubble) are used interchangeably in biomaterial research [Antonietti 2003; 
Walde 2001]. This is due to the fact that unilamellar vesicles, in particular GUVs, are 
only greater in magnitude as compared to liposomes, with an average size of a few tens of 
micrometers [Bagatolli 2000; Bagatolli 2006; Korlach 1999; Suga 2013; Walde 2001; 
Wesolowska 2009]. It is their greater size, similar to the range of the membrane of a cell, 
which makes GUVs an excellent membrane model system because single vesicles can be 
directly visualized using different microscopy techniques. Some of these techniques 
include phase contrast, immunoelectron, fluorescence, and confocal fluorescence 
microscopy [Bagatolli 2000; Bagatolli 2006; Juhasz 2012; Kalvodova 2005; Korlach 
1999; Morales-Penningston 2010; Veatch 2003; Wesolowska 2009]. Therefore, vesicles 
have been extensively studied as a membrane model to comprehend the mechanistic 
nature of lipid – lipid, lipid – DNA, lipid – RNA, and lipid – protein interactions 
[Bagatolli 2006; Korlach 1999; Kalvodova 2005; Nunes 2011; Suga 2013; Wesolowska 
2009]. Another notable advantage of using vesicles as a membrane model system lies in 
the ability to control the mixture composition, PEG content as well as experimental 
conditions such as temperature, pH, osmotic pressure, and etc. [Akashi 1996; Bagatolli 
2006; Korlach 1999; Mathivet 1996; Nunes 2011; Veatch 2003; Wesolowska 2009]. 
Hence, this report will include the complete preparation protocols of PEGylated 
phosphocholine giant and small unilamellar vesicles membrane models (GUVs and 
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SUVs) as well as their use to understand various properties of membrane and 
protein/membrane interactions.  
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Figure 1.4: Cartoon sketch of phospholipid unilamellar vesicle as a membrane model in 
aqueous media. Sketch is constructed based on information from Bozzuto 2015; Collier 
2001 and Kneidl 2014.  
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1.8.2. Selection of Matrix Phospholipid for Membrane Models. 
 
 Two disaturated phospholipids bearing either C16 (DPPC) or C18 (DSPC) aliphatic 
chains have been selected as the host matrix phospholipids in this study. Both synthetic 
phospholipids, dipalmitoyl phosphocholine (DPPC) and distearoyl phosphocholine 
(DSPC) are zwitterionic with a difference of only 2 CH2 groups in their aliphatic chain, 
as can be seen in Figure 1.5 [Lewis 2000]. Zwitterions generally contain both negatively 
and positively charged groups thus making them overall neutral phospholipids [Lewis 
2000]. Phosphatidylcholines (PC) have been found to be one of the most abundant 
phospholipids in natural plasma membranes, in particular in the exterior layer of the 
erythrocytes [Conde 2011; Lewis 2000; Li 2015; Nunes 2011]. In fact, lipid components, 
in particular zwitterionic phosphatidylcholines, comprising the exterior surface of the 
erythrocytes membrane are known to be non-thrombogenic [Lewis 2000]. This 
phenomenon leads to the distinct development of membrane-mimetic surfaces containing 
phosphocholine phospholipids and their structural analogues [Lewis 2000]. Indeed, 
reports show that liposomes resembling the outer layer of erythrocytes are more resistant 
to clearance by mononuclear phagocyte system (MPS) [Lewis 2000; Nunes 2011]. 
Hence, PC-based surfaces have been successfully used in many biomedical applications 
including soft contact lenses due to high water and oxygen transmissibility as well as low 
fouling properties [Chou 2002; Conde 2011; Lewis 2000]. Zwitterionic phosphocholine 
phospholipids, with even numbers of carbons, have also been used widely in several 
biomedical studies due to their favorable characteristics including stability, low surface 
tension, lateral rigidity, non-toxicity, biodegradability, and low fouling properties [Bedu-
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Addo 1996; Belsito 2000; Chou 2002; Dos Santos 1999; Ickenstein 2003; Kim 2004; Li 
2015; Lozano 2009a; Lozano 2009b; Maruyama 1997; Papahadjopoulos 1973; 
Stepniewski 2011; Walde 2001; Vermette 2003]. Thus, phosphocholines, with C16 or C18 
acyl chain length, grafted with PEG-phospholipids have been used in this study to 
comprehend the phase states and various other aspects to aid in improving the efficiency 
of membrane-mimetic surfaces, in particular under physiological conditions. 
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Figure 1.5: Chemical structures of (a) DSPC and (b) DPPC. Structure is made based on 
information from Kneidl 2014; Lewis 2000; Luna 2011; and Stepniewski 2011. 
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1.8.3. Selection of PEG-Phospholipid Conjugate for Membrane Models. 
 
  Two PEG-phospholipid conjugates, DPPE-PEG2000 and DSPE-PEG2000, have 
been selected to be introduced in the host phosphocholine membrane models in this 
study. DPPE-PEG2000 and DSPE-PEG2000 contain C16 and C18 aliphatic chains, 
respectively, with a phosphoethanolamine headgroup bearing poly(ethylene glycol) of 45 
PEG monomers with a molecular mass of 2000 g/mol (Figure 1.6). PEGylated 
phospholipids, in particular DSPE-PEG2000 and DPPE-PEG2000, have been widely 
used in various biomedical formulations due to low toxicity, biocompatibility, bio-non-
fouling as well as ease of excretion properties [Belsito 1998; Janout 2012; Luna 2011; 
Maruyama 1997; Pappalardo 2005; Vukovic 2011]. These formulations include micelles, 
immunoliposomes, vesicles, and ultrasound contrast reagents. Most importantly, DSPE-
PEG2000 is a key component in a U.S. FDA approved pharmaceutical formulation, 
known as Doxil [Janout 2012; Jin 2014; Li 2015]. Doxil is a PEGylated liposomal carrier 
loaded with an anti-cancer drug (doxorubicin) for the treatment of various diseases 
including ovarian cancer and AIDS-related Kaposi sarcoma. PEG-phospholipids have 
also been studied for cell-specific targeting where a target-specific ligand is covalently 
attached to the distal end of PEG molecule to allow active targeting via receptor mediated 
endocytosis [Maruyama 1997; Morille 2008]. Moreover, PEG-phospholipid (DPPE-PEG 
or DSPE-PEG) has also been successfully used in vitro to conjugate anti-thrombogenic 
enzyme (urokinase) on the islets’ cell surface in order to control thromobosis formation 
and improve the treatment of type I diabetes [Takemoto 2011]. Over the years, numerous 
studies have been carried out to explore different aspects of phospholipid membranes 
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grafted with DPPE-PEG2000 or DSPE-PEG2000 in order to improve the performance of 
membrane-mimetic surfaces [Belsito 1998; Chou 2002; Janout 2012; Kneidl 2014; 
Lozano 2009a; Luna 2011; Maruyama 1997; Pappalardo 2005; Stepniewski 2011; Walde 
2001; Vermette 2003; Vukovic 2011]. However, the effect of PEG-phospholipids and its 
lateral distribution on the phase behavior of phosphocholine membrane, in physiological 
conditions, have not been deeply explored [Kim 2004]. Hence, one of the main objectives 
of this study is to probe the effect of PEG-phospholipid on the phase behavior of 
phosphocholine membranes under physiological conditions relevant to in vivo 
applications including phosphate buffered saline (PBS) at 20 
o
C. The results obtained can 
serve as a guideline in interpreting and tuning the properties of PEGylated membrane-
mimetic surfaces.  
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Figure 1.6: Chemical structures of (a) DSPE-PEG2000 and (b) DPPE-PEG2000. 
Chemical structures are drawn based on Kneidl 2014; Luna 2011; and Stepniewski 2011. 
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1.8.4. Selection of Insulin as a Model Protein. 
 
Human insulin has been chosen as a representative of small size proteins for this 
study to understand the non-specific interactions of proteins with membrane models 
(Figure 1.7). The reason for selecting a small protein is due to the fact that non specific 
interactions of large proteins (such as bovind serum albumin (BSA)) and PEGylated 
membrane models have been studied extensively [Rahmati 2008; Vermette 2003; Zhao 
2002]. Additionally, PEG chains on the surfaces have shown significant steric repulsion 
towards large proteins but might not experience the compression and do not efficiently 
reduce the penetration of small proteins and hence has been the focus of our study 
[Rahamati 2008; Vermette 2003]. Insulin is a small protein with 51 amino acids and bears 
an overall negative charge, –2 per monomer, in the presence of PBS subphase with a pH 
of about 7.4 [Farias 1989; Henry 2008]. The hydrodynamic diameter of zinc-free human 
insulin monomer has been approximated to be 3 nm with molecular dimensions of 2 x 2.5 
x 2 nm
3
 [Liu 2002; Henry 2008]. The interaction surface of insulin is comprised of two 
segments including a hydrophobic binding core and a hydrophilic surface [Liang 1994]. 
Insulin is also considered to be a protein, which can promote the hydrophobic interactions 
in order to avoid exposure to the aqueous environment by inserting its hydrophobic 
residues into the aliphatic region of the phospholipid membrane [Birdi 1976; Farias 1989; 
Grudzielanek 2007; Kadima 1993; Liang 1994; Liu 2002; Nieto-Suarez 2008; Rand 
1972; Vermette 2002; Yang 2011]. Few reports have also suggested that insulin changes 
its conformation by partially submerging its hydrophilic residues in to the subphase 
[Nieto-Suarez 2008]. Although bearing an overall net negative charge, insulin has shown 
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attractive electrostatic interactions towards negatively charged surfaces, depending on its 
orientation [Nylander 1994; Vermette 2003]. Hence, it is of great interest to obtain a 
sound understanding of such unique and complex interactions of insulin with PEGylated 
membranes. The findings of such a study can aid to improve the quality and performance 
of various bio-non-fouling membrane-mimetic surfaces.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: The structure of human insulin (PDB ID: 2JV1; Bocian et. al. 2008). 
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1.9. Methodology.  
  
 A comprehensive analysis of PEGylated phosphocholine membranes models has 
been carried out by utilizing different methodologies under various experimental 
conditions, as outlined below.  
 
1.9.1. Surface Characterization of Monolayer Model at Air/PBS Interface. 
 
 Mixed monolayers of a matrix phosphocholine and a PEG-phospholipid grafted 
with a PEG chain of molecular weight 2000 (PEG2000) were formed on PBS subphase at 
20 
o
C. Two types of binary mixtures selected for this study include DPPC/DPPE-
PEG2000 and DSPC/DSPE-PEG2000 with a PEG content of 1, 3, 6, and 9 mol%. 
Analysis of phase behavior in terms of phase state and phase transitions was performed 
by π – A isotherm measurements. These measurements were further used for miscibility, 
PEG conformational, and compressibility analyses at physiological conditions including 
temperature and PBS subphase, pH ~7.4.  
 
1.9.1.1. Surface (Lateral) Pressure – Area, π – A, Isotherm. 
 
 When a Langmuir monolayer is compressed, change in surface (lateral) pressure 
is recorded with respect to the change in area per phospholipid molecule. This produces a 
π – A isotherm (Figure 1.9) [Dhruv 2009; Gaines 1966; Li 2014]. Changes in the slope of 
the isotherm can reveal crucial information about the phospholipid packing, phase state, 
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etc. In particular, as shown in the Figure 1.9, when the phospholipid solution is spread on 
to the aqueous subphase, all the phospholipids are apart from each other and are in a 
disordered phase. This phase is referred to as the gaseous phase (G). Upon compression, 
the molecules start to come close to each other and this phase is known as the liquid 
expanded phase (LE). A plateau may emerge, which corresponds to the coexistence of the 
liquid expanded and liquid condensed phase. At this point, half of the phospholipid 
molecules are believed to be in a random orientation while others begin to align close to 
each other. Further compression leads to a steep straight line after the plateau, known as a 
low-compressibility region in the π – A isotherm [Mohwald 1990]. This refers to a liquid 
condensed (LC) phase of the monolayer. Eventually, the isotherm reaches a point where 
the monolayer collapses [Gaines 1966; Nakahara 2014]. A collapse point (C) corresponds 
to a pressure where the monolayer loses it stability by disruption in the phospholipid 
packing [El-Khouri 2009; Gaines 1966]. Advantages of π – A isotherm also include 
determining the limiting area of a phospholipid molecule in a closely packed state. This is 
achieved by extrapolating the low-compressibility region of the π – A isotherm to π = 0 
mN/m as indicated by the dashed line in Figure 1.9. π – A isotherm can, hence, be a very 
beneficial tool in order to understand the effect of different mixture compositions and 
packing states on monolayer phase behaviour.   
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Figure 1.8: Cartoon sketch illustrating a phospholipid monolayer model at air/aqueous 
subphase on a trough. Cartoon is prepared based on Li et al. 2014. 
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Figure 1.9.: A Schematic diagram of a typical phospholipid monolayer π – A isotherm at 
air/aqueous interface with cartoons depicting development of various unique phases 
during compression for illustration purpose. This includes gaseous phase depicted as a G 
phase in the diagram, liquid expanded phase represented as a LE phase, coexistence 
phase as LE/LC phase, liquid condensed phase shown as a LC phase and collapse point 
of the monolayer. Drawings made are based on Gaines 1966 and Dhruv 2009. 
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1.9.2. Monolayer Area Expansion Measurements. 
 
 Langmuir trough can also be used to monitor protein/membrane interactions by 
measuring the protein-induced expansion of monolayer area. The measurement is carried 
out by first preparing the monolayer compressing it to a preset surface pressure, π, value. 
The monolayer surface pressure is then kept constant while monolayer area is allowed to 
expand upon insulin injection in the subphase underneath the monolayer. The 
measurements afford the quantification of insulin/monolayer interactions including 
change in monolayer molecular area, ∆A, insulin penetration area, Ains, and binding 
degree of insulin, χins calculations. Details about carrying out the measurements and 
quantification of insulin/monolayer interactions are explained in Chapter 4.  
   
1.9.3. In-Situ EFM Imaging. 
 
 The major goal of this study was to visualize different aspects of the monolayers 
including the morphology, coexisting phases as well as the lateral distribution of PEG-
phospholipid in the phosphocholine matrix. For this, a unique two-channel 
epifluorescence microscopy (EFM) setup with the use of two different fluorescent probes 
has been utilized. This technique has been selected to simultaneously monitor both phase 
state and lateral distribution of PEG-phospholipid or protein binding under various 
experimental conditions.   
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 The principle of fluorescence lies behind the emission of fluorescent light, usually 
within nanoseconds, after exciting the fluorophore [Lichtman 2005; Shahid 2013; Hou 
2014]. The difference between the peaks of excitation and emission spectra is known as 
the Stokes shift [Lichtman 2005]. A better way to understand the phenomenon of 
fluorescence excitation and emission is through visualizing the Jablonski diagram 
sketched in Figure 1.10. Fluorophore resides in the ground state, So, and upon absorbing 
light, the fluorophore is excited to higher states (within femtoseconds) known as excited 
singlet states, S1 and S2. Most molecules usually return back to their So state within 
nanoseconds resulting in the emission of fluorescence at a specific wavelength, as 
displayed in Figure 1.10 [Lichtman 2005; Hou 2014]. 
 
Epifluorescence microscopy (EFM) has proven to be a powerful tool to image 
numerous aspects of living systems both at the cellular and molecular level [Gao 2014; 
Hou 2014; Lichtman 2005]. Epifluorescence microscopy has also been playing a key role 
in understanding the heterogeneity and phase behavior of various membrane models 
[Baumgart 2007; Lichtman 2005; Nag 1990; Veatch 2003]. This is due to the fact that it 
offers direct selection and specific detection of molecules of interest yet with a good 
signal to background ratio [Lichtman 2005; Yuste 2005]. Epifluorescence configured 
microscope is useful in a way that its objective not only serves for imaging the specimen 
but also plays a role as a condenser to illuminate it. One of the great advantages of epi-
illumination lie in the possibility of blocking only a small amount of exciting light being 
reflected off the specimen in the return light path as compared to the transmitted or 
diascopic microscopes [Lichtman 2005]. A major obstacle with this configuration is the 
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overlap between the excitation light and fluorescence emissions, which is resolved by the 
use of beam splitters referred to as a dichroic mirror and filter sets as will be explained 
later in this section (Figure 1.11) [Cullander 1994; Koyama-Honda 2005; Lichtman 
2005]. There are two types of epifluorescence microscopes available commercially and 
known as upright and inverted microscopes. Unlike upright microscope, inverted 
epifluorescence microscope has an objective at the bottom of the specimen and light is 
illuminated on the specimen from the top. For the purpose of our study, the inverted 
epifluorescence microscope was utilized for in-situ imaging of unilamellar vesicles. The 
upright epifluorescence microscope, on the other hand, was interfaced with the NIMA 
Trough for monolayer imaging, as illustrated in Figure 1.11 [Nag 1990; Plasencia 2005]. 
CCD camera was attached to both types of EFM for a direct in-situ imaging of membrane 
models.  
 
The technical specification of EFM includes a light source which can be a 
halogen, mercury, or xenon lamp [Lichtman 2005]. The light reflects down where the 
fluorescence is collected from the surface by an objective and passes through the dichroic 
mirror (beamsplitter) and barrier/emission filter that blocks the excitation light and 
permits the emission light to reach towards the detector as shown in Figure 1.11 
[Lichtman 2005]. Different kinds of optical filter sets with different wavelength ranges, 
depending on the choice of chromophore, are used for the excitation light to pass through 
the excitation bandpass filters.  A CCD camera is used to capture the images from the 
membrane models and is also used to detect the difference in emission light intensities. 
Mostly low-light level cameras are used for high performance and maximum image 
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stability. The digital resolution of the images can be set to 3 pixels/µm or less for better 
images. The images can be recorded and stored directly to computer memory by an on-
line image processor. The EFM setup is usually placed on an active vibration isolation 
table to avoid external vibrations which may cause discrepancy in the results [Lichtman 
2005; Nag 1990].   
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Figure 1.10: A Jablonski Diagram illustrating the phenomenon of fluorescence. 
Fluorophore in resting configuration reside at the lowest vibrational state known as 
ground state, So. Upon absorbing energy, the fluorophore gets excited to a higher singlet 
state, S1. Most fluorophores would emit a photon in the form of fluorescence, upon 
relaxing back to the So state. Diagram sketched is based on Hou 2014 and Licthman 
2005.  
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Figure 1.11: Cartoon of an upright epifluorescence microscope interfaced with a NIMA 
trough shown at the bottom. (A) Light from the source passes through the filter cube, in 
particular an exciter, that selectively excites the fluorophore at a specific wavelength 
(Green light in this particular example). (B) The dichroic mirror is a special type of beam 
splitter usually at a 45
o
 that separates excitation from the emission. (C) The barrier filter 
is used in EFM to allow the emitting light of a longer wavelength (red in this case) to 
pass and prevents the exciting light (green light) to reach the detector. The diagram is 
sketched based on the reference of Lichtman 2005. 
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1.9.4. Insulin Conformational Analysis upon Interactions with Vesicles by CD. 
 
This study also examined the conformational changes of insulin upon non-specific 
interaction with the membrane model using circular dichroism, CD, spectroscopy. The 
small unilamellar vesicle (SUV) of PEGylated phosphocholine has been selected as a 
membrane model to probe the effect on insulin conformational structure during 
insulin/membrane interactions. The conformational changes of insulin upon interactions 
with the vesicle membrane will be evaluated in terms of α-helical content. The effect of 
varying PEG content in the vesicles on the insulin conformational structure as well as 
folding/unfolding state will also be examined. CD spectroscopy data analysis will be 
summarized in a CD phase diagram in order to determine the existence of different states 
of insulin species upon non-specific membrane interactions with varying PEG content. 
  
Circular dichroism works on the principle of measuring the difference in 
absorbance between the left and right-handed circularly polarized light that arises from a 
chiral or optically active molecule [Greenfield 1996; Kelly 2005; Shahid 2013; Sreerama 
2004]. CD spectroscopy has proven to be a remarkable tool to extract structural 
information about macromolecules, in particular proteins [Kelly 2009; Greenfield 1996; 
Sreerama 2004]. CD can provide dynamic information about proteins including 
secondary structure composition, tertiary structure, conformational changes, cofactor 
binding sites, protein-ligand interactions as well as protein folding [Ahmad 2004; 
Greenfield 1996; Kelly 2005; Kelly 2009; Kuznetsova 2002; Sreerama 2004; Tah 2014]. 
The molecule can be chiral for several reasons, in particular if it contains one or more 
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chiral centers, it is placed in an asymmetric environment, or it is covalently attached to a 
chiral center [Kelly 2009; Greenfield 1996]. In general, CD spectrometer operates on the 
same principle as demonstrated in Figure 1.12. Light from the source passes through the 
monochromator, which linearly polarizes light with respect to wavelength [Breeze 1972]. 
Light then enters photoelastic modulator where it splits into left and right circularly 
polarized light [Breeze 1972; DiNitto 2012; Kelly 2009]. The modulator is usually a 
piezoelectrical crystal whose unique axis is 45
o
 and it oscillates at a resonance frequency 
of about 50 kHz. The left and right circularly polarized light enters (LCP and RCP) the 
sample compartment [DiNitto 2012; Kelly 2009; Shahid 2013]. If there is no sample 
present in the compartment then the light hitting the detector (usually photomultiplier 
tube (PMT)) would be constant. However, if the chiral sample is present in the 
compartment then one of the circularly polarized lights will be absorbed more than the 
other and the resulting combined radiation will be elliptically polarized and thus the 
signals will get across the PMT (Figure 1.12) [Breeze 1972; DiNitto 2012; Kelly 2005; 
Kelly 2009]. The photomultiplier tube generates a signal comprised of a DC and AC 
component [Breeze 1972; DiNitto 2012]. A DC voltage corresponds to the average light 
intensity transmitted over time, which is usually held constant. AC component of the 
signal, on the other hand, refers to the intensity modulation resulting from the differential 
absorption of the sample, which is usually amplified and rectified with respect to DC 
component [Breeze 1972]. Hence, the ratio of AC and DC component (ignoring other 
factors) can be simply used to measure the CD signal and subsequently the molar 
ellipticity [Breeze 1972; DiNitto 2012]. The processed data is further applied to produce 
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a spectrum of the sample’s ellipticity as a function of wavelength of light, as illustrated in 
Figure 1.12.  
 
CD spectra can be used to obtain secondary structure information of proteins. For 
instance, proteins containing β-sheets will exhibit a CD spectrum with a positive band 
around 198 nm and a negative band around 215 nm [Greenfield 1996; Greenfield 2006; 
Kelly 2005; Sreerama 2004]. The CD spectrum of proteins with α-helical content can be 
characterized by one positive band at 192 nm and two negative bands of 208 and 222 nm. 
The two CD signals at 208 and 222 nm can also be further used in estimating the α-
helical content of the protein [Greenfield 1969; Kelly 2005; Seelig 2000]. CD 
spectroscopy has been used in several studies to monitor the changes in the protein 
secondary structure, by estimating the α-helical content, upon interactions with 
membranes and various other molecules [Mollmann 2006; Nosrati 2009; Pal 2011; Seelig 
2000; Shahid 2013; Tah 2014]. Hence, far-UV CD spectroscopy has been utilized in this 
study to assess the folding/unfolding states as well as conformational changes in the 
insulin’s secondary structure, in terms of α-helical content, upon interactions with small 
unilamellar vesicles as membrane models. 
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Figure 1.12.: Schematic diagram demonstrating the technical specification of CD 
spectroscopy. Light from the light source passes through the monochromator and 
then photoelastic modulator (PEM) which splits the light into left and right 
circularly polarized light. This light enters the sample compartment and differential 
absorbed light hits the photomultiplier tube (PMT) which processes the data and 
yields a CD spectrum of mean residue ellipticity with respect to wavelength. The 
diagram is based on Applied Photophysics; Breeze 1972 and DiNitto 2012.  
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Chapter 2: Experimental. 
 
 
  
 The main focus of this study was to assess different aspects of PEGylated 
phosphocholine membrane models including phase state, miscibility, morphology, composition, 
aliphatic chain length, as well as PEG distribution and its conformations. Two types of 
PEGylated phospholipid membrane models were selected (i) Langmuir monolayers as well as (ii) 
giant (GUV) and small unilamellar vesicles (SUV). The binary mixtures of PEG-grafted 
phospholipids and host matrix of phosphocholine selected were DPPC/DPPE-PEG2000 and 
DSPC/DSPE-PEG2000. The binary mixtures of PEG-grafted phospholipids and phosphocholine 
possessed same aliphatic chain length, C18/C18 and C16/C16. Human insulin was chosen as a 
model protein in order to understand the mechanisms involved in the non-specific interactions of 
PEG-grafted phospholipid membrane models with small proteins. The techniques used in this 
study include Langmuir technique, epifluorescence microscopy (EFM) as well as circular 
dichroism spectroscopy (CD). A variety of fluorescent probes were used in membrane models 
for EFM imaging including (i) DOPE-Rh for phase behavior imaging, (ii) fluorescent analogues 
of the PEG-phospholipids, DPPE-PEG2000-FITC and DSPE-PEG2000-FITC, for PEG 
distribution imaging and (iii) FITC-insulin for imaging the protein binding.  
 
2.1. MATERIALS. 
 
 All phospholipids and fluorescent probes were purchased from Avanti Polar Lipids and 
used as received. This includes poly(ethylene glycol)-grafted phospholipid with a PEG average 
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molecular weight of 2000, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly(ethylene 
glycol)2000] (DSPE-PEG2000), its fluorescent analog, 1,2-distearoyl-sn-glycero-3- 
phosphoethanolamine-N-[poly(ethylene glycol)2000-N′-carboxyfluorescein] (DSPE-PEG2000-
FITC), poly(ethylene glycol)-grafted phospholipid with a PEG average molecular weight of 
2000, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[poly(ethylene glycol)2000] 
(DPPE-PEG2000), a fluorescent probe, rhodamine-dioleoyl-phosphatidylethanolamine  labeled 
at the headgroup 1,2-dioleoyl-sn-glycero-3-phosphadtidylethanolamine-N-(lissamine rhodamine 
B sulfonyl) (DOPE-Rh), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and 1,2- 
distearoyl-sn-glycero-3-phosphocholine (DSPC). The fluorescent analog of DPPE-PEG2000, 
DPPE-PEG2000-FITC, was synthesized in the present study as will be discussed in Chapter 3. 
For this, a Boc-protected NHS-ester, α-Nhydroxysuccinimidyl-ω-tert-butoxycarbonyl 
[poly(ethylene glycol)2000] (NHS-PEG2000-Boc) was obtained from JenKem. Human insulin 
was purchased from Sigma Aldrich. Fluorescein isothiocyanate (FITC) fluorophore to label 
insulin was obtained from Molecular Probes. HPLC grade chloroform and methanol were 
purchased from Fisher Scientific and used as received. Phosphate-buffered saline (PBS) from 
Sigma containing 0.01 M phosphate salt, 0.12 M NaCl, and 0.0027 M KCl at pH 7.4 was used as 
the subphase. Deionized water produced by a Milli-Q Synthesis water purification system was 
used in all experiments. The specific resistivity of water was 18 × 10
6
 Ω·cm (pH 6.2 in 
equilibrium with atmospheric carbon dioxide). All solutions were stored in the dark at 4 °C. 
 
 Stock solutions of DPPC, DSPC, and PEG2000-grafted phospholipids and fluorescent 
probes were typically prepared at concentrations of 0.1 – 0.5 mg/mL by dissolution in 
chloroform for monolayer studies. The concentrations of the mixtures for unilamellar vesicles 
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were 20 mg/mL for phosphocholine and 2 mg/mL, for PEG-phospholipid. The stock solutions 
were prepared in chloroform/methanol mixture (60:40 v/v). Stock solutions were mixed in 
various molar ratios to obtain spreading solutions containing 1, 3, 6, and 9 mol% PEG-
phospholipid. Insulin solutions were prepared at a concentration of ~0.3 mg/mL (~0.5 μM) by 
dissolving in phosphate buffer pH ~7.4 containing 0.009 M KH2PO4 and 0.03 M Na2HPO4.  
 
2.2. EXPERIMENTAL TECHNIQUES. 
 
 Monolayer studies were carried out in a Langmuir trough using different methodologies. 
This includes surface pressure, compressibility analysis, area expansion measurements and 
epifluorescence microscopy (EFM). The experimental techniques used for studying unilamellar 
vesicles (GUV and SUV) as membrane models include optical and epifluorescence microscope 
as well as circular dichroism spectroscopy (CD).    
  
 
2.2.1. Preparation of Langmuir Monolayers for π – A Isotherm Measurements. 
 
Two types of custom made Langmuir troughs, KSV2000SP and NIMA, were utilized to 
study the phospholipid monolayers at the air/aqueous interface. A KSV2000SP Langmuir trough 
(KSV Instruments Ltd., Finland) was used to study the phase transition, lateral organization and 
protein-membrane interactions of mixed monolayers whereas NIMA trough (NIMA technology 
Ltd., UK) was employed to image the morphology of monolayers upon compression 
simultaneously by EFM. KSV Langmuir trough has an effective surface area of 75 × 760 mm 
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and NIMA trough has an effective area of 70 x 460 mm. Both troughs are equipped with two 
moveable barriers to compress or decompress the amphiphilic monolayers, as illustrated in 
Figure 2.1. The monolayers were compressed at a constant speed of 10 and 7 mm/min, 
respectively, to ensure equilibrium surface pressure values at each molecular area [Nakahara 
2014]. A filter paper, Wilhelmy plate, was used to measure the surface pressure, π, of the 
monolayer to an accuracy of 0.1 mN/m. The trough was thermostated to maintain the subphase 
temperature with an accuracy of ± 1 °C.  
 
The troughs were cleaned by ethanol and milli-Q water before spreading the monolayers. 
A reference run of milli-Q water was conducted without phospholipids to ensure cleanliness of 
the subphase. The cleaning of the trough was repeated if the surface pressure rose above 0.2 
mN/m. After the cleaning procedure, the phospholipids solubilized in chloroform were slowly 
spread drop wise on the trough subphase to prevent unwanted surface pressure change. The 
chloroform was allowed to evaporate for 15 min and the compression commenced by two 
barriers to record the surface pressure – area (π – A) isotherms. Each isotherm was repeated at 
least three times.  
To study the monolayer – protein interactions area expansion measurements were 
performed. The monolayer was prepared by spreading the PEGylated phospholipid binary 
mixtures with appropriate molar ratios on the trough and allowed to compress to a preset surface 
pressure, π, value using the barriers. The π was kept constant throughout the experiment using an 
electronic feedback device. The insulin solution at a desired concentration was injected in the 
subphase underneath the monolayer. The monolayer area expansion was then measured with 
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respect to time. The technical details of area expansion measurements are described in detail in 
Chapter 4.     
 
2.2.2. Epifluorescence Microscopy (EFM) Imaging of Monolayer Models.  
 
EFM images of monolayers were acquired by using a custom designed NIMA trough 
(NIMA Technology Ltd., U.K.) interfaced with an upright Nikon Eclipse FN1 Epifluorescence 
microscope (Nikon, Japan). The π - A isotherm measurement parameters were adjusted to 
precisely match those of the KSV2000SP trough. To observe the fluorescence from the 
fluorescein fluorophore attached to the distal end of the PEG2000 chain on the DPPE-PEG2000-
FITC and DSPE-PEG2000-FITC molecule, Nikon CFI infinity optics, a blue excitation filter set 
(B-1E filter combination, 480CWL excitation filter, 505LP dichroic mirror, and 540CWL barrier 
filter) was used. On the other hand, a green excitation filter set (TRITC HYQ filter combination, 
545CWL excitation filter, 570LP dichroic mirror and 620CWL barrier filter) was utilized to 
detect the fluorescence from the DOPE-Rh molecule. Each of the two channels was equipped 
with a 10x objective (Nikon CFIPlan 10) to enable imaging. The images were captured by a 
Hamamatsu CCD camera, ORCA ER(AG) (Hamamatsu, Japan) and visualized directly onto a 
computer screen using an advanced Simple PCI 6 software (Compix Inc., PA).  
 
The main goal of our study was to simultaneously visualize changes in the membrane 
morphology and insulin/membrane interactions. Hence, a two channel EFM (TRITC and FITC 
channels) was utilized, which afforded the use of two fluorophores of different spectral profiles, 
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to achieve our goals. A rhodmine-labelled phospholipid probe, DOPE-Rh, and fluorescein-
isothiocyanate (FITC) conjugated with either PEG-phospholipid or insulin are the two types of 
fluorescent probes used for our membrane models studies (Figure 2.1). This is due to the fact that 
their excitation and emission wavelengths are different from each other and hence, can be 
selectively detected through the use of different filter sets in two channel EFM [Cullander 1994; 
Licthman 2005; Shahid 2013]. For instance, the excitation range of rhodamine lies in the range 
between 530 – 560 nm with its absorption maximum of about 545 nm which is far from 
excitation range of FITC from 470 – 490 nm with its absorption maximum of about 488 nm, as 
described in detail elsewhere [Shahid 2013; Tanwir 2012]. Similarly, the emission intensity 
range of rhodamine is between 590 – 650 nm which is different from the range of FITC from 510 
– 560 nm [Shahid 2013; Tanwir 2012]. In this case, TRITC channel detects fluorescence from 
rhodamine fluorophore while cutting off FITC fluorescence whereas FITC channel detects 
fluorescence from FITC while cutting off rhodamine fluorescence. A sophisticated approach of 
switching between TRTIC and FITC channels in EFM can make the use of two fluorophores 
possible for the purpose of our study. Hence, in-situ imaging of phase state and lateral PEG 
distribution was performed by using DOPE-Rh as well as DPPE-PEG2000-FITC and DSPE-
PEG2000-FITC. The insulin/membrane interactions study, on the other hand, was carried out by 
using DOPE-Rh and FITC-insulin. 
 
 The phase state imaging of membrane models was performed by using a headgroup-
labelled phospholipid probe, DOPE-Rh. Headgroup-labelled phospholipids are usually used for 
phase state imaging since bulky fluorophore attached to the aliphatic chain may disrupt the lipid 
packing in the membrane model [Manley 2008]. DOPE-Rh is comprised of two unsaturated 
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aliphatic chain and a headgroup with a bulky fluorophore attached to it due to which it 
preferentially partitions into liquid expanded/liquid disordered (LE or Ld) phase and is mainly 
excluded from the liquid condensed/gel (LC or Lβ’) phase [Baumgart 2007; Klymchenko 2014; 
Samsonov 2001]. The bright regions represent the LE phase which is rich in DOPE-Rh 
fluorophore whereas the dark region in the membrane model corresponds to the DOPE-Rh 
excluded area or LC phase [Klymchenko 2014; Tsoukanova 2008]. This property makes DOPE-
Rh useful for the phase state imaging to visualize LE and LC coexisting phase in the membrane 
at various surface pressure and PEG content.  
 
 The lateral distribution of PEG-phospholipid in the host phosphocholine matrix was 
carried out by detecting fluorescence from a FITC fluorescent probe attached at the distal end of 
the PEG2000 chain. DSPE-PEG2000-FITC is readily available commercially but DPPE-
PEG2000-FITC was synthesized in our lab due to lack of commercial availability. Both 
fluorescent analogues, DSPE-PEG2000-FITC and DPPE-PEG2000-FITC mix well and stay with 
their counterparts, DSPE-PEG2000 and DPPE-PEG2000 in the membrane models. Hence, use of 
both fluorophores can aid in locating the DSPE-PEG2000 and DPPE-PEG2000 molecules as 
well as make that region appear green in the EFM images. The FITC analogue of each PEG-
phospholipid was added together with the DOPE-Rh in order to study the lateral PEG 
distribution as well as phase behaviour of binary mixtures of phosphocholine and PEG-
phospholipid, simultaneously. This was done by capturing images through both TRITC and 
FITC channel from the same area of the membrane model. Comparative analysis of TRITC and 
FITC images then afforded determining the distribution of PEG-phospholipid between the LE 
and LC phase [Tanwir 2012]. 
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 Two channel EFM has also been employed to monitor the interactions between insulin 
and membrane models. This was executed by adding one type of fluorophore in the membrane 
model to monitor changes in the membrane morphology whereas attaching the FITC or 
rhodamine fluorophore to insulin to visualize the insulin binding. Insulin has been labelled with 
FITC and characterized for numerous applications in many reports [Gok 2004; Hentz 1997; 
Shahid 2013]. Insulin labelled with FITC is a mono-substituted species which is modified at the 
N-terminus of the B-chain. The substitution made on B-chain of insulin molecule has shown to 
retain similar biological activity as compared to unlabelled insulin molecule [Gok 2004; Hentz 
1997]. Thus, in this study, FITC-insulin and Rh-insulin were prepared in our lab as will be 
described in Chapter 5. To achieve our goal, FITC channel was used to visualize FITC-insulin 
binding whereas TRITC channel was employed to image the changes in LE/LC of membrane 
model upon insulin binding using DOPE-Rh. The above procedure was also performed by using 
Rh-insulin and FITC-labelled PEG-phospholipid but no noticeable differences were observed in 
the results. Hence, the results provided herein will only be discussed for DOPE-Rh and FITC-
insulin in the membrane models.  
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Figure 2.1.: The chemical structures of fluorescently labelled phospholipids (A) DOPE-Rh, (B) 
DPPE-PEG2000-FITC, and (C) DSPE-PEG2000-FITC. 
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2.2.2.1. Enhancement of Low-Resolution FITC Imaging. 
  
The major obstacle associated with the HBO mercury lamp supplied by Nikon was the 
poor contrast and low resolution imaging in the FITC channel. This is due to the fact that 
mercury lamp, in the visible range, has all its major bands positioned at 365, 405, 436, 546, and 
579 nm. The band at 546 nm is positioned right in the excitation window of the TRITC filter set 
resulting in the optical output power of 76 mW/cm
2
. This produces high contrast images due to 
optimum fluorescence emission from the rhodamine probe. However, the mercury band closest 
to the FITC range is 436 nm, which falls outside the excitation window resulting in a low optical 
output power of 20 mW/cm
2
. This produces very low contrast and low intensity monolayer 
images through FITC channel. Hence, an innovative scheme was designed to improve the 
sharpness and resolution of FITC channel without compromising that of TRITC channel.  
 
 A HBO lamp was first replaced by a X-Cite technology Hg lamp (120 W) from EXFO 
Photonic Solutions Inc. This lamp improved the FITC optical output power to about 34.8 
mW/cm
2
 but with a slightly reduced power of about 67.4 mW/cm
2
 in TRITC channel. This lamp 
offered a considerable improvement in the FITC images without compromising the resolution of 
TRITC images. However, a power of 34.8 mW/cm
2
 was still not sufficient enough to produce a 
high FITC fluorescence for which the acquisition time had to be raised. This made the 
monolayers move faster throughout the image frame while making it difficult to obtain high 
quality images. Hence, the EFM setup was further aligned with a laser to improve the contrast 
and sharpness of images in the FITC channel. The laser was purchased from Laser Glow 
Technology Inc., ON and had an excitation output power of about 100 mW at 473 nm for FITC. 
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The laser has the capacity to excite the fluorophore directly at the desired wavelength in order to 
provide maximum excitation and high fluorescence emission. The setup was further aligned with 
a convex lens in order to focus all of the 100 mW output power of the laser at a certain focal 
point of the monolayer covering a diameter of about 500 μm, and has been discussed in detail 
elsewhere [Shahid 2013]. This has reduced the acquisition time and enhanced the contrast and 
crispiness of the FITC images.  
   
2.2.3. EFM Imaging of GUV Models. 
 
GUV imaging was performed in an imaging cell with a glass bottom, a diameter of ~15 
mm, using an inverted Nikon Eclipse TE2000 microscope (Nikon, Japan) through visible and 
two channel EFM (TRITC and FITC channel). The technical specifications of two channel EFM 
used for GUV imaging is the same as those of monolayer EFM imaging (described above). 
Vesicle dispersions were prepared at a concentration of ~3 mg/mL and hydrated with a swelling 
solution of either 0.1 M NaCl containing 1 vol% glycerol or PBS. The vesicle dispersion was 
gently transferred in the cell and visualized using inverted Nikon Eclipse TE2000 microscope 
(Nikon, Japan) through TRITC, FITC and visible channel. TRITC channel was used to image the 
morphology of the vesicles with a DOPE-Rh fluorophore whereas the insulin binding on the 
vesicle was monitored by the FITC channel using FITC labeled insulin, FITC-insulin. The 
visible channel was used to monitor the size and lamellarity.  
 
 
   
64 
 
2.2.4. CD Spectroscopy of SUV Models. 
 
CD spectroscopy was used to study the conformational changes in insulin upon non-
specific interactions with PEGylated phosphocholine vesicle membranes. The CD measurements 
were performed using a Jasco J-180 spectropolarimeter, which is equipped with a temperature 
controlled holder. Prior to the measurements, nitrogen gas was purged for about 10 minutes to 
eliminate oxygen and ozone formation from the instrument. The CD measurements of insulin 
were performed with SUV membrane models. The SUV solution for each binary mixture was 
prepared in PBS. Vesicle dispersion was visualized with visible microscopy to ensure the 
formation of vesicles as discussed in detail in Chapter 6. Vesicle dispersion was then transferred 
into a rectangular cell with a path length of 10 mm. After measuring the CD of vesicles, insulin 
solution was injected and the measurements were performed. The Far-UV CD spectrum was 
recorded between 260 – 200 nm with a scan rate of 10 nm/min and 1 nm bandwidth at 20 oC. All 
spectra were collected by averaging the signal at every 0.5 nm for 2 s. The PBS baseline was also 
measured to be used to subtract from all the average CD scans. Moreover, the spectra of insulin 
interacting with SUVs were obtained by subtracting the spectra of vesicles alone in PBS. Each 
plot shows the average of three spectra. Every measurement was carried out three times. The 
data analysis is discussed in detail in Chapter 6. 
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Chapter 3: Examining the Lateral Distribution of PEG-Grafted 
Phospholipids and Phase Behavior of Phosphocholine Membranes. 
 
 
 In this study, a comparative analysis of binary mixtures of phosphocholine, DPPC 
and DSPC, and PEG-phospholipids including DPPE-PEG2000 and DSPE-PEG2000 with 
varying PEG-phospholipid content is performed to systematically examine the effect of 
PEG-phospholipids on the lateral organization and phase behavior of the phospholipid 
membranes. All studies have been carried out in the aqueous media of physiological 
relevance (PBS) at 20 
o
C. Two channel epifluorescence microscopy imaging has been 
used to directly image the lateral distribution of PEG-phospholipid and its effect on the 
phase behavior of the binary mixtures. With the help of phase drawings and phase 
diagrams, it can be suggested that there is a complex relationship between the PEG-
phospholipid lateral distribution and the membrane phase behavior. This may aid in 
developing a fundamental knowledge on non-specific interactions of dissolved proteins 
with PEG-grafted membranes which will allow us to develop general guidelines to the 
rational design of bio-nonfouling membrane-mimetic surfaces.  
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3.1. RESULTS. 
 
In this study, several types of mixed monolayers were used as model membranes. 
All the monolayers were comprised of a matrix phosphocholine component (DSPC or 
DPPC) and a PEG-phospholipid (DSPE-PEG2000 or DPPE-PEG2000). However, for 
EFM imaging, three types of mixtures compositions containing different fluorescent 
probes were prepared. These include (i) mixtures labeled with 0.5 mol% of DOPE-Rh, 
(ii) mixtures in which 0.5 mol% of the entire PEG content was replaced with PEG 
fluorescent probe (DSPE-PEG2000-FITC or DPPE-PEG2000-FITC), and (iii) mixtures 
labeled with both DOPE-Rh and PEG fluorescent probes. DOPE-Rh was used to image 
the phase state of the binary mixtures. This specifically includes analyzing the liquid-
expanded (LE) and liquid-condensed (LC) phases of the mixtures [Discher 1999; El-
Khouri 2011; Shahid 2011]. In a typical membrane, the LE phase corresponds to the 
liquid-disordered (Ld) phase whereas the LC packing refers to the gel phase (Lβ or Lβ’) 
[Kenworthy 1995; Ickenstein 2003; Eeman 2010; Tenchov 2001]. The term Lβ’ is usually 
used for DPPC and DSPC membrane as they both are known to form the tilted gel phase 
[Kenworthy 1995; Ickenstein 2003; Eeman 2010; Tenchov 2001]. In contrast, PEG 
fluorescent probes (DSPE-PEG2000-FITC and DPPE-PEG2000-FITC) were used to 
enable imaging the lateral distribution of the PEG-phospholipids in the phosphocholine 
matrix [Kinsinger 2010; Tanwir 2008]. The imaging was performed simultaneously with 
both DOPE-Rh and PEG fluorescent probes to determine the composition of coexisting 
phases in the binary mixtures as discussed below. 
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3.1.1. π – A Isotherms of DPPE-PEG2000 and DSPE-PEG2000. 
 
π – A isotherms have been used as a simple yet efficient tool to characterize and 
understand the phase and conformational transitions in PEG-grafted phospholipid 
monolayers [Baekmark 1995; El-Khouri 2011; Lozano 2009a; Nunes 2011; Naumann 
2001; Shahid 2011; Tanwir 2008; Tanwir 2012; Vermette 2003; Zhao 2002]. The 
isotherms of PEG-phospholipids, DPPE-PEG2000 and DSPE-PEG2000, on PBS at 20 
○
C 
are presented in Figure 3.1. The lift-off (the area per molecule wherein the neighboring 
phospholipid molecules start to interact with each other) in DPPE-PEG2000 and DSPE-
PEG2000 isotherms was observed at ~17 nm
2
/molecule. Both isotherms exhibit a 
pseudoplateau with a midpoint at ~12 mN/m. This region corresponds to the 
conformational transition in the grafted PEG2000 chains, πt,PEG [Shahid 2011]. The 
plateau is described as a conformational transition from pancake to pseudobrush in the 
polymeric moiety [Tsoukanova, 2008, Arhens, 2000]. A second change in the slope is 
also observed in the isotherms at high surface pressures and will be referred to as a high-
pressure transition, πt,high. DPPE-PEG2000 isotherm exhibits the second change in slope, 
πt,high, with a midpoint at ~42 mN/m (solid curve in Figure 3.1A). The high-pressure 
transition in DSPE-PEG2000 might be occurring at ~26 mN/m but does not appear to be 
very prominent in the isotherm (solid curve in Figure 3.1B). Lateral compressibility 
analysis can be very helpful in detecting even a slight change in the isotherm [Baekmark 
1995; Naumann 2001; Shahid 2011; Tanwir 2012]. Hence, the π – A isotherms of DPPE-
PEG2000 and DSPE-PEG2000 monolayers were analyzed in terms of lateral area 
compressibility, C, to better identify such transitions [Baekmark 1995; Gaines 1966; 
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Lozano 2009a; Naumann 2001; Shahid 2011; Tanwir 2012; Yu 2002]. The insets present 
in Figure 3.1 show the lateral compressibility plot with respect to surface pressure, which 
is obtained by numerical differentiation of π – A isotherm values using the equation 
shown below 
 
                                           
T
p
A
A
C 






 1      3.1 
 
The C – π plot for DSPE-PEG2000 at 20 oC indeed shows a peak at ~26 mN/m which can 
be referred to as a high-pressure transition, πt,high (solid curve in inset of Figure 3.1B) 
[Baekmark 1995; Naumann 2001; Shahid 2011; Tanwir 2012].  
 
 
 
  
 
 
 
 
 
 
 
 
 
71 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
Figure 3.1. π – A isotherms of (A) DPPE-PEG2000 and (B) DSPE-PEG2000 on PBS at 
20 ° C (solid curve). Insets display the C – π plots obtained using numerical 
differentiation of the π – A isotherms. Red arrows display the peaks in the C – π plots 
corresponding to the conformational transition of PEG2000, πt,PEG and the high-pressure 
transition, πt,high. The πt,PEG and πt,high values determined from the C – π plots are also 
indicated on the π – A isotherms as red dotted lines. 
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3.1.2. Fluorescent Probes for PEG-Phospholipids. 
 
DSPE-PEG2000-FITC is commercially available and has been used as a fluorescent 
probe for DSPE-PEG2000 previously [Borden 2006; Kinsinger 2010; Tanwir 2008]. The 
fluorescent probe for DPPE-PEG2000, DPPE-PEG2000-FITC, was synthesized in our 
lab to examine the lateral distribution of PEG-phospholipid in the phosphocholine matrix. 
The synthesis was performed by reacting dipalmitoylphosphatidylethanolamine (DPPE) 
with an excess of NHS-PEG2000-Boc but with little modifications in the procedure from 
the previously reported data [Mattson 1993; Miura 2006]. An N-hydroxysuccinimidyl 
(NHS) is an ester activated group to react with the amino group of DPPE whereas Boc is 
a protective group for an amino group of PEG, which was removed to label the distal end 
of the PEG chain with the FITC fluorophore [Mattson 1993; Miura 2006]. First, DPPE 
(42 mg, 0.06 mmol) was dissolved in 3 ml of chloroform containing 15% of methanol by 
heating for 30 min at ~30 °C. Further, 20 μL of basic medium, Triethylamine, and NHS-
PEG2000-Boc (148 mg, 0.074 mmol) in 2 ml of dichloromethane were added [Miura 
2006; Slaughter 2007; Sorgi 2001]. The reaction mixture was stirred for 4 h at 60 °C and 
then left overnight at 30 °C. Afterwards, 2 mL of Trifluoroacetic acid (TFA) was added 
to the reaction mixture at ~4 °C to remove the protecting Boc group [Miura 2006; Martin 
1994]. The solution was stirred for 30 min and then the mixture was extracted into 
chloroform. The excess solvent was removed under reduced pressure, and the crude was 
precipitated into cold diethyl ether [Miura 2006; Sukhishvili 2002]. The crude product 
was further washed with ether to remove the excess unbound NHS-PEG2000-Boc 
[Sukhishvili 2002]. After drying in vacuum, a PEG-phospholipid conjugate, DPPE-
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PEG2000-NH2, was obtained as a white solid with a mass of 118 mg and a yield of 69%. 
Peaks in 
1
H NMR (CD2Cl2, 600 MHz, δ ppm) are categorized as; 0.85 (t, 6H, –CH3), 1.23 
(br, 56H, –CH2–), 3.65 (br, 218H, PEG). MS (C128H58N3O54P, turbo spray, positive): M + 
H
+
 = 2749.8 g/mol. To label PEG-lipid with fluorescent probe (FITC), DPPE-PEG2000-
NH2 (20 mg, 0.007 mmol) was dissolved in 1 mL of dicholormethane and reacted with 
0.5 mL of ethanol solution containing FITC (3 mg, 0.008 mmol) [Miura 2006]. The 
reaction mixture was stirred overnight at ~40 °C. DPPE-PEG2000-FITC mixture was 
then precipitated into cold diethyl ether. The precipitate was washed with ether to remove 
any unbound FITC [Sukhishvili 2002]. After drying in vacuum, a yellow-orange solid (16 
mg, yield 83%) was obtained. The product was used without further purification in our 
imaging study.  
 
 To test the properties of DPPE-PEG2000-FITC as a probe for DPPE-PEG2000, 
the π – A isotherm was recorded. The isotherm of DPPE-PEG2000-FITC appeared 
virtually identical to that of DPPE-PEG2000 (data not shown). This implies that FITC 
fluorophore attached to the PEG2000 chain is not likely to affect the intermolecular 
interactions and conformational behavior of PEG-phospholipid molecules to any 
significant extent. To verify the miscibility, mixtures of DPPE-PEG2000 and DSPE-
PEG2000 containing 1 mol% of their fluorescent probes were also prepared and imaged 
using EFM (data not shown). EFM imaging displayed uniform fluorescent monolayers 
without any artifacts thus confirming their ideal miscibility. Hence, DPPE-PEG2000-
FITC and DSPE-PEG2000-FITC fluorescent probes can be used to investigate the phase 
state properties of membrane models. 
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3.1.3. Surface Pressure – Area (π – A) Isotherms of DPPC and DSPC. 
 
 The π – A isotherm of DPPC on PBS at 20 oC is demonstrated in Figure 3.2A. The 
lift-off of the DPPC isotherm is observed at ~1 nm
2
/molecule as can be seen by the black 
curve in Figure 3.2A. The plateau depicting the LE – LC transition of DPPC 
phospholipids develops at about 5 mN/m, which appears as a peak in C – π plot in the 
figure inset. The monolayer of DPPC collapses at ~52 mN/m. The data is in good 
agreement with the reported literature values [Albrecht 1978; Chou 2000; Discher 1999; 
Kinsinger 2010; Luna 2011; Yu 2002]. 
 
 Figure 3.2B shows the isotherm of DSPC on PBS at 20 °C. DSPC forms a 
condensed type monolayer, as can be seen from the figure. The isotherm lift-off was 
observed at ~0.65 nm
2
/molecule followed by a steep rise in surface pressure until the 
monolayer collapsed at A ~0.4 nm
2
/molecule and π ~58 mN/m, which is in good 
agreement with literature [Chou 2002; Chou 2003; Tanwir 2008]. The inset in Figure 
3.2B displays the compressibility plot of DSPC. The DSPC C – π plot does not exhibit 
any LE-LC transition peak, as compared to the one seen in DPPC compressibility plot 
(Figure 3.2B).    
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Figure 3.2. π – A isotherms of (A) DPPC and (B) DSPC on PBS at 20 °C. Insets display 
the C – π plots obtained using numerical differentiation of the π – A isotherms. Peaks in 
the C – π plots correspond to the LE – LC transition of DPPC, πt,DPPC.  
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3.1.4. π – A Isotherms of Mixed DPPC/DPPE-PEG2000 Monolayers on PBS at 20 
o
C. 
 
 
Figure 3.3 shows the π – A isotherms of mixed DPPC/DPPE-PEG2000, C16/C16-
PEG2000, monolayers containing 1 – 9 mol % PEG2000-phospholid on PBS subphase. 
As seen in the figure, the isotherms of mixed DPPC/DPPE-PEG2000 monolayers show 
features of both components at 20
 o
C. The plateau depicting the LE – LC transition of 
DPPC phospholipids develops at about 5 mN/m. This data is in good agreement with  
reported literature values [Albrecht 1978; Chou 2000; Discher 1999; Kinsinger 2010; 
Luna 2011; Yu 2002]. The isotherms shifted to the right towards more expanded phase 
with increasing PEG2000-phospholipid content in the mixed monolayers. The effect of 
PEG2000 content in the low-compressibility region, however, disappears since all the 
mixed monolayers almost converge very close to each other. The collapse pressure of all 
DPPC/DPPE-PEG2000 mixtures is observed at ~52mN/m. It is also observed that with 
increasing PEG content, the LE – LC transition plateau in the isotherms becomes less 
noticeable. To substantiate this trend, the isotherms of DPPC/DPPE-PEG2000 mixtures 
were further analyzed in terms of lateral area compressibility, C – π, format (inset of 
Figure 3.3). As seen in the figures, the C – π plots predominantly exhibit two peaks. One 
of the peaks aligns well with peak in DPPC monolayers’ C – π plots (green dotted curve 
in Figure 3.3). This peak can be attributed to the LE – LC phase transition, which is 
associated with the ordering of DPPC aliphatic chains in all-trans conformation [Albrecht 
1978]. The second peak, however, appears in the range of surface pressures that 
corresponds to the πt,PEG in the compressibility plots of PEG-phospholipids (red dotted 
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curve in inset of Figure 3.3). Thus, the second peak seen in the C – π plots of binary 
mixtures can be attributed to the conformational transition in the grafted polymer chains.  
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Figure 3.3.: π – A isotherms of DPPC and DPPE-PEG2000 binary mixtures containing 1, 
3, 6, and 9 mol % PEG2000-phospholipid spread on PBS subphase at 20 
o
C. Insets show 
the C – π plots obtained by numerical differentiation of the π – A isotherms. Green curves 
represent DPPC alone, whereas red curve is for DPPE-PEG2000. Peaks in the C – π plots 
correspond to DPPC LE – LC phase transition, πt,DPPC, whereas the PEG2000 
conformational transition, πt,PEG. Both transitions, πt,DPPC and πt,PEG, are also highlighted 
by corresponding color dotted lines in the isotherms.  
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3.1.5. Surface Pressure (π – A) Isotherms of Mixed DSPC/DSPE-PEG2000 
Monolayers on PBS at 20 
o
C. 
 
The π – A isotherms of mixed DSPC/DSPE-PEG2000, C18/C18-PEG2000, 
monolayers containing 1 – 9 mol % of the PEG2000-phospholid on the PBS subphase at 
20 
o
C are demonstrated in Figure 3.4. As presented in the figure, all isotherms show three 
major regimes: (i) an expanded region below ~8 mN/m, (ii) a pseudo-plateau between 9 – 
18 mN/m, and (iii) a low-compressibility region above ~20 mN/m. The isotherms shifted 
to the right into more expanded phase with increased mean molecular area upon 
increasing PEG2000-phospholipid content in the mixed monolayers. The effect of 
PEG2000 content in the low-compressibility region, however, disappears since all the 
mixed monolayers almost converge very close to each other. The collapse pressure of the 
binary mixtures increased from ~60 mN/m at 1 mol% PEG2000-phospholipid in the host 
DSPC monolayer to ~67 mN/m at 9 mol %.  
 
All the binary mixtures containing DSPC overall show condensed type isotherms 
as opposed to the ones of DPPC (cf. isotherms in Figures 3.3, 3.4). Indeed, this behavior 
correlates well with the properties of DSPC matrix. DSPC bears C18 aliphatic chains and 
predominantly forms the LC (Lβ’) phase [Ducharme 1990; Petriat 2004; Stepniewski 
2011; Suzuki 1985; Tanwir 2008; Tenchov 2001]. Thus, the transitions seen in the 
isotherms of DSPC and PEG2000 binary mixtures are mainly associated with the PEG-
phospholipids (Figure 3.4). The C – π plots in the insets of Figure 3.4 yield better 
understanding about the transitions. The peaks in the C – π plots of binary mixtures 
appear in the same range of surface pressures corresponding to the conformational 
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transitions of PEG (πt, PEG) and the high-pressure transition (πt,high) seen in the isotherms 
of pure PEG-phospholipids (cf. Figure 3.1 and 3.4). Interestingly, the πt,high peak is only 
observed in the DSPC/DSPE-PEG2000 mixture containing 9 mol% PEG2000. Hence, the 
miscibility of all the binary mixtures was further investigated at 20 °C in order to obtain 
clear results about the mixing behavior of all binary mixtures. 
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Figure 3.4.: π – A isotherms of DSPC and DSPE-PEG2000 binary mixtures containing 1, 
3, 6, and 9 mol % PEG2000-phospholipid spread on PBS subphase at 20 
o
C. Insets show 
the C – π plots obtained by numerical differentiation of the π – A isotherms. 
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3.1.6. Miscibility in Phosphocholine and PEG-Phospholipids Mixtures. 
 
Miscibility between the matrix phosphocholine and PEG-phospholipids was 
assessed by analyzing the π – A isotherms in terms of excess area, Aexc, of the mixture 
[Chou 2002; Chou 2003; Shahid 2011; Tanwir 2008]. As described in the literature, if the 
matrix phosphocholine and PEG-phospholipids behave immiscibly or form a complete 
ideal binary mixture, the mean molecular area, Aid/im, of the mixed monolayers should 
then be the sum of areas of separated individual components [Chou 2002; Chou 2003; 
Shahid 2011; Tanwir 2008].Thus, the relation between the Aid/im, and mol fractions of the 
individual components, at any given surface pressure, should obey the equation below 
 
              idphospholipPEGidphospholipPEGPCPCimid AAA  /                        3.2 
 
In equation 3.2, χPC and χPEG-phospholipid are the mol fractions of components and APC and 
APEG-phospholipid represent the molecular areas of each component in their pure monolayers 
at the same surface pressure [Chou 2002; Chou 2003; Gaines 1966; Tanwir 2008]. 
However, if the binary mixtures do not obey equation above, then any deviation from the 
rule can be quantitatively defined as Aexc using equation 
 
)(
/ idphospholipPEGidphospholipPEGPCPCimidexc
AAAAAA

                3.3 
 
where A is the mean molecular area in the π – A isotherms at any given surfaces pressure. 
By definition, if the two components are completely immiscible or form an ideal mixture 
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then the Aexc would be zero, whereas any deviation from zero, either negative or positive, 
would indicate the nonideal miscibility in the mixed monolayers. Immiscible mixture 
refers to a mixture where both components do not mix with each other and stay 
heterogeneous. In this case, the monolayer of two immiscible components will exhibit the 
properties of two separate individual component monolayers [Gaines 1966].  Miscible 
mixture refers to a mixture where both components mix homogeneously. However, 
miscible mixtures can behave ideally or non-ideally. The term ideal mixture is used 
where the interaction between two different components is similar to the interactions 
between identical molecules. In contrast, non-ideal mixture has dissimilar interactions 
between both components of the mixture and would be observed as two different phases 
in the monolayer [Luna 2011]. The Aexc calculations in this study were performed 
between 15 – 35 mN/m, which is relevant to the lateral pressures of a typical membrane, 
as estimated in the literature [Lozano 2009a; Konttila1988]. The values for Aexc 
calculated for all the binary mixtures are summarized in Tables 3.1 and 3.2. As can be 
seen, most of the Aexc values are negative suggesting a nonideal miscibility in the 
mixtures. The negative deviations of Aexc seem to be more pronounced with an increase in 
surface pressure and PEG content in all the binary mixtures. 
  
Another supportive argument for the nonideal miscibility in the mixtures arises 
from the surface phase rule. According to the rule, if two components are miscible then 
the mixed monolayer collapse point will vary based on the composition [Chou 2002; 
Chou 2003; Gaines 1966; Tanwir 2008]. Conversely, if two components are immiscible, 
then the monolayers will have two different collapse points, each at their own surface 
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pressures, regardless the composition [Chou 2002; Chou 2003; Gaines 1966; Tanwir 
2008]. As can be seen in Figures 3.3 and 3.4, the collapse pressures of all mixtures 
changed with an increase in PEG content from 1 mol% to 9 mol%. This change in 
collapse point clearly indicates a nonideal mixing for most of the phosphocholine and 
PEG-phospholipid mixtures. Although miscibility analysis clearly points towards the 
nonideal mixing behavior in the mixed monolayers but “immiscible mixed phases” of 
different compositions may coexist in the mixtures [Baekmark 1995; Tanwir 2008]. 
Hence, EFM imaging of the binary mixtures was performed to further investigate the 
mixing behavior of phosphocholine and PEG-phospholipids on PBS at 20 °C. 
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 Table 3.1. 
 
Excess Area, Aexc, Calculated for Binary Mixtures of DPPC/DPPE-PEG2000 at 20 
o
C. 
 
       Aexc, nm
2
 
 
π, mN/m           1 mol% PEG      3 mol% PEG      6 mol%      9 mol% PEG  
 
                                                  
    15         -0.03  -0.06  -0.09  -0.10 
    25         -0.02  -0.06  -0.09  -0.10 
    35         -0.02  -0.04  -0.08  -0.12 
 
Each value of Aexc calculated is an average of three isotherm measurements. Standard 
deviations calculated for Aexc are based on a series of three measurements are within ± 
0.01 nm
2
.  
 
 
 
Table 3.2.  
 
Excess Area, Aexc, Calculated for Binary Mixtures of DSPC/DSPE-PEG2000 at 20 
o
C. 
 
       Aexc, nm
2
 
 
π, mN/m           1 mol% PEG      3 mol% PEG      6 mol%      9 mol% PEG 
                                                    
 
    15          0.03  -0.03  -0.05  -0.08 
    25          0.02  -0.02  -0.04  -0.06 
    35          0.02  -0.01  -0.03  -0.04 
 
Each value of Aexc calculated is an average of three isotherm measurements. Standard 
deviations calculated for Aexc are based on a series of three measurements and within ± 
0.01 nm
2
.  
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3.1.7. EFM Imaging of DPPC and DPPE-PEG2000 Mixtures.  
 
 The coexistence of phospholipid phases and formation of liquid condensed (LC) 
phase in DPPC/DPPE-PEG2000 binary mixtures was visualized by introducing DOPE-
Rh as a fluorescent probe. DOPE-Rh, like many other dyes, is known to possess high 
affinity towards LE phase due to its unsaturated aliphatic chains [Sezgin 2012; Shahid 
2011; Tsoukanova 2008]. Thus, the red stain of DOPE-Rh chromophore in the TRITC 
channel indicated the LE phase while the dark background represented the LC phase of 
the mixtures. Conversely, the lateral distribution of PEG in the phosphocholine matrix 
was monitored using the FITC channel by detecting the fluorescence from DPPE-
PEG2000-FITC, which bears a fluorescein fluorophore at the distal end of the PEG2000 
chain. The green stain of FITC fluorophore in the FITC channel corresponds to the areas 
where PEG-phospholipid molecules were present [Borden 2006; Kinsinger 2010; Tanwir 
2008].  
 
 The EFM imaging was performed throughout the monolayer compression. 
Monolayers of type (i) containing DOPE-Rh probe and (ii) containing FITC labelled 
PEG-phospholipid showed the same imaging sequence as the monolayers of type (iii) 
containing both probes using two channel EFM. The two channel imaging, thus, did not 
produce any artifacts. Hence, for the clarity of discussion, this study will only include 
results obtained by two channel EFM imaging. The EFM images shown in the present 
study is limited to the typical range of membrane pressures as discussed above, which is 
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15 – 35 mN/m. The images obtained through FITC and TRITC channel are displayed 
from the same patch of the monolayer for a better comparison, whenever possible.  
 
 Figure 3.5 displays the LE/LC phases and lateral distribution of DPPE-PEG2000-
FITC in DPPC matrix at 15, 25, and 35 mN/m. The binary mixtures of DPPC/DPPE-
PEG2000 showed dark domains that began nucleating above π ~4 mN/m (images not 
shown). At about 15 mN/m, both TRITC and FITC images displayed a great proportion 
of dark domains for the mixed DPPC/DPPE-PEG2000 monolayers (Figure 3.5). In the 
low-compressibility region, the TRITC channel showed the fusion of dark domains for 
DPPC/DPPE-PEG2000 mixtures (image B1 and C1 in Figure 3.5) and then all the 
mixtures converted to a continuous dark LC phase with very small fluorescent spots of 
DOPE-Rh chromophore at π above 35 mN/m (images not shown). Conversely, FITC 
channel had a somewhat different sequence as compared to the TRITC channel. The 
green stained areas, containing DPPE-PEG2000-FITC, started to expand above 20 
mN/m, as shown in images B2 and C2 in Figure 3.5. Moreover, the DPPE-PEG2000-
FITC excluded domains were observed in the FITC channel but getting significantly 
smaller above 35 mN/m (images not shown).  
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Figure 3.5: Epifluorescence microscopy images of mixed DPPC/DPPE-PEG2000 
monolayers containing 3 mol% PEG2000 content at 15, 25, and 35 mN/m, at 20 
o
C. Red 
Fluorescent background represents LE phase and dark domains show the LC phase 
whereas green fluorescent in the images show the distribution of PEG containing DSPE-
PEG2000FITC and dark domains represent the PEG-FITC excluded domains. Image size 
is 250 × 250 μm2. Based on our study [Tanwir et. al. 2012]. 
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3.1.8. EFM Imaging of Binary Mixtures of DSPC and DSPE-PEG2000.  
 
In the TRITC images, the binary mixtures containing DSPC as matrix 
phospholipids exhibited more dark LC phase as compared to the DPPC mixtures at 20 
°C.  The dark circular LC phase domains in the fluorescent background began to nucleate 
at ~4 mN/m for DSPC/DSPE-PEG2000 mixtures. Most of the binary mixtures of DSPC 
DSPC-PEG2000 converted into a continuous dark LC phase above 15 mN/m, as seen in 
the images in Figure 3.6. Moreover, the size of LC phase domains in DSPC mixtures 
appeared smaller than those in DPPC mixtures. As seen in the FITC images, the domain 
boundaries started to “melt” continually in the DSPC/DSPE-PEG2000 mixtures and the 
monolayer morphology changed to a single homogeneous fluorescent phase upon 
compression (cf. images A2, B2 and C2 in Figure 3.6). The surface pressure at which the 
morphology changed varied depending on the PEG2000-phospholipid concentration in 
the mixtures. A single homogeneous florescent phase was achieved for 1 mol % at ~ 48 
mN/m and for 9 mol % at ~ 13 mN/m. Surprisingly, mixed monolayers containing 6 and 
9 mol % PEG2000-FITC had few irregular shaped fluorescent DSPE-PEG2000FTC-rich 
domain that appeared in the low-compressibility region at π above 30 mN/m (images not 
shown). These irregular shaped domains were not observed in other type of mixed 
monolayers at 20 
o
C.  
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Figure 3.6.: Epifluorescence microscopy images of mixed DSPC/DSPE-PEG2000 
monolayers containing 6 mol% PEG2000 content at 15, 25, and 35 mN/m, at 20 
o
C. 
Image parameters are as same as in Figure 3.7. Image size is 250 × 250 μm2. Based on 
our study [Tanwir et. al. 2012]. 
 
 
 
 
 
 
 
 
 
 
 
B1: 25 mN/m 
C1: 35 mN/m C2: 35 mN/m 
B2: 25 mN/m 
A1: 15 mN/m A2: 15 mN/m 
TRITC channel 
(LE and LC phase) 
FITC channel 
(PEG distribution) 
T = 20 C 
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3.2. DISCUSSION. 
 
 The mixing behavior of phosphocholine matrix with PEG2000-grafted 
phospholipids has been studied extensively at different temperatures at air/water interface 
[Borden 2006; Heeb 2009; Lozano 2009]. The main goal of this study was to analyze the 
effect of PEG content on the morphology and phase behavior of phosphocholine 
membrane on air/PBS interface. By analyzing the π – A isotherms at 20 oC, it can be 
elucidated that PEG has a profound impact on the binary mixtures of phosphocholine and 
PEG-phospholipid. This can be seen from the development of a pseudo-plateau at ~10 
mN/m, which was broadened upon increasing PEG2000 content in the mixtures. This 
pseudo-plateau is considered as a unique property of the conformational transition in 
grafted PEG chains (πt,PEG) and usually termed as a change from pancake to pseudo-3D 
conformation. The latter has been described in the literature as a mushroom, a cigar, and 
a brush conformation [Backmann 2010; Baekmark 1995; El-Khouri 2011; Kinsinger 
2010; Luna 2011; Majewski 1998; Naumann 2001; Vermette 2003; Zhao 2002]. At low 
surface grafting density, PEG chains form a pancake like structure by spreading on the 
surface and do not interact with each other [Baekmark 1995]. With increasing the surface 
grafting density, PEG chains begin to form mushroom structure with coil dimension to 
avoid interactions with each other [Backmann 2010; Baekmark 1995; Kato 2003]. Upon 
further increase in the grafting density, PEG chains are forced to stretch away from the 
surface by forming elongated brushes to avoid overlapping and in turns play a key role in 
optimal protein repellence [Backmann 2010; Baekmark 1995; Dhruv 2009; Kato 2003; 
Zhao 2000]. These terms mainly apply to the PEG conformation at the air/water 
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interface. However, we are not presenting any experimental data in this report that could 
enable us to conclude about the most adequate model in describing conformation of the 
PEG2000 chains in the binary mixtures of phosphocholine and PEG-phospholipids. Thus, 
the term “pseudo-3D conformation” will be used throughout this study to refer to the 
PEG conformation adopted upon the transition at π ~ 10 mN/m. This simply suggests that 
grafted PEG chains largely squeeze out of the phospholipid headgroup region and extend 
away from the membrane during its conformational transition [Baekmark 1995; 
Majewski 1998; Naumann 1999; Naumann 2001; Shahid 2011; Stepniewski 2011; 
Tanwir 2008; Vermette 2003; Zhao 2002]. As can be seen from the upper limit of the 
πt,PEG peak in the compressibility plots, the conformational transition is almost completed 
around 20 mN/m (insets of Figures  3.1, 3.3 and 3.4). Therefore, it is believed that the 
grafted PEG2000 chains are likely in the pseudo-3D conformation in a surface pressure 
range of 15 – 35 mN/m, which is relevant to the membrane lateral pressures. 
 
Based on the DSPC/DSPE-PEG2000 mixtures at 20 °C, it can be suggested that 
excluded volume interactions between PEG2000 chains in the pseudo-3D conformation 
might force the PEG-phospholipid molecules to distribute uniformly throughout the 
membrane at higher PEG grafting densities [Tanwir 2008]. Indeed, these mixtures form a 
continuous LC phase with homogeneous distribution of DSPE-PEG2000 with increase in 
pressures and PEG contents (images C1 and C2 in Figure 3.6). Interestingly, previous 
studies on DSPC/DSPE-PEG2000 mixtures have also reported the coexistence of 
immiscible phases over a temperature range of 25 – 55 °C [Bedu-Addo 1996; Borden 
2006]. Moreover, Borden et al. have reported an increase in the phase separation in 
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DSPC/DSPE-PEG2000 mixtures with increasing PEG content at 25 – 55 °C [Borden 
2006]. However, this conclusion completely contradicts the trend observed at 20 °C 
[Tanwir 2008; Kinsinger 2010]. This signifies towards a great need to develop a more 
comprehensive understanding of the phase behavior of PEGylated phosphocholine 
membranes and construct phase diagrams. The first step to construct such diagrams is to 
identify the coexisting phases. This is usually done by a comparative analysis of π – A 
isotherms and EFM images obtained with a single fluorescent probe to stain the LE phase 
[Lozano 2009a; Shahid 2011]. In this study, the lateral distribution of PEG was also 
determined by using an additional fluorescent probe (DPPE-PEG2000-FITC or DSPE-
PEG2000-FITC) in EFM imaging. This has allowed us locating the PEG-phospholipid 
molecules in the coexisting phases of the mixtures. Using this unique approach, we have 
found a more complex and intricate behavior of PEGylated phosphocholine membranes 
than previously comprehended. Hence, our major goal will be to identify all possible 
coexisting phases in the model PEGylated phosphocholine membranes. 
 
 The mixing behavior, phase state, and morphology of phosphocholine and PEG-
phospholipid mixtures with different aliphatic chain length have also been studied in this 
project. These mixtures include DPPC/DSPE-PEG2000 (C16/C18) and DSPC/DPPE-
PEG2000 (C18/C16). The π – A isotherms of binary mixtures bearing different aliphatic 
chain length (data not shown) appeared similar to those of mixtures bearing same 
aliphatic chain length. Some differences were observed in the morphology of 
DPPC/DSPE-PEG2000 mixtures as compared to DPPC/DPPE-PEG2000 mixtures as 
well as between the mixtures of DSPC/DPPE-PEG2000 and DSPC/DSPE-PEG2000 at 
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higher surface pressures (images not shown). However, this surface pressure range does 
not lie in the typical range of membrane surface (lateral) pressure. Hence, for the clarity 
of discussion, the results of DPPC/DSPE-PEG2000 and DSPC/DPPE-PEG2000 mixtures 
containing 1, 3, 6, and 9 mol% PEG will not be included in this report.  
 
3.2.1. Coexisting Phases in Phosphocholine and PEG-Phospholipids Binary 
Mixtures.  
 
The comparative analysis of EFM images obtained through TRITC and FITC 
channels has revealed several phases in the phosphocholine and PEG-phospholipid binary 
mixtures. Schematic diagrams depicting the coexisting phases in the binary mixtures are 
shown in Figure 3.7. These diagrams are constructed by superimposing the red and green 
fluorescent backgrounds seen in both TRITC and FITC channels.  
 
EFM images of some of the binary mixtures at 20 °C often show the coexistence 
of two phases, where dark domains are present in a fluorescent background (Figures 3.6). 
Dark domains in the TRITC channel correspond to the LC phase of the phosphocholine 
matrix, LCPC, which is nucleating out of the fluorescent background (LEmix phase) 
[Baekmark 1995; El-Khouri 2011; Lozano 2009; Shahid 2011]. PEG-phospholipid 
molecules usually tend to reside outside the LC phase domains and this correlates well 
with the identical patterning of fluorescence observed in both TRITC and FITC images 
(cf. images A1 and A2 Figure 3.6). Hence, Figure 3.7A shows a coexistence of two 
phases displaying an identical non-homogeneous fluorescence in both images and can be 
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inferred as two immiscible phases: one refers to as LC phase of the DSPC matrix and the 
second one as a mixed LE phase containing both LCPC and LEmix.   
 
Interestingly, binary mixtures of DPPC/DPPE-PEG2000 at 20 °C exhibit a 
somewhat more complex type of coexistence phase. For instance, the binary mixtures of 
DPPC/DPPE-PEG2000 images at π ~ 15 mN/m show identical fluorescence patterns of 
typical LCPC + LEmix phase coexistence in both TRITC and FITC channel (cf. images A1 
and A2 in Figure 3.5). However, the fluorescent patterning in TRITC and FITC start to 
differ at higher surface pressures. The FITC images exhibit more fluorescent staining 
with respect to the TRITC images (cf. images C1 and C2 in Figure 3.5). This is 
suggestive of the infiltration of DPPE-PEG2000 molecules into the LC phase domains of 
DPPC, yet only at a minute level. Thus, it can be inferred that the coexistence phase that 
depicts a non-homogeneous fluorescence along with the non-identical patterning in both 
TRITC and FITC channel comprise of three phases LEmix + LCPC + LCmix (Figure 3.7B). 
LEmix phase is rich in the PEG-phospholipid, the LCPC phase includes only 
phosphocholine LC phase, while mixed LC phase, LCmix, is considered to be rich in both 
the phosphocholine and PEG-phospholipid molecules. 
 
It has been seen that DPPC/DPPE-PEG2000 mixtures eventually form a 
continuous LC phase at higher pressures well above the membrane pressure range. These 
mixtures show an almost complete dark field in the TRITC images but still show DPPE-
PEG2000-FITC excluded domains in the FITC images (images not shown). This type of 
pattern refers to a non-uniform distribution of PEG chains throughout the LC DPPC 
96 
 
matrix [Tanwir 2008]. Thus, DPPC/DPPE-PEG2000 mixtures at higher pressures contain 
two phases in the LC state: (i) LCPC phase and (ii) a mixed LC phase, LCmix as sketched 
in Figure 3.7C. 
 
Binary mixtures of DSPC/DSPE-PEG2000 have shown a remarkable 
homogeneous mixing of the two components in the LC state at 20 
o
C. This can be seen in 
the images in Figure 3.6 that features a “miscibility transition” at intermediate pressures. 
Indeed, TRITC image in B1 of Figure 3.6 exhibits two phases, LE and LC, whereas the 
FITC image in B2 of Figure 3.6 display a uniform fluorescence field. This observation 
points towards an almost homogeneous distribution of DSPE-PEG2000 molecules 
between these phases. This suggests that both phases are mixed phases and can be 
recognized as the LEmix + LCmix coexistence phase (Figure 3.7D). Furthermore, the dark 
field seen in TRITC image C1 in Figure 3.6, at higher pressures, corresponds to the 
formation of a continuous LC phase whereas, FITC image C2 in Figure 3.6 displays a 
uniform distribution of DSPE-PEG2000-FITC molecules. Therefore, this phase refers to 
as a single mixed LC phase, LCmix, and is schematically shown in Figure 3.7E. 
 
 The phases identified in our model study correlate well with the literature data for 
PEGylated phosphocholine membranes [Bedu-Addo 1996; Borden 2006; Kenworthy 
1995; Pu 2005; Tanwir 2008]. However, a direct comparison is not always possible due 
to a limited literature data for PEGylated phosphocholine model membranes. For 
instance, a study by Kenworthy et al. has reported a single Lβ’ phase for the DSPC/DSPE-
PEG2000 bilayer membranes, at low PEG grafting densities [Kenworthy 1995]. On the 
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other hand, Bedu-Addo et al. reports on the coexistence of two immiscible phases, Ld and 
Lβ’ for membranes of liposomal drug carriers [Bedu-Addo 1996]. This coexistence phase 
resembles the LCPC + LEmix phase depicted in Figure 3.7A in the present study. The 
presence of two immiscible (Ld and Lβ’) phases as well as three phase coexistence has 
also been reported in phospholipid-coated microbubble membranes for implications in 
diagnostic agent delivery [Borden 2006; Pu 2005].  
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Figure 3.7: Schematic diagrams depicting the coexistence phases in the binary mixtures 
of phosphocholine and PEG-phospholipids. (A) the coexistence of two immiscible 
phases, LEmix + LCPC, (B) three phase coexistence, LEmix + LCPC + LCmix, (C) 
coexistence of two immiscible LC phases, LCPC + LCmix, (D) the coexistence of two 
immiscible mixed phases, LEmix + LCmix, (E) the mixed LC phase, LCmix. 
Phosphocholine and PEG-phospholipid molecules are drawn with black and green 
headgroups. Red and green fluorescent areas show fluorescence staining observed in 
TRITC and FITC channel, respectively. The diagrams are based on our study [Tanwir et. 
al. 2012]. 
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3.2.2. Phase Diagrams of Phosphocholine and PEG-Phospholipid Binary Mixtures. 
 
To better demonstrate the phase behavior of phosphocholine and PEG-
phospholipid binary mixtures, phase diagrams are constructed over a wide range of 
surface pressures using π – A isotherms and EFM image analysis (Figure 3.8 and 3.9). 
The data in the diagrams are shown for a range of PEG contents of 1 – 9 mol% for the 
clarity of the presentation. In the figures, black curves depict the onset (lower pressures) 
and completion (higher pressures) of the LC phase formation [Lozano 2009]. These 
curves make the upper limit boundary for the LE state, seen as the white area at the 
bottom of the diagram, and also mark the lower limit of the LC phase, which is shown as 
the grey area in the phase diagram (Figure 3.8 and 3.9).  The solid grey line in the 
diagram indicates the collapse point of all the monolayers. The dashed curve in Figure 
3.8 depicts the surface pressures where fluorescence staining in both TRITC and FITC 
images started to diverge. In DSPC/DSPE-PEG2000 mixtures, this trend corresponds to 
the miscibility transition. However, in DPPC/DPPE-PEG2000 mixtures, this curve 
indicates the infiltration of DPPE-PEG2000 molecules into the LCPC domains. The pink 
shaded area represents the two immiscible phases, LEmix and LCPC. The light green area 
either depicts the two immiscible, LEmix + LCmix, or three immiscible phase coexistence, 
LEmix + LCmix + LCPC. The area shaded with grey color depicts the LCmix and LCPC phase 
coexistence whereas a single mixed LC phase, LCmix, is displayed as a green color. The 
PEG-phospholipid conformational transitions are shown as dotted curves using π values 
from the C – π peaks, which correspond to the πt,PEG at ~12 mN/m and πt,high above 20 
mN/m.  
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Phase diagram for DSPC/DSPE-PEG2000 mixtures mainly shows the phase 
coexistence of LEmix + LCPC. For DSPC/DSPE-PEG2000 mixtures, the LEmix + LCPC 
phase coexistence appears at low surface (lateral) pressures but these mixtures begin to 
undergo the miscibility transition. At 3 – 9 mol% PEG, the onset of the miscibility 
transition (dashed curve in Figure 3.9 ) correlates well with the completion of the PEG 
conformational transition (Dotted curve in Figure 3.9). The mixtures eventually form a 
single LCmix phase where the two components mix homogeneously (green area in Figure 
3.9).  
 
Furthermore, as can be seen in the phase diagrams, PEG-phospholipids and 
phosphocholine tend to mix in the LE state as opposed to the LC state. This is in good 
agreement with previous studies [Bedu-Addo 1996; Naumann 2001]. However, a closer 
look at the diagrams in Figure 3.8 and 3.9 reveal a homogeneous mixing of PEG-
phospholipids and phosphocholine in the LC state for some mixtures as well. For 
instance, a unique mixture composition of DSPC/DSPE-PEG2000 containing 3 mol% 
PEG-phospholipid exhibits a single LCmix phase above 20 mN/m (lower π edge of the 
green shaded area in Figure 3.9). The π at which single LCmix phase was achieved in the 
rest of the DSPC/DSPE-PEG2000 mixtures differ, as can be seen in Figure 3.9. 
Identifying such mixture compositions that form a complete LC (Lβ’) state along with a 
homogeneous PEG-phospholipid distribution can be of great importance in various 
biomedical applications including therapeutic delivery systems.  
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 DPPC mixtures also exhibit different coexisting phases in the diagram in Figure 
3.8 shows the most interesting phase diagram of DPPC/DPPE-PEG2000 at 20 °C. The 
diagram shows three different stages throughout the compression. At lower pressures, 
binary mixtures of DPPC/DPPE-PEG2000 exhibits mixed LE phase. At intermediate 
pressures, mixtures display LEmix + LCPC phase due to phase separation which then 
changes to LEmix + LCPC + LCmix due to partial re-mixing. The mixtures eventually 
convert to a LC phase containing two immiscible LCPC + LCmix phases, at higher 
pressures. A direct correlation between the onset of the steep portion of the isotherm 
(corresponds to the closest packing of phospholipid molecules) and the formation of a 
continuous LC phase, LCmix, LCPC, was observed for DPPC/DPPE-PEG2000 mixtures.  
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Figure 3.8: Phase diagrams for the binary mixtures of DPPC/DPPE-PEG2000 on PBS 
subphase at 20 °C. Details of diagram parameters are in the discussion. The diagram is 
based on our study [Tanwir et. al. 2012]. 
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Figure 3.9: Phase diagrams for the binary mixtures of DSPC/DSPE-PEG2000 on PBS 
subphase at 20 °C. Details of diagram parameters are in the discussion. The diagram is 
based on our study [Tanwir et. al. 2012]. 
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3.2.3. Implications in Designing the PEGylated Phosphocholine Membranes. 
 
     The results of the present study, in particular the phase diagrams, suggest an 
intricate interplay between the phase state of the mixtures and factors such as (i) PEG 
content and (ii) aqueous medium. Surface (lateral) pressure is another factor contributing 
towards the phase state of the binary mixtures. Based on the data analysis, several 
observations can be made about the factors influencing the phase behavior of PEGylated 
phosphocholine membranes, as stated below. 
 
3.2.3.1. Effect of PEG Content on the Phase State of Phosphocholine Membranes. 
 
 An increase in PEG content in the phosphocholine membranes shifted both 
liquidus and solidus transitions to considerably high surface (lateral) pressures, as seen in 
the diagrams in Figure 3.8 and 3.9. This suggests that high PEG content introduces more 
disorder in the phosphocholine membranes, which may result in a significant change in 
the phase behavior of the membranes. For instance, DSPC/DSPE-PEG2000 mixtures 
containing 1 mol% PEG mainly exist as the LC (Lβ’) state whereas mixtures containing 
more than 3 mol% PEG have appreciable amount of LE (Ld) phase for the range of 
membrane lateral pressures (Figure 3.9). Similarly, a coexistence of LE (Ld) and LC (L β’) 
phase is suggested for the DPPC/DPPE-PEG2000 mixtures below 3 mol% PEG, but a 
single LE (Ld) phase is noticed for higher PEG densities (Figure 3.8). Moreover, the 
appearance of the phase coexistence (light green area), LEmix + LCmix, as well as a single 
LCmix phase (green area) in the diagram in Figure 3.9 clearly indicates that DSPE-
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PEG2000 becomes uniformly distributed throughout the DSPC matrix upon increasing 
PEG content.  
 
3.2.3.2. Effect of Aqueous Medium on Phase State of Phosphocholine Membranes.  
 
 Aqueous medium, to which membrane is exposed, is also a key factor 
contributing towards the phase behavior of PEGylated phosphocholine membranes. Upon 
comparison with the data available in the literature, it is found that the diagrams obtained 
for the mixtures in Figure 3.9 on PBS subphase differ from the one reported previously 
on water [Lozano 2009]. In particular, the solidus transition in DSPC/DSPE-PEG2000 
mixtures at 20 °C on PBS appear ~15 mN/m higher than those shown on water [Lozano 
2009].  
 
 The above findings may play a pivotal role in understanding the phase state of 
PEGylated phosphocholine membranes in various biomedical applications. However, it is 
noteworthy that there might be a complex interplay between several factors governing the 
phase state of the model membranes. It is very essential to have a fundamental 
knowledge of these factors contributing towards the phase state of the model membranes. 
Therefore, the set of data obtained under identical experimental conditions on PBS may 
offer a new tool for the rational design of PEGylated phosphocholine membranes. This 
may help understanding and controlling the properties of model membranes in aqueous 
media of physiological relevance. 
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3.3. CONCLUSIONS. 
 
 Comprehensive analysis of phosphocholine and PEG-phospholipids binary 
mixtures has given a new insight on the mixing behavior of PEGylated phosphocholine 
membranes on PBS in a range of 1 – 9 mol% PEG. Depending on the composition, both 
homogeneous mixing and completely immiscible phases have been observed in the 
mixtures. For instance, remarkable changes in the phase behavior of DSPC/DSPE-
PEG2000 mixtures have been observed upon increasing PEG content from 1 – 9 mol%. 
DSPC/DSPE-PEG2000 mixture containing 1 mol% PEG predominantly forms 
immiscible LC phase which turns to the coexistence of mixed LE and LC phases in 
mixture containing 9 mol%. In fact, there is a unique mixture composition seen at 3 
mol% PEG, which features a single homogenously mixed phase in the LC state. This 
unique mixture exists is in a very small range of PEG content and hence was not 
identified in previous studies. These findings thus imply that the phase behavior of 
PEGylated phosphocholine membranes may significantly change in response to slight 
changes in composition which can be used for rational design of PEGylated membranes 
mimetic surfaces for various biomedical applications including diagnostic devices, 
exclusion filters for microfluidic devices, as well as nanocarriers for therapeutic and 
diagnostic agents. 
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Chapter 4: Determining the Parameters of Insulin Binding with 
Phosphocholine and PEG-Phospholipids Binary Mixtures. 
 
 
 Understanding the effect of non-specific protein binding on the PEGylated 
membrane mimetic surfaces has been the key interest to the efficiency of numerous 
biomedical applications [Allen 2002; Takmoto 2011; Rahmati 2008; Ratner 2004;  
 Shimanouchi 2014; Zhao 2002]. This chapter is exclusively devoted to gain insight into 
the mechanisms involved in the interactions of small protein, e.g. insulin, with the binary 
mixtures of phosphocholine and PEG-phospholipid. Monolayer has been used as a 
membrane model for this study. The binary mixtures of DPPC/DPPE-PEG2000 and 
DSPC/DSPE-PEG2000 containing 1, 3, and 6 mol% PEG2000 have only been used for 
this study. The conventional monolayer area expansion technique has been utilized for 
insulin monolayer interactions in the PBS subphase at 20 
o
C. The change in mixed 
monolayers induced by insulin has also been investigated upon varying the PEG content. 
The data obtained for DPPC/DPPE-PEG2000 and DSPC/DSPE-PEG2000 has been 
further analyzed in terms of insulin penetration area, Ains, and binding degree, χins. Most 
importantly, the analysis of various factors affecting the degree of insulin binding on the 
monolayers has also been performed. This knowledge can contribute immensely to 
understanding the interactions between small proteins and PEGylated phosphocholine 
membranes. 
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4.1. RESULTS. 
 
4.1.1. Area Expansion Measurements of Monolayers upon Insulin Interactions. 
  
 Area expansion measurements is a unique approach to monitor changes in the 
monolayer induced by proteins e.g. insulin [Hanakam 1996; Seelig 1987]. It’s a simple 
approach that can provide useful quantitative information about penetration area and 
binding degree of insulin in the mixed DPPC/DPPE-PEG2000 and DSPC/DSPE-
PEG2000 monolayers containing 1, 3, and 6 mol% PEG. In this section, the methodology 
as well as the monolayer area expansion measurements upon insulin interaction will be 
described in detail. 
 
4.1.1.1. Methodology for Area Expansion Measurement Studies. 
 
 The effect of insulin interactions on the monolayer mean molecular area was 
examined by area expansion, ∆A, measurements at different surface pressures [Seelig 
1987; Shahid 2013; Hanakem 1996]. At first, the monolayer was prepared by spreading 
the phospholipid binary mixtures of 1, 3, and 6 mol% PEG with appropriate molar ratios 
on the trough and allowed to compress to a preset surface pressure, π, value using the 
barriers. The π was kept constant throughout the experiment using a unique electronic 
feedback device while the trough was thermostated to maintain the desired temperature of 
the subphase. The creep test was also performed since creeps in the monolayers may 
change the area of the monolayer, ∆A, due to conformational rearrangements of the 
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molecules or collapse of the monolayer over the period of time and hence, should be 
examined before/after the area expansion measurements [Gaines 1966; Rahmati 2008]. 
 
 This was done by keeping the monolayer at a preset surface pressure for at least 
20 min without the insulin injection to verify the stability of the monolayer over time. 
The monolayer ∆A of ~3% with respect to time infers monolayer to be stable. Hence, 
after verifying the stability of the monolayer, the insulin with a concentration of ~75 
ng/mL was injected in the subphase underneath the monolayer to monitor the area 
expansion with respect to time. The measurements were usually conducted for a 2 – 6 h 
period. However, this report will only include the data for 2 h experiment time since ∆A 
of the monolayers usually remained unchanged after reaching the steady state. Besides 
the creep test, a reference run for each monolayer was also measured to account for any 
changes in the monolayer resulting from the creep in the monolayer over the 2 h period. 
The reference run was performed, at a preset π value, by recording the ∆A of the 
monolayer for 2 h experiment time without insulin injection. This reference run for each 
monolayer was further used for subtraction to obtain the corrected ∆A – t curves upon 
insulin interactions. Each measurement was performed three times and the difference in 
the ∆A values from a series of measurements lies within 10 – 15%.  
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4.1.1.2. Area Expansion Measurements of Phosphocholine and PEG-Phospholipid 
Binary Mixtures upon Insulin Interactions. 
 
 The mixed phosphocholine and PEG-phospholipid monolayers area expansion 
measurements upon insulin interactions were performed for a surface pressure range 
between 13 – 17 m/Nm with a surface pressure increment of 2 mN/m because the area 
expansion measurements above this range did not detect significant changes in the mean 
molecular area upon insulin interactions (data not shown). The area expansion for each 
mixed phosphocholine and PEG-phospholipid monolayer upon insulin injection was 
monitored over time shown as ∆A – t curve in Figure 4.1. Each measurement was 
repeated three times at each surface pressure. All three curves were then averaged as the 
one shown in Figure 4.1 for binary mixture of DPPC and DPPE-PEG2000 containing 1 
mol% PEG at π ≈15 mN/m. The reference run for each individual mixed monolayer was 
also measured to obtain the actual change in area, ∆A, upon insulin interactions as the 
one shown in Figure 4.1. The averaged and subtracted ∆A – t curves for all mixed 
DPPC/DPPE-PEG2000 monolayers containing 1, 3, and 6 mol% PEG at different surface 
pressures are presented in Figure 4.2 to 4.4. As seen in the figures, the molecular area of 
phospholipid monolayer changes, ∆A, immediately after the insulin injection at about t ≈ 
0 but then levels off at a steady state, ∆Ass. The time it takes a given monolayer to attain 
the ∆Ass varied upon the preset surface pressure value. The steady state value decreased 
with increasing the preset π value. This can be seen in Figure 4.2, where the ∆Ass value 
for binary mixture of DPPC/DPPE-PEG2000 containing 1 mol% PEG is ~0.137 nm
2
 at π 
= 13 mN/m which decreased to 0.014 nm
2
 at π = 17 mN/m. Similar trends were observed 
for binary mixtures of DPPC/DPPE-PEG2000 containing 3 and 6 mol% PEG as well 
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where the ∆Ass values at π = 13 mN/m are ~0.139 and 0.156 nm
2
 that decreased to 0.0155 
and 0.0132 nm
2
 at π = 17 mN/m, respectively (Figure 4.3 and 4.4). The positive change 
in the molecular area of all the monolayers upon insulin injection in the surface pressure 
range between 13 – 17 mN/m indeed implies that the area expansion of the monolayer is 
due to the interactions between insulin and monolayer. Furthermore, change in the lateral 
surface pressure also has a great impact on the insulin/monolayer interactions. This effect 
was further investigated by obtaining the ∆Ass values from the exponential fits of all ∆A – 
t curves (solid curves in Figure 4.2 – 4.4) and then plotted as a function of π. The ∆Ass – π 
plot displayed in Figure 4.5 shows a significant expansion of monolayers upon insulin 
interactions below 17 mN/m. However, the ∆Ass values vary depending on the PEG 
content of each binary mixture. This phenomenon can be grasped by relating the ∆Ass of 
the monolayers containing 1 – 6 mol% PEG upon insulin interactions, 0.14 – 0.16 
nm
2
/molecule, with their mean molecular area, A, found between 0.58 – 0.78 
nm
2
/molecule, at 13 mN/m. This indeed exhibits a considerable monolayer expansion 
induced by insulin interactions from about 24% – 20% in the binary mixtures of DPPC 
and DPPE-PEG2000 containing 1 – 6 mol% PEG. 
 
  The area expansion measurements on binary mixtures of DSPC/DSPE-PEG2000 
also exhibited similar behavior as binary mixtures of DPPC/DPPE-PEG2000 (cf. Figure 
4.2 – 4.4 and Figure 4.6 – 4.8). The molecular area of phospholipid monolayer changes, 
∆A, followed by insulin injection at about time ≈ 0 min, which then levels off at a steady 
state, ∆Ass. The time it takes a given monolayer to obtain the ∆Ass varied with respect to 
the preset surface pressure value. Similar to the binary mixtures of DPPC/DPPE-
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PEG2000, the ΔAss value of mixed DSPC/DSPE-PEG2000 monolayers upon insulin 
injection decreased with increasing the preset π value. For instance, the ∆Ass value for 
binary mixture of DSPC/DSPE-PEG2000 containing 1 mol% PEG is ~0.037 nm
2
 at π = 
13 mN/m which decreased to 0.0023 nm
2
 at π = 17 mN/m. Similar behavior was seen for 
binary mixtures of DSPC/DSPE-PEG2000 containing 3 and 6 mol% PEG where the ∆Ass 
values at π = 13 mN/m are ~0.046 and 0.090 nm2 that decreased to 0.0036 and 0.0080 
nm
2
 at π = 17 mN/m, respectively (Figure 4.6 and 4.8). Interestingly, the ∆Ass values of 
binary mixtures of DSPC and DSPE-PEG2000 are much lower than the ∆Ass values 
obtained for the binary mixtures of DPPC and DPPE-PEG2000 (cf. Figure 4.2 – 4.4 with 
Figure 4.6 – 4.8). Most importantly, change in surface pressure also seems to have a 
greater effect on the insulin/monolayer interactions. The plot of ∆Ass values as a function 
of π in Figure 4.9 reveals a noticeable monolayer area expansion induced by insulin 
molecules, which decreases with the increase of surface pressure.  
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Figure 4.1. A schematics demonstrating the data analysis for area expansion 
measurements: (A) (i) A – t curves obtained for a monolayer upon insulin injection in the 
subphase (ii) without insulin, as a reference run. Both curves are obtained for a 
monolayer containing 1 mol% PEG held at a preset π of 15 mN/m. (B) ΔA – t curve is 
obtained by subtracting from the reference run depicted as (ii) from A – t curves for 
insulin/monolayer interactions represented as (i). Dotted curve is the subtracted curve 
whereas solid curve represents the exponential curve fit in order to determine the steady-
state ΔAss values. For clarity, the creep test portion of the ΔA – t curve is removed and the 
insulin injection point at t= 20 min is shifted to t = 0 min as shown by the arrow in part B 
of the figure. Hence, ΔA – t curves in Figures 4.2 – 4.4 and Figures 4.6 – 4.8 illustrate ΔA 
rise at time of ≈ 0 min.  
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Figure 4.2. Change in mean molecular area, ∆A, of DPPC/DPPE-PEG2000 monolayer 
containing 1 mol% PEG induced by insulin with respect to time. Dotted curves represent 
the actual averaged and subtracted ∆A-t curves upon insulin injection at a predefined π of 
(a) 13, (b) 15, and (c) 17 mN/m whereas solid curves are the exponential fit to the actual 
measured ∆A-t curves. 
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Figure 4.3. Change in mean molecular area, ∆A, of DPPC/DPPE-PEG2000 monolayer 
containing 3 mol% PEG induced by insulin as a function of time. Dotted curves represent 
the actual averaged and subtracted ∆A-t curves upon insulin injection at a predefined π of 
(a) 13, (b) 15, and (c) 17 mN/m whereas solid curves are the exponential fit to the actual 
measured ∆A-t curves. 
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Figure 4.4. Change in mean molecular area, ∆A, of DPPC/DPPE-PEG2000 monolayer 
containing 6 mol% PEG induced by insulin as a function of time. Dotted curves represent 
the actual averaged and subtracted ∆A-t curves upon insulin injection at a predefined π of 
(a) 13, (b) 15, and (c) 17 mN/m whereas solid curves are the exponential fit to the actual 
measured ∆A-t curves. 
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Figure 4.5. ΔAss values obtained for mixed DPPC/DPPE-PEG2000 monolayers plotted 
against surface pressure, π, containing different mol% PEG: (●) 1, (■) 3, (▲) 6 mol% 
PEG2000. Error bars indicate ± standard deviation. 
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Figure 4.6. Change in mean molecular area, ∆A, of DSPC/DSPE-PEG2000 monolayer 
containing 1 mol% PEG induced by insulin as a function of time. Dotted curves represent 
the actual averaged and subtracted ∆A-t curves upon insulin injection at a predefined π of 
(a) 13, (b) 15, and (c) 17 mN/m whereas solid curves are the exponential fit to the actual 
measured ∆A-t curves. 
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Figure 4.7. Change in mean molecular area, ∆A, of DSPC/DSPE-PEG2000 monolayer 
containing 3 mol% PEG induced by insulin as a function of time. Dotted curves represent 
the actual averaged and subtracted ∆A-t curves upon insulin injection at a predefined π of 
(a) 13, (b) 15, and (c) 17 mN/m whereas solid curves are the exponential fit to the actual 
measured ∆A-t curves. 
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Figure 4.8. Change in mean molecular area, ∆A, of DSPC/DSPE-PEG2000 monolayer 
containing 6 mol% PEG induced by insulin as a function of time. Dotted curves represent 
the actual averaged and subtracted ∆A-t curves upon insulin injection at a predefined π of 
(a) 13, (b) 15, and (c) 17 mN/m whereas solid curves are the exponential fit to the actual 
measured ∆A-t curves. 
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Figure 4.9. ΔAss values obtained for mixed DSPC/DSPEPEG2000 monolayers plotted 
against surface pressure, π, containing different mol% PEG: (●) 1, (■) 3, (▲) 6 mol% 
PEG2000. Error bars indicate ± standard deviation. 
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4.2. DISCUSSION. 
 
 Insulin is a small protein and bears an overall negative charge, –2 per monomer, 
in the presence of PBS subphase with a pH of ~7.4 [Farias 1989; Henry 2008]. 
Phosphocholine molecules are zwitterionic but PEG possesses a negative charge [Allen 
2002; Baekmark 1995; Tanwir 2008; Vermette 2003]. This overall negative charge 
distribution should create a repulsive environment between insulin and mixed 
monolayers. PEG should also play as a steric and entropic repulsive barrier protecting the 
monolayers upon insulin interactions [Baekmark 1995; Stepniewski 2011; Tanwir 2012; 
Vermette 2003; Zhao 2002]. However, insulin is known to promote the hydrophobic 
interactions in order to avoid exposure to the aqueous environment by inserting its 
hydrophobic residues into the aliphatic region of the phospholipid membrane [Birdi 
1976; Farias 1989; Grudzielanek 2007; Kadima 1993; Liang 1994; Nieto-Suarez 2008; 
Rand 1972; Vermette 2002]. Furthermore, few reports have also purported that ions in 
the PBS subphase, most importantly cations, can also have a great impact on the 
protein/membrane, protein/PEG, PEG/membrane interactions [Kadima 1993; 
Stepniewski  2011; Rand 1972]. Hence, this section will aim at elucidating the effect of 
varying PEG content in the binary mixtures of phosphocholine and PEG-phospholipid by 
determining the insulin binding parameters including the insulin penetration area, Ains, 
and degree of insulin binding, χins. The effect PEG content on the phase state of mixed 
monolayers and its correlation with the χins will also be discussed in detail herein. 
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4.2.1. Determination of Insulin Penetration Area, Ains, for the Binary Mixtures of 
Phosphocholine and PEG-Phospholipid. 
 
  
 The study of non-specific protein interactions with phospholipid membrane has 
been found to be very intricate process since every protein possesses unique biophysical 
properties and thus behaves differently upon interactions with the membrane 
[Boguslavsky 1994; Hanakem 1996; Seelig 1987]. An estimation of protein penetration 
area using monolayer area expansion measurements can be an efficient tool to deduce the 
mechanistic behavior of various types of proteins upon interactions with membranes. For 
this study, the penetration area of insulin, Ains, in to the binary mixtures of 
phosphocholine and PEG-phospholipid with varying PEG content of 1, 3, and 6 mol% 
was calculated using the equation below [Hanakam 1996] 
 
  ΔAss/A ≈ K exp (– πAins/kT)      4.1 
 
where ΔAss represents the expansion of monolayer mean molecular area due to 
penetration of protein, A is the area per molecule of phospholipid monolayer without 
protein, K is constant, π represents the lateral surface pressure, Ains is the area of 
penetrated insulin on to the monolayer, k is the Boltzmann constant, and T represents the 
absolute temperature. Rearranging the equation can yield 
 
  Ln (ΔAss/A) ≈ – (Ains/kT)π      4.2 
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A straight line of the ln (ΔAss/A) curve with respect to surface pressure, π, can thus be 
used to determine the penetration area of the insulin, Ains, on to the monolayer. To 
calculate ln (ΔAss/A), the values of ΔAss were taken from Figure 4.5 and 4.9 whereas A 
values were directly obtained from the isotherms of Chapter 3 and 4 in Figure 3.3 and 3.4 
for the same surface pressures. Figure 4.10 and 4.11 display the plots of ln (ΔAss/A) as a 
function of π from 13 – 17 mN/m for all the binary mixtures of DPPC/DPPE-PEG2000 
and DSPC/DSPE-PEG2000. As can be seen in the figures, the plots yield a straight line 
for all the monolayers which demonstrates that the penetration of insulin is proportional 
to the Boltzmann factor, exp(–πAins/kT) and is further used to calculate the penetration 
area of insulin, Ains, on the mixed monolayers [Boguslavsky 1994; Hanakam 1996]. The 
calculated values of Ains for all the phosphocholine and PEG-phospholipid monolayers 
containing 1, 3, and 6 mol% PEG are summarized in Table 4.1 and 4.2. Overall, a 
decreasing trend of the insulin penetration area is observed with increasing PEG content 
on both types of binary mixtures from 1 – 6 mol% PEG. For instance, the Ains of insulin 
on mixed DPPC/DPPE-PEG2000 monolayer containing 1 mol% PEG was determined to 
be 2.21 ± 0.04 nm
2
 which decreased to 1.95 ± 0.06 nm
2 
for monolayer containing 6 mol% 
PEG. Similarly, penetration of insulin, Ains, on mixed DSPC/DSPE-PEG2000 monolayer 
containing 1 mol% PEG was calculated to be 2.72 ± 0.05 nm
2
 which decreased to 2.25 ± 
0.07 nm
2
 on monolayer containing 6 mol% PEG. Interestingly, the penetration area of 
insulin determined herein is relatively smaller than the ones in reported data. For 
instance, the molecular dimension of a wedge shaped insulin monomer has been found to 
be 2 x 2.5 x 2 nm
3
 [Henry 2008; Liu 2002]. The hydrodynamic diameter of insulin 
monomer has been reported to be 3 nm [Liu 2002; Kadima 1993]. Moreover, Rand et al. 
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study has estimated the cross-sectional area of insulin molecule to be about 4.35 nm
2
 
[Rand 1972]. However, a direct comparison of the insulin penetration area determined in 
this study with the reported data might not correlate well due to different experimental 
conditions applied. Based on our results, two proposed models might rationalize the 
relatively small area of insulin, Ains, upon non-specific interactions with the binary 
mixtures of phosphocholine and PEG-phospholipids. (i) Insulin molecule may change its 
conformation to a more compact configuration to facilitate the penetration on to the 
mixed monolayers. In fact, insulin and various other proteins have shown a tendency to 
change their conformation in order to penetrate depending on the monolayer’s physical 
properties [Jorgensen 2011; Nieto-Suarez 2008; Shahid 2013]. This phenomenon has also 
been reported by Tah et al. where insulin molecule conforms to a more compact or folded 
state in order to interact with the vesicle membranes [Tah 2014]. Few reports have also 
suggested that insulin changes its conformation by partially submerging its hydrophilic 
residues in to the subphase, when the monolayer mean molecular area changes [Nieto-
Suarez 2008]. This conformational change might explain the penetration area of insulin 
on to the monolayers to decrease in the presence of higher PEG content Table 4.1 and 
4.2. On the other hand (ii) Insulin molecule interacts through inserting a small 
hydrophobic loop/domain instead of entirely inserting itself in to the phospholipid 
membrane. This is considered as the primary driving force for the non-specific binding of 
protein on to the membrane [Grudzielanek 2007; Hanakam 1996; Liang 1994]. 
According to Liang et al. the interaction surface of insulin is comprised of two segments 
including a hydrophobic binding core and a hydrophilic surface [Liang 1994]. The 
hydrophobic binding core of insulin has an area of 1.5 nm
2
 which is surrounded by polar 
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and charged amino acids forming a hydrophilic zone. This justifies the relatively small 
Ains upon interactions with the monolayers in the present study which decreased with an 
increase of PEG content, as can be seen in Table 4.1 ad 4.2. Further studies would yield 
more insights to discover the most predictable scheme. Hence, the effect of PEG content 
on the Ains estimated in this report can be another step towards selecting the optimal 
mixture composition for developing controlled bio-non-fouling membrane-mimetic 
surfaces for numerous biomedical applications.  
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Figure 4.10.: A Semilogarithmic plot of ΔAss/A for the binary mixtures of DPPC/DPPE-
PEG2000 as a function of surface pressure, π, with different mol % PEG:(●) 1, (■) 3, 
(▲) 6mol% PEG2000. The dotted lines represent the linear fits to the ln(ΔAss/A) – π 
values. The slopes of the linear fits were used to determine the penetration area of insulin, 
Ains (elaborated in text in more detail). The insulin concentration used in data is ~75 
ng/mL in the PBS subphase. Error bars indicate ± standard deviation. 
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Figure 4.11.: A Semilogarithmic plot of ΔAss/A for the binary mixtures of DSPC/DSPE-
PEG2000 as a function of surface pressure, π, with different mol % PEG:(●) 1, (■) 3, 
(▲) 6mol% PEG2000. The dotted lines represent the linear fits to the ln(ΔAss/A) – π 
values. The slopes of the linear fits were used to calculate the penetration area of insulin, 
Ains (elaborated in text in more detail). The insulin concentration used in data is ~75 
ng/mL in the PBS subphase. Error bars indicate ± standard deviation. 
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Table 4.1. Insulin Penetration Area, Ains, for binary mixtures of DPPC and DPPE-
PEG2000 containing 1, 3, and 6 mol% PEG2000.  
 
Binary Mixture of DPPC and DPPE-
PEG2000 
Insulin Penetration Area, Ains, nm
2
 
  
1 mol% PEG2000 2.21 ± 0.04  
3 mol% PEG2000 2.08 ± 0.05 
6 mol% PEG2000 1.97 ± 0.06 
 
Standard deviations calculated for Ains are based on a series of three measurements. 
 
 
 
 
Table 4.2. Insulin Penetration Area, Ains, for binary mixtures of DSPC and DSPE-
PEG2000 containing 1, 3, and 6 mol% PEG2000.  
 
Binary Mixture of DSPC and DSPE-
PEG2000 
Insulin Penetration Area, Ains, nm
2
 
  
1 mol% PEG2000 2.72 ± 0.05  
3 mol% PEG2000 2.54 ± 0.05 
6 mol% PEG2000 2.25 ± 0.07 
 
Standard deviations calculated for Ains are based on a series of three measurements. 
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4.2.2. Binding Degree of Insulin, χins, for Binary Mixtures of Phosphocholine and 
PEG-Phospholipid.  
 
  
 The calculated Ains values were further used to determine the degree of insulin 
binding on to mixed DPPC/DPPE-PEG2000 and DSPC/DSPE-PEG2000 monolayers 
containing 1, 3, and 6 mol% PEG [Boguslavsky 1994; Hanakam 1996; Shahid 2013]. The 
term χins is a ratio between the number of moles of insulin binding on to the monolayer, 
np, and moles of phospholipid molecules constituting the monolayer, npl. The area 
expansion measurement can also be used to determine the χins based on the equation 
below [Hanakam 1996] 
 
   χins = nins/npl = (ΔA/A)(Apl/Ains)     4.3 
 
where ΔA/A is the relative area increase of monolayer upon insulin binding as mentioned 
above, Ains represents the penetration area of insulin (obtained from Table 4.1 and 4.2), 
and Apl is the effective area of phospholipid in a closely packed configuration. Apl can be 
estimated by extrapolating the low-compressibility region of the monolayer’s π – A 
isotherm to π = 0 mN/m [Shahid 2013]. The effective area of phospholipid, Apl, in the 
binary mixtures of DPPC/DPPE-PEG2000 containing 1, 3, and 6 mol% PEG2000 is also 
determined from their monolayer’s π – A isotherms from Figure 3.3A. Similarly, Apl, in 
the mixed DSPC/DSPE-PEG2000 monolayers containing 1, 3, and 6 mol% PEG2000 is 
also determined from their monolayer’s π – A isotherms  (Figure 3.5). Table 4.3 and 4.4 
summarize the calculated degree of insulin binding, χins, for all the binary mixtures based 
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on the information mentioned above. As seen in Table 4.3, the value for χins increases 
with an increase in PEG content in the mixed DPPC/DPPE-PEG2000 and DSPC/DSPE-
PEG2000 monolayers from 1 – 6 mol% PEG. However, the change in the degree of 
insulin binding for binary mixtures of DPPC/DPPE-PEG2000 is relatively minimal. For 
instance, at π ~ 13 mN/m, the χins value for mixed DPPC/DPPE-PEG2000 monolayers 
containing 1 mol% PEG is 0.060 which increases to 0.067 when the PEG content 
increases to 6 mol% PEG. In contrast, the χins value for binary mixtures of DSPC/DSPE-
PEG2000 containing 1 mol% PEG is calculated to be 0.013 which increases to 0.032 with 
PEG increment to 6 mol% PEG at π ~ 13 mN/m. The number of moles of insulin bound 
to binary mixtures DSPC and DSPE-PEG2000 is relatively smaller than the binary 
mixtures of DPPC and DPPE-PEG2000 at all surface pressures presented herein. 
Interestingly, surface pressure seems to have a greater impact on the χins values for all the 
monolayers than the PEG content. The χins values for the DPPC/DPPE-PEG2000 binary 
mixtures ranged from 0.056 – 0.079 at π ~ 13 mN/m, depending on the PEG content, 
which decreased to 0.005 – 0.007 at π ~ 17 mN/m (Table 4.3). Similarly, the values of χins 
for the binary mixtures of DSPC/DSPE-PEG2000 containing 1, 3 and 6 mol% PEG also 
decreased from 0.013 – 0.032 at 13 mN/m to 0.0008 – 0.0034 at 17 mN/m, respectively. 
This reveals that the number of insulin molecules interacting with monolayers for both 
types of binary mixtures decreases upon increasing the surface pressures. This might 
justify almost no monolayer area expansion detection at surface pressures above 17 
mN/m (data not shown) [Vermette 2003]. Hence, the analysis in this report reveal that 
increasing the surface pressure has a more pronounced effect in reducing the number of 
insulin molecules binding to the phosphocholine and PEG-phospholipid binary mixtures.      
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Table 4.3. Determined degree of insulin binding, χins, for binary mixtures of DPPC and 
DPPE-PEG2000 containing 1, 3, and 6 mol% PEG2000 using equation 4.3.  
 
π, mN/m 1 mol% PEG2000 3 mol% PEG2000 6 mol% PEG2000 
    
13 0.056 ± 0.004 0.071 ± 0.004 0.079 ± 0.003 
15 0.023 ± 0.003 0.028 ± 0.004 0.038 ± 0.006 
17 0.005 ± 0.001 0.007 ± 0.001 0.007 ± 0.001 
 
Standard deviations calculated for χins are based on a series of three measurements. 
 
 
 
 
 
Table 4.4. Determined degree of insulin binding, χins, for binary mixtures of DSPC and 
DSPE-PEG2000 containing 1, 3, and 6 mol% PEG2000 using equation 4.3.  
 
π, mN/m 1 mol% PEG2000 3 mol% PEG2000 6 mol% PEG2000 
    
13 0.013 ± 0.002 0.016 ± 0.003 0.032 ± 0.003 
15 0.0031 ± 0.0003 0.0058 ± 0.0006 0.010 ± 0.001 
17 0.00080 ± 0.0001 0.0015 ± 0.0003 0.0034 ± 0.0005 
 
Standard deviations calculated for χins are based on a series of three measurements. 
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4.2.3. Grafted PEG Chains Impact on Insulin/Monolayer Interactions.  
 
 Based on the results obtained, it can be clearly seen that the incorporation of 
grafted PEG-phospholipid in to host phosphocholine matrix, DPPC/DPPE-PEG2000 and 
DSPC/DSPE-PEG2000, indeed aid in reducing the insulin penetration area. Among both 
binary mixtures, DSPC/DSPE-PEG2000 seems to have a greater impact in reducing the 
insulin penetration area upon increasing PEG content from 1 – 6 mol% than mixtures of 
DPPC/DPPE-PEG2000, as can be compared in Table 4.1 and 4.2. Surprisingly, the 
increment of PEG content in the binary mixtures of DPPC/DPPE-PEG2000 and 
DSPC/DSPE-PEG2000 seems to reduce the insulin penetration area yet increase the 
degree of insulin binding, χins. Indeed, the degree of insulin binding has increased for 
both types of binary mixtures at all surface pressures studied herein (Table 4.3 and 4.4). 
The increase in degree of insulin binding can be attributed to the increase in liquid 
expanded (LE) phase in the mixed monolayers at higher PEG contents. It has been 
suggested that increase in PEG content in the binary mixtures of phosphocholine and 
PEG-phospholipid may contribute towards homogenous distribution of PEG chains but 
introduce greater separation between the components in order to accommodate the bulky 
PEG chains and increase the LE phase of the membrane, at any given surface pressure, π 
[Baekmark 1995; Borden 2006; Kinsinger 2010; Lozano 2009; Tanwir 2008; Tanwir 
2012]. To better comprehend the interplay, χins and %LE phase of the membrane are 
plotted as a function of PEG content at π ~ 15 mN/m, as shown in Figure 4.12 and 4.13. 
As can be seen in the figures, %LE phase and χins increase as the PEG content increase in 
both binary mixtures of DPPC/DPPE-PEG2000 and DSPC/DSPE-PEG2000. Similar 
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trends were also observed at π of 13 and 17 mN/m where an increase in PEG content 
introduces more disorder in the membrane, which eventually causes more insulin to bind 
to the membrane (data not shown) [Baekmark 1995; Lozano 2009]. Binary mixtures of 
DPPC/DPPE-PEG2000 exhibit an overall higher χins and LE phase than those of 
DSPC/DSPE-PEG2000 mixtures, at all PEG content studied herein (cf. Figure 4.12 and 
4.13). Hence, these findings can aid in selecting the suitable mixture composition as well 
as tuning and controlling the properties of model membranes for various spectra of 
biomedical applications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12.: Change in the degree of insulin binding (χins) and % liquid expanded 
(%LE) phase with respect to the PEG content in the binary mixtures of DPPC and DPPE-
PEG2000 containing 1, 3, and 6 mol% PEG. Solid lines depict the linear fit to the values. 
Pink markers and line represent the χins whereas purple markers and line represent the 
%LE phase of the mixtures.  
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Figure 4.13.: Change in the degree of insulin binding (χins) and % liquid expanded 
(%LE) phase with respect to the PEG content in the binary mixtures of DSPC and DSPE-
PEG2000 containing 1, 3, and 6 mol% PEG. Solid lines depict the linear fit to the values. 
Pink markers and line represent the χins whereas purple markers and line represent the 
%LE phase of the mixtures.  
 
 
 
 
 
0.012
0.010
0.008
0.006
0.004
0.002
654321
60
50
40
30
20
10
0
χ i
n
s 
%
 L
E
 p
h
a
se
 
mol % PEG  
   
142 
 
4.3. CONCLUSION. 
 
Analysis of insulin interactions with PEGylated phosphocholine monolayers has 
indeed revealed an interesting phenomenon through area expansion measurement studies. 
Insulin penetration area, Ains, decreased from 2.21 nm2 to 1.97 nm2 in the binary 
mixtures of DPPC/DPPE-PEG2000 and from 2.72 nm2 to 2.25 nm2 in the binary 
mixtures of DSPC/DSPE-PEG2000 when the PEG content was increased from 1 – 6 
mol% PEG, respectively. This shows an overall decrease in Ains with an increase of PEG 
content in both types of PEGylated phosphocholine mixtures. However, the degree of 
insulin binding, χins, increases upon increasing the PEG content from 1 – 6 mol% PEG in 
both types of binary mixtures. Interestingly, surface (lateral) pressure significantly 
reduced the degree of insulin binding, χins, as compared to the PEG content in both type 
of binary mixtures. Among both mixtures, DSPC/DSPE-PEG2000 mixtures had an 
overall reduced insulin degree of binding upon increasing PEG content as compared to 
the DPPC/DPPE-PEG2000 mixtures. The increase in χins can be directly attributed to an 
increase in LE phase with an increase of PEG content in both types of PEGylated 
phosphocholine membranes. Hence, it can be inferred that the optimal PEG content in the 
PEGylated phosphocholine membrane should be in the range of 1 – 3 mol% PEG for the 
optimal performance of membrane-mimetic surfaces with reduced non-specific small 
protein interactions.  
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Chapter 5: Imaging Co-existing Phases in Poly(Ethylene Glycol) 
Grafted Phosphocholine Membranes. 
 
 
This study was performed by analyzing two different types of PEGylated 
phosphocholine giant unilamellar vesicles (GUVs) as membrane model. DPPC/DPPE-
PEG2000 and DSPC/DSPE-PEG2000 with varying PEG content were selected as 
phosphocholine and PEG-phospholipid mixtures. The morphology, lateral structure, 
coexisting domains and various other aspects including size, lamellarity, and 
heterogeneity of the GUVs were visualized and examined by EFM. Moreover, a 
comparative analysis of the phase state and the lateral surface pressure has been 
performed to understand the correlation between PEGylated phosphocholine vesicle 
membrane and monolayer. The effect of different preparation methods and aqueous 
media on the size, shape, and morphology of vesicle membrane was also investigated. 
Furthermore, the effect of varying PEG content on the phase behavior of phosphocholine 
vesicles has also been extensively studied, which can be of great interest for the design of 
many biomedical applications including carriers for therapeutic and diagnostic agents. 
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5.1. Preparation Procedures for PEGylated phosphocholine GUVs. 
 
5.1.1. Protocol 1: Gentle Hydration Method. 
 
The DPPC/DPPE-PEG2000 and DSPC/DSPE-PEG2000 GUVs with varying 
PEG2000 phospholipid content from 1 – 9 mol% were prepared by hydrating the dry 
phospholipid film technique with slight modifications [Akashi 1996; Bagatolli 2000; 
Manley 2008; Yamashita 2002; Jesorka 2008]. Stock solutions of phosphocholine with a 
concentration of 20 mg/mL and PEG-phospholipid, 2 mg/mL, were prepared in 
chloroform/methanol mixture (60:40 v/v). Pre-calculated volumes of phosphocholine, 
PEG-phospholipid and 0.05 mol% of DOPE-Rh stock solution with the appropriate molar 
ratios were mixed in a 1 mL conical glass vial to obtain a 100 μL solution with the final 
concentration of ~3 mg/mL. The vial was always covered with aluminum foil for light-
sensitive components. The solvent mixture was then evaporated in the desiccator attached 
to a vacuum pump for 3 – 4 hours and was left overnight in the fumehood. Next day, a 
thin dried film was formed at the bottom of the glass vial. The dried film was pre-
hydrated for ~ 30 minutes using warm, moist air. This was done by bubbling the air 
through deionized water warmed on a hotplate at 50 – 55 ˚C and was directed into a 
sealed lipid-coated glass conical vial. The vial was filled with the swelling solution of 0.1 
M NaCl containing 1 vol% glycerol and was then incubated in an oven overnight at 50 – 
60 ˚C to produce GUVs. The temperature of the swelling solution was kept more than the 
chain-melting transition temperature, Tm, of DPPC (~41.8 ˚C), DSPC (~54.5 ˚C) and 
when mixed with DPPE-PEG2000 at a concentration ≤10 mol% (~41.8 ˚C). This is 
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usually done to make the hydrocarbons more flexible and gauche conformation [Akashi 
1996; Bagatolli 2000; Belsito 2000; Manley 2008; Montesano 2001; Pappalardo 2005; 
Walde 2001; Zawada 2004]. The phospholipids hydrophobic chains below Tm 
predominantly exist as a rigid and extended all trans conformation, which is not suitable 
for the vesicle formation [Walde 2001]. The dried film during the incubation was then 
stripped off from the bottom of the vial surface and formed an opalescence solution 
containing unilamellar vesicles. The vesicles were then harvested from the center of the 
vial and gently transferred into an imaging cell. The vesicles in the cell were visualized 
using an inverted Nikon Eclipse TE2000 microscope (Nikon, Japan) through visible and 
TRITC channels. In the TRITC channel, the contrast was derived from differences in 
partitioning of DOPE-Rh into ordered (liquid condensed) and disordered (liquid 
expanded) phospholipid phases [Manley 2008; Sezgin 2012; Shahid 2011; Tsoukanova 
2008]. Headgroup-labeled lipid probe such as DOPE-Rh are typically used for imaging 
studies since bulky fluorophore attached to the aliphatic chain may interfere with the 
ordering of the phospholipids in the membrane [Manley 2008]. The red staining in the 
images thus depicts the LE phase whereas the dark domains correspond to the LC or Lβ’ 
phase in the vesicles. Images were captured using a CCD camera (ORCA ER (AG), 
Hamamatsu, Japan) through different objectives (10 – 40 X) onto a computer screen by 
Simple PCI 6 software (Compix Inc. PA). Images most representative of the membrane 
morphology were chosen for analysis in each series of imaging. Image analysis in terms 
of the percentage of dark domains, % dark domains, was performed with the Quantify 
package of Simple PCI 6. In the Quantify package, the value of % dark domains is found 
by relating the area occupied by domains to the area of the image. Each type of solution 
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was repeated at least three – five times to obtain highly resolved GUV images. GUVs 
were also prepared using this protocol but with NaCl and 1 vol% sucrose as the swelling 
medium. This method, however, did not produce highly resolvable and good quality 
images. Hence, the images captured from this protocol will not be discussed in detail in 
this report. 
 
5.1.2. Protocol 2: Solvent Evaporation Method. 
 
The GUVs of the binary mixtures of DPPC and DPPE-PEG2000 in this protocol 
were prepared using solvent evaporation method as proposed by Moscho and Bagatolli 
but with slight modifications [Moscho 1996; Bagatolli 2000; Zawada 2004]. DPPC and 
DPPE-PEG2000 were first dissolved in chloroform/methanol (60:40 v/v) solvent mixture 
with a concentration of ~20 mg/mL and 2 mg/ml respectively. Pre-calculated volumes of 
phosphocholine and PEG-phospholipid stock solution with the appropriate molar ratios 
were mixed in a 1 mL glass vial to obtain a 100 μL solution with the final concentration 
of ~3 mg/mL. DOPE-Rh was also added in the mixtures at a concentration of ~0.05 
mol% for imaging studies.  About 3 mL of PBS solution with and without 1 vol% 
glycerol was added in a 4 mL flat glass vial and heated with constant stirring for ~15 min 
at 50 – 55 °C, which was above the Tm of phospholipids. The solution containing the 
phospholipid mixture was then slowly injected (drop wise) into stirred PBS along the 
wall of the flask. The phospholipid containing PBS solution was stirred for ~30 min at 
~60 °C without caps to evaporate the organic solvent [Zawada 2001]. The solution was 
left to cool down to room temperature (~20 – 21 °C). The vesicles were harvested from 
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the center of the vial, gently transferred into an imaging cell with a drop of PBS 
containing 1 vol% of glycerol and observed using an inverted Nikon microscope as 
described above. Each binary mixture solution was repeated five times to obtain highly 
resolved GUV images. 
 
5.2. RESULTS.  
 
The main goal of this study was to prepare and study the co-existing phases in the 
GUVs using EFM. GUVs of DPPC/DPPE-PEG2000 and DSPC/DSPE-PEG2000 with 
varying PEG content from 1 – 9 mol% were prepared. Two different protocols were used 
for the preparation of GUVs including gentle hydration and solvent evaporation method. 
DPPC/DPPE-PEG2000 GUVs were actually prepared using both protocols [Akbarzadeh 
2013; Akashi 1996; Manley 2008; Moscho 1996; Thevenot 2007; Walde 2001]. 
However, GUVs of DSPC/DSPE-PEG2000 were only prepared by the gentle hydration 
method [Akashi 1996; Manley 2008; Walde 2001]. DOPE-Rh was used as an imaging 
probe to study the phase state of the GUV as a membrane model. This specifically 
includes the liquid-disordered (Ld) and gel (Lβ’) phases of the membrane model [Bagatolli 
2006; Discher 1999; El-Khouri 2011; Manley 2008; Shahid 2011]. Ld phase corresponds 
to the fluid or liquid expanded phase (LE) whereas Lβ’ represents the liquid condensed 
phase (LC) in a phospholipid monolayer [Bagatolli 2006; Ickenstein 2003; Eeman 2010; 
Tenchov 2001]. The vesicles were also loaded with 1 vol% glycerol solution, which 
increased the rigidity of vesicle by osmotic pressure and further enhanced the contrast 
and resolution of the vesicles’ imaging [Akashi 1996; Sun 2005]. Hence, direct imaging 
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of PEGylated phosphocholine GUVs phase coexistence can be very valuable to correlate 
phase behavior of GUVs with that of monolayers. 
 
5.2.1. Imaging the Coexisting Domains in DPPC/DPPE-PEG2000 Vesicles 
Containing 1 mol% PEG Using Protocol 1. 
 
 The morphology of DPPC/DPPE-PEG2000 vesicle membranes containing 1 
mol% PEG2000 phospholipid was observed through the EFM’s visible and TRITC 
channel. Figure 5.1 shows both visible light images and the corresponding fluorescence 
images of DPPC/DPPE-PEG2000 giant unilamellar vesicles (GUV) morphology 
containing 1 mol% PEG2000-phospholipid. The vesicles were primarily spherical in 
shape. The size of the vesicles observed was ranged from 1 – 85 μm. In visible channel, 
the edges of most of the vesicles appeared thick and dark (Figure 5.1 A – C). This is 
described as the result of different refractive indices of internal and external media 
[Akashi 1996]. Each single band corresponds to a bilayer shell and can be considered as 
unilamellar vesicle [Akbarzadeh 2013; Akashi 1996; Immordino 2006; Walde 2001]. 
Aside from GUVs, several multilamellar vesicles, myelin, irregular shaped, and debris 
were also observed (images not shown). However, these structures did not interfere 
during the observation and resolution of the desired GUV at a time. 
 
In the TRITC channel, the dark band in the visible channel appeared red, as can 
be seen in Figure 5.1 D – F. The intensities of unilamellar vesicles with a single dark 
band were significantly lower (Figure 5.1 D – F) than the vesicles with multiple bands 
(images not shown) [Akashi 1996; Yamashita 2002].  The former were, hence, used for 
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further analysis (Figure 5.1 D – F). As can be seen in the figure, two phases can be 
distinctly seen in the GUVs: (1) liquid-disordered phase stained red with DOPE-Rh 
fluorescence along with (2) dark DOPE-Rh-excluded liquid-ordered phase domains. The 
coexistence of these two phases was vividly observed in all sizes of vesicles ranging from 
15 to 85 μm in diameter (Figure 5.1). EFM images of GUVs have revealed that the 
DPPC/DPPE-PEG2000 membranes containing 1 mol% PEG constitute 73% ± 5 of Lβ’ 
phase domains, regardless the vesicle size. However, individual L β’ domains appeared 
smaller in small sized vesicles. Vesicles with diameter below 15 μm showed somewhat 
heterogeneity but the dark L β’ phase could not be clearly visualized and quantified. Thus, 
it can be said that the Ld – L β’ coexistence phase is most probably an inherent property of 
the DPPC/DPPE-PEG2000 membrane morphology.  
 
 
 
 
 
 
 
 
 
 
 
 
152 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.: Images of different sizes of DPPC/DPPE-PEG2000 vesicles containing 1 
mol% PEG content. [A-C] show images of different sizes of vesicles containing DOPE-
Rh probe captured through visible channel. [D-F] Co-existence phase, Ld-Lβ’, seen 
through TRITC channel and  distinguished in all sizes of vesicle of ~73%. T = 23 ºC.  
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5.2.2. Imaging the Coexisting Domains in DPPC/DPPE-PEG2000 Vesicles 
Containing 3 – 9 mol% PEG Using Protocol 1. 
 
DPPC/DPPE-PEG2000 containing 3, 6, and 9 mol% PEG vesicles were also 
prepared by the gentle hydration method. The vesicles images in both visible and TRITC 
channel appeared spherical shaped but rather smaller in size as compared to GUVs 
containing 1 mol% PEG2000 phospholipid. The diameter of the vesicles observed ranged 
from 1 – 40 μm. The most typical vesicle structures found in the samples are similar to 
the ones shown in Figure 5.2. Most of the vesicles seen had a single band around the 
edges, corresponding to unilamellarity, similar to the ones shown in the visible images 
(Figure 5.2). Visualizing the coexistence phase in the vesicle membrane morphology 
containing 3 and 6 mol% PEG2000 content was somewhat difficult as compared to 
GUVs containing 1 mol% PEG. As quantified, the Lo phase in the vesicle membrane 
morphology containing 3 and 6 mol% PEG2000-phospholipid content was 62% ± 7 and 
53% ± 5, respectively. These values were slightly lower than the vesicles containing 1 
mo% PEG with Lo phase of 73%. Furthermore, DPPC/DPPE-PEG2000 membrane 
vesicles containing 9 mol% PEG appeared blurry and small in size with a diameter of 1 – 
5 μm, while the quantity of vesicles produced was also significantly reduced.  
 
Interestingly, the samples containing 3 and 6 mol% PEG content had several 
vesicles attached to each other making oblique trajectories or tubes as shown in Figure 
5.3. This type of structure has also been reported previously for vesicles with and without 
the incorporation of PEG-phospholipid [Antonietti 2003; Bagatolli 2000; Collier 2001; 
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Mathivet 1996; Li 2011]. Upon resolving the images, it is observed that most of the tubes 
were unilamellar containing only single band around the edge of the vesicles, as can be 
seen in the figure. The coexisting domains were also observed in the tubes but hard to 
resolve due to the smaller size of the vesicles Figure 5.3.  
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Figure 5.2.: Images corresponds to DPPC/DPPE-PEG2000 vesicles containing [A] 3 
mol%, [B] 6 mol%, and [C] 9 mol% PEG2000 content. Co-existence phase can be 
observed in vesicles with 3 and 6 mol% PEG but not in vesicles with 9 mol% PEG. T = 
23 ºC. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.: EFM Images of DPPC/DPPE-PEG2000 vesicles containing [A] 3 and [B] 6 
mol% PEG000 content forming tubes or oblique trajectories. Co-existence phase exists 
but not very clear. 
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5.2.3. Imaging the DSPC/DSPE-PEG2000 Vesicles Prepared by Protocol 1. 
 
GUVs of DSPC/DSPE-PEG2000 were also prepared by protocol 1 as discussed above.  
The vesicles were predominantly spherical shaped similar to the DPPC/DPPE-PEG2000 
GUVs. The size of the vesicles mostly ranged from 1 – 5 μm in diameter. Although 
several vesicles were unilamellar but the size was quite small (images not shown). The 
presence of various multilamellar structures and debris in the sample also made it 
difficult to observe a single unilamellar vesicle at a time. Figure 5.4 shows both visible 
light image and the corresponding fluorescence image of DSPC/DSPE-PEG2000 vesicle 
containing 1 mol% PEG2000-phospholipid. The vesicle shown in the figure is 
unilamellar, due to a single band around the edge, with the diameter of ~12 μm. Further, 
as can be seen in the figure, the coexisting domains are not clearly visible in the vesicle 
as compared to the DPPC/DPPE-PEG2000 GUVs (cf Figure 5.4B and Figure 5.1). The 
size and quantity of the vesicles reduced significantly with increasing PEG content from 
1 – 9 mol% (images not shown). In fact, most of the vesicles were very small in size and 
could not be resolved. 
 
 
 
 
 
 
 
 
157 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4.: [A] Visible and [B] TRTIC images of DSPC/DSPE-PEG2000 vesicles 
containing 1 mol% PEG2000-phospholipid. Scale bar is 25 μm. 
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5.2.4. Imaging the Coexisting Domains in DPPC/DPPE-PEG2000 Vesicles Using 
Protocol 2. 
 
 
 Protocol 2, solvent evaporation method, was also used to prepare the vesicles of 
DPPC/DPPE-PEG2000 with varying PEG content. The vesicles mostly appeared circular 
in shape and smaller in size in the range of 1 – 10 μm in diameter. However, a very few 
vesicles with the diameter slightly more than 10 μm were also observed using this 
protocol. For the clarity of presentation, Figure 5.5 displays the visible and TRITC 
images of such DPPC/DPPE-PEG2000 vesicle containing 1 mol% PEG with a diameter 
of ~30 μm. The visible image of the vesicle shows a clear single band depicting the 
unilamellarity of the vesicle Figure 5.5A. The TRITC image in Figure 5.5B shows a 
bright fluorescent spherical shaped vesicle but the coexistence domains were not clearly 
seen. The size of the vesicles did not change significantly with the increment of PEG 
content from 1 – 6 mol% (images not shown). The tubular structures, similar to the ones 
seen in protocol 1, were also not observed in samples prepared by protocol 2. 
Interestingly, the DPPC/DPPE-PEG2000 vesicles containing 9 mol% PEG2000 could not 
be formed using this preparation method. 
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Figure 5.5.: [A] Visible and [B] TRTIC images of DPPC/DPPE-PEG2000 vesicles 
containing 1 mol% PEG2000-phospholipid. Scale bar is 25 μm.  
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5.3. DISCUSSION. 
 
 
A comprehensive analysis of results presented above illustrates that many factors affect 
the properties of vesicles including size, shape, lamellarity as well as morphology. 
Among these factors, mixture composition, PEG2000 content as well as the preparation 
procedure utilized, play a key role and hence will be the focus of this discussion 
[Immordino 2001; Popovska 2013]. Most importantly, various challenges are also 
involved in producing and imaging giant unilamellar vesicles, in particular upon 
inclusion of PEG content. A careful overview of the results herein provides crucial 
information about the effectiveness of each method as well as the mechanism of vesicle 
formation. Based on the results, it can also be seen that DPPC/DPPE-PEG2000 GUVs 
prepared by gentle hydration method were giant and highly resolvable as compared to the 
solvent evaporation technique. Moreover, the mixture composition also has a significant 
impact on the vesicle formation as well as morphological properties and will be discussed 
below. Hence, this report will highlight some of the key factors involved in the vesicle 
formation as well as the change in morphology with respect to different experimental 
conditions including variation in PEG content. 
 
5.3.1. Imaging the Phase Coexistence in DPPC/DPPE-PEG2000 GUVs with Varying 
PEG2000 Content. 
 
  
 Imaging the phase coexistence in GUVs by fluorescence microscopy has gained 
great interest in recent years to better comprehend the lateral organization and physical 
properties of membrane models for numerous biomedical applications [Akashi 1996; 
161 
 
Bagatolli 2006; Bagatolli 2000; Veatch 2003; Walde 2001]. However, the complexities 
involved including preparation procedures, mixture composition selection, addition of 
cholesterol as well as experimental conditions such as temperature and aqueous media 
has made it a very difficult task to achieve [Akashi 1996; Bagatolli 2006; Bagatolli 2000; 
Edwards 1997; Immordino 2001; Korlach 1999; Sun 2005; Veatch 2003; Walde 2001; 
Wesolowska 2009]. Most importantly, formation of vesicles and imaging the phase 
coexistence in PEGylated vesicles without the addition of cholesterol or negatively 
charged phospholipids has also been very challenging [Akashi 1996; Edwards 1997; 
Sezgin 2012; Veatch 2003]. Edwards et al. study has reported that most lipid mixtures 
incorporate about 30 – 50 mol% of cholesterol to produce liposomes [Edwards 1997]. In 
this project, we have not only successfully prepared phosphocholine GUVs with varying 
PEG2000 content but also visualized the phase coexistence without any other additives 
stated above. Upon detailed analysis, it was observed that various factors can have a 
substantial impact on the quantity, size, shape as well as the morphology of GUVs. 
Among these factors, PEG has shown to play a significant role in the formation of GUVs. 
For instance, an increase in PEG content significantly reduced the number of GUVs 
formed in each binary mixture. Increase in PEG content from 1 to 9 mol% has also 
affected the size of GUVs from 100 to 10 μm, respectively. Further, a change in PEG 
content from 1 to 9 mol% also affected the phase coexistence as well as the resolution 
capability of GUVs. GUVs containing 1 mol% PEG were easily resolved whereas 
vesicles containing 9 mol% PEG2000 were very small and hard to resolve. High amount 
of small vesicles and phospholipid aggregates were also observed in these GUVs. This 
could be due to the formation of micelles or other plausible types of phospholipid 
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aggregates with an increase of PEG content, which made it difficult to resolve by EFM 
technique. This is also consistent with a previous study which reports on the formation of 
phosphocholine micelles and open bilayer discs when PEG content was present at a 
concentration of ~10 mol% [Edwards 1997]. This could be attributed to bulky headgroup 
of DPPE-PEG2000, which upon increasing PEG content causes disruption in the vesicle 
formation [Kastantin 2009]. These results are also consistent with the literature data on 
PEGylated phosphocholine membrane models [Bedu-Addo 1996; Belsito 2000; Edwards 
1997; Ickenstein 2003; Montesano 2001; Lasic 1991; Szleifer 1998]. In particular, 
Belsito et al. have reported a strong influence of PEG content on the size of the 
phosphocholine aggregates [Belsito 2000]. A study by Lasic et al. has shown a reduction 
in the radius of egg yolk phosphatidylcholine dispersions with inclusion of DPPE-
PEG2000 content [Lasic 1991]. Bedu-Addo et al. also reported that the size of the 
phosphocholine liposomes significantly reduced upon increasing PEG-phospholipid 
content [Bedu-Addo 1996]. Moreover, a report by Szleifer showed a decrease in the 
aggregates size with the incorporation of PEG-phospholipid content from 0.2 to 10 mol% 
[Szleifer 1998]. Another study by Edwards et al. reports a formation of open bilayer discs 
with high PEG2000 concentration (~10 mol%) in phosphocholine mixtures which would 
not be useful for drug delivery options [Edwards 1997]. Hence, it can be inferred that as 
the amount of PEG content increases in the DPPC/DPPE-PEG2000 vesicles, the Ld phase 
also consequently increases. This in turns prevents the formation of vesicles and induces 
the formation of micelle and other plausible phospholipid aggregates. 
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5.3.2. Effect of PEG Content on the Phase State of PEGylated Phosphocholine 
Vesicle Membrane Models. 
 
  
 An increase in PEG content increased the phase separation in the phosphocholine 
membranes vesicles. This suggests that high PEG content introduces more disorder in the 
phosphocholine membranes, which may result in a significant change in the phase 
behavior of the vesicle membrane models and might not be optimal for engineering 
efficient bio-non-fouling membrane-mimetic surfaces. For instance, DSPC/DSPE-
PEG2000 mixtures containing 1 mol% PEG contain ~73% of LC (Lβ’) state, which 
reduces to ~ 53% in vesicles with 6 mol% PEG content. This indicates that DPPC/DPPE-
PEG2000 vesicle membrane model containing 1 mol% PEG mainly exist as the LC (Lβ’) 
whereas mixtures containing more than 3 mol% PEG have appreciable amount of LE (Ld) 
phase. These results correlate well with literature suggesting that an increase in PEG 
content reduces the Lβ’ phase and induces phase separation in the membrane models 
[Bedu-Addo 1996; Belsito 2000; Edwards 1997; Montesano 2001; Lasic 1991; Szleifer 
1998]. Hence, it can be proposed that incorporating 1 – 6 mol% PEG content in the 
PEGylated phosphocholine binary mixtures can be useful for liposomal formulations with 
efficient bio-non-fouling properties. 
 
 
 
5.3.3. Relevance Between DPPC/DPPE-PEG2000 Monolayers and Vesicles Phase 
Behavior. 
 
 
 GUVs are considered as an intermediate step between a typical biological 
membrane and simple model systems including monolayers and bilayers [Bagatolli 2006; 
Nag 2002]. However, it has been found to be a fairly challenging task to image the 
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morphology and coexisting phases in GUVs without the addition of cholesterol or 
negatively charge phospholipid molecules [Akashi 1996; Bagatolli 2000; Bagatolli 2006]. 
Furthermore, data demonstrating a direct comparison of the vesicle morphology with 
simple model systems such as monolayers are also very scarce [Lozano 2009b]. Figure 
5.6 illustrates a direct comparison between DPPC/DPPE-PEG2000 membrane model 
systems including monolayers and GUVs with varying PEG2000 content from 1 to 6 
mol%. As seen in the figure, all GUVs show morphological resemblance with mixed 
monolayers of the same composition at π ≈ 15 mN/m. This is in good agreement with the 
literature which states that the lateral surface pressure of a typical biological membrane 
lies between the range of 15 – 35 mN/m [Lozano 2009a; Kontilla1988]. Both membrane 
models including vesicles and monolayer of DPPC/DPPE-PEG2000 containing 1 mol% 
PEG2000 constitutes up to 75% Lβ’ phase. Similarly, the membrane morphology of 
DPPC/DPPE-PEG2000 containing 3 and 6 mol% PEG2000 also display significant 
resemblance with respect to the Lβ’ phase, as illustrated in Figure 5.6. Furthermore, an 
increase in PEG content from 1 to 6 mol% shows a substantial reduction in the Lβ’ phase 
from 75% to 58% in monolayers as well as from 73% to 53% in GUVs. This correlates 
well with the literature data which states that an increase in PEG content reduces the Lβ’ 
phase in the membrane models [Bedu-Addo 1996; Belsito 2000; Edwards 1997; 
Montesano 2001; Lasic 1991; Szleifer 1998]. In fact, further increase in PEG2000 
content to 9 mol% hindered the formation of large sized GUVS as well as made it 
difficult to image the coexistence of vesicles. Therefore, a direct comparison of 
DPPC/DPPE-PEG2000 membrane models containing 9 mol% will not be discussed in 
this report. Based on the comparative analysis, it can be concluded that the membrane 
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morphology of GUVs indeed display similar features as for the monolayer membrane 
model systems. Thus, monolayers can certainly serve as a simple yet efficient platform of 
a typical biological membrane to assess the properties of membrane-mimetic surfaces 
including phase behavior, mixture compositions, as well as lateral organization for 
numerous biomedical applications including nanosensor templates, biomedical implants, 
diagnostic devices and nanocarriers.    
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Figure 5.6.: EFM images of DPPC/DPPE-PEG2000 membrane with varying PEG 
content from 1 to 6 mol % PEG2000. Image A, B, C display the monolayer morphology 
of DPPC/DPPE-PEG2000 mixtures containing 1, 3, 6 mol% PEG at π = 15 mN/m. Image 
D, E and F depicts GUVs membrane morphology of the same mixture compositions as 
the monolayer.  
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5.3.4. Effect of Aqueous Medium on the DPPC/DPPE-PEG2000 GUVs. 
 
Aqueous medium has shown to play a pivotal role towards the phase behavior of 
phosphocholine and PEG-phospholipid membrane, as discussed thoroughly in Chapter 3. 
Interestingly, the vesicles of DPPC/DPPE-PEG2000 also appeared quite differently when 
incubated in different aqueous medium. For instance, DPPC/DPPE-PEG2000 GUVs 
containing 1 mol% PEG were highly resolvable with good quality images when 
incubated in 0.1 M NaCl containing 1 vol% glycerol swelling solution (Figure 5.1). In 
contrast, vesicles of the same binary mixture were not highly resolvable when prepared in 
0.1 M NaCl containing 1 vol% sucrose swelling solution (images not shown). Although, 
high concentration of salt solutions containing little amount of sucrose and glucose, as a 
swelling medium, has been suggested to produce high contrast images of GUVs [Akashi 
1996; Bagatolli 2000]. Furthermore, DPPC/DPPE-PEG2000 GUVs did not grow very 
large in size when incubated in PBS containing 1 vol% glycerol with those incubated in 
0.1 M NaCl solution containing 1 vol% glycerol [cf. Figure 5.1 and 5.5]. The images 
were also not highly resolvable to visualize the coexistence domains, when PBS was used 
as a swelling solution. This difference was quite remarkable since both solution, PBS and 
0.1 M NaCl, contained 1 vol% glycerol. In addition, PBS solution has been used in 
several studies to produce vesicle and liposomes [Montesano 2001; Moscho 1996; 
Zawada 2004]. Hence, it can be said that DPPC/DPPE-PEG2000 GUVs images were 
highly resolvable when incubated in 0.1 M NaCl swelling solution containing 1 vol% 
glycerol.  
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5.3.5. Trends in DPPC/DPPE-PEG2000 and DSPC/DSPE-PEG2000 Vesicles. 
 
 A change in the aliphatic chain length from C16 to C18 for both phosphocholine 
and PEG-phospholipid has shown a remarkable effect on the phase behavior of GUVs 
prepared by the gentle hydration method (protocol 1) (cf. Figure 5.1 and 5.4). The 
DPPC/DPPE-PEG2000 GUVs obtained by protocol 1 grew large in size with up to 85 μm 
in diameter whereas the DSPC/DSPE-PEG2000 GUVs remained considerably small with 
the maximum size of ~12 μm. Interestingly, both types of GUVs were spherical in shape 
which is rather difficult to obtain without the addition of cholesterol [Edwards 1997,  
Veatch 2003]. The amount of debris, myelin and multilamellar structures was also 
considerably high in the DSPC/DSPE-PEG2000 samples as compared to the 
DPPC/DPPE-PEG2000 samples (cf. Figure 5.1 and 5.4). Hence, locating and imaging the 
unilamellar vesicles in DSPC/DSPE-PEG2000 samples was a challenging task. The 
formation of debris and multilamellar structures using this type of protocol has also been 
reported by some earlier studies [Akashi 1996; Bagatolli 2000]. These types of structures 
are usually attributed to modifications on the lipid film imposed by tangential forces 
during hydration that dominate the vesicle formation and causes high heterogeneity in the 
internal structure of the vesicles [Bagatolli 2000].  
 
Furthermore, coexistence domains were only observed in DPPC/DPPC-PEG2000 
GUVs but not in DSPC/DSPE-PEG2000. This is in fact consistent with the reported data 
where microbubbles comprised of DPPC and PEG2000 formed domains as compared to 
the DSPC and PEG2000 membrane model [Lozano 2009b]. This is also in good accord 
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the literature data where monolayer composed of DSPC as host matrix completely forms 
a condensed type membrane above 15 mN/m [Chou 2002; Chou 2003; Tanwir 2012]. 
 
5.3.6. Formation of Vesicles Tubes or Trajectories. 
 
One of the most interesting observations in vesicles containing more than 1 mol% 
PEG2000 content is the existence of tubes/tethers or trajectories connecting several 
vesicles together like pearls of a necklace (Figure 5.3) [Antonietti 2003; Bagatolli 2000; 
Mathivet 1996]. It has been suggested by Antonietti et al. and other reports that many 
factors are usually involved in the formation of these structures including temperature 
fluctuation, inclusion of high polymer content as well as their interactions within the 
matrix [Antonietti 2003; Schara 2009; Stuklej 2013]. This might explain the reason that 
these tubes were not observed in the vesicles containing only 1 mol% of PEG2000 
content. Most of the vesicles in the trajectories had similar features and morphology as 
individual vesicles of the same mixture. This behavior has also been reported by 
Bagatolli et al., which points towards similar phospholipid packing between the tubes and 
vesicles [Bagatolli 2000]. Furthermore, these kinds of tubes or tethers are also considered 
as one of the main component of the cloud, which is observed in the sample after 
preparation using both gentle hydration and solvent evaporation method [Angelova 1992; 
Bagatolli 2000]. In the case of our study, the formation of tubes was not observed for 
GUVs prepared by solvent evaporation method. The main cause of these structures 
formation is still unknown. However, a model proposed by Mathivet et al. suggests that 
unilamellar structures form tubular shapes to make a network by connecting vesicles for 
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possible biological relevance including protein and solutes transportation as well as cell – 
cell communication system [Angelova 1992; Bobrovska 2013; Collier 2001;  Mathivet 
1996; Schara 2009; Stukelj 2013]. These types of structures containing PEG-
phospholipids can also have great implications in tissue engineering as well as in 
application for controlled release of drugs [Collier 2001; Shi 2010; Taguchi 2011; 
Takeuchi 2013]. Hence, it can be deduced that DPPC/DPPE-PEG2000 GUVs containing 
PEG2000 somewhere in the range of 3 – 6 mol% promotes the formation of tubes since 
these tubular structures were not observed in vesicles containing 1 and 9 mol% PEG2000 
content. Hence, these findings can expand new horizons for possible implications in the 
field of biomedical applications.    
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5.4. CONCLUSIONS. 
 
The morphology of DPPC/DPPE-PEG2000 and DSPC/DPPE-PEG2000 GUVs 
was visualized by EFM. A comparative analysis has revealed that the coexisting phases 
were present in GUVs bearing 1 – 6 mol% of PEG content. Increasing PEG2000 content 
increased phase separation and resulted in an overall increase in Ld phase in the vesicles. 
Furthermore, a reduction in the amount and size of GUVs was also observed with 
increase in PEG-phospholipid content. In particular, GUVs with 9 mol% PEG2000-
phospholipid were unable to form giant vesicles that might be associated to high 
concentration of PEG-phospholipid. Formation of vesicle tubes has also been observed in 
DPPC/DPPE-PEG2000 GUVs containing 3 and 6 mol% PEG2000. Most importantly, the 
membrane morphology of DPPC/DPPE-PEG2000 GUVs containing 1, 3 and 6 mol% 
PEG2000 has shown a great resemblance with the monolayers of the same binary 
mixtures at ~15 mN/m. These findings are remarkable in terms of using a simple 
membrane model such as a monolayer to study various aspects of membrane mimetic 
surface at a fundamental level, which might be challenging with other membrane models. 
In conclusion, it can be proposed that PEG content somewhere between 1 – 6 mol% 
might be useful in order to develop efficient drug delivery system with controlled bio-
non-fouling properties without comprising their structural stability.  
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Chapter 6: Examining the Non-Specific Interactions of Insulin 
with DPPC/DPPE-PEG2000 Model Membranes. 
 
 
This chapter will highlight some of the key aspects associated with the possible 
changes in the phase behavior of DPPC/DPPE-PEG2000 membrane model upon 
interactions with insulin. The changes in the insulin conformation, in particular, prior and 
after interacting with the DPPC/DPPE-PEG2000 model membrane have also been 
examined comprehensively. Giant (GUVs) and small unilamellar vesicles (SUVs) have 
been used as typical membrane models for the insulin-membrane interactions study. The 
preparation protocol for SUVs will only be discussed herein since preparation procedures 
for GUVs have already been discussed in detail in Chapter 5. Two-channel 
epifluorescence microscopy (EFM) has been utilized to examine the changes in the phase 
behavior of GUVs upon insulin binding. Furthermore, circular dichroism spectroscopy 
(CD) has been employed to attain complementary information about insulin conformation 
and its secondary structure upon binding onto the DPPC/DPPE-PEG2000 SUVs. 
Importantly, the conformational changes of insulin upon interactions with the SUVs have 
been analyzed in terms of α-helical content. The effect of varying PEG content in SUVs 
on the insulin conformation will also be analyzed in detail. CD data analysis has been 
summarized in terms of CD phase diagram to determine different states of insulin species 
present upon interactions with SUVs with varying PEG content. 
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6.1. Molecular Dimension and Conformational Behavior of Insulin Molecule. 
 
 Insulin is a small protein with 51 amino acids with considerable α–helical 
structure and bears an overall negative charge, –2 per monomer, in the presence of PBS 
subphase with a pH of about 7.4 [Farias 1989; Henry 2008]. Insulin primarily exists as 
three structural states in blood stream known as a monomer, dimer (possess 2 
monomers), and hexamers (possess 6 insulin molecules) [Henry 2008; Liu 2002]. The 
hydrodynamic diameter of zinc-free human insulin monomer has been approximated to 
be 3 nm and exhibits a wedge shape with molecular dimensions of 2 x 2.5 x 2 nm
3
 [Liu 
2002; Henry 2008]. An insulin monomer is considered to be the biologically active form 
[Liu 2002; Perez-Lopez 2011] Insulin dimer exhibits an oblong shape with molecular 
dimensions of 2 x 2.5 x 4 nm
3
 [Henry 2008]. Insulin hexamer, on the other hand, has 
molecular dimensions of 4.9 x 3.4 nm
2
 and considered to be the inactive form of insulin 
[Henry 2008; Perez-Lopez 2011]. The existence of insulin structural state is primarily 
dependent on the concentration of the solution. The concentration range for the 
monomeric state of insulin lies between 0.1 – 1 μM [Pocker 1980] and hence a 
concentration of 0.7 μM  of insulin has been used in our study. 
 
 Studies have shown that Insulin changes its conformational behavior as well as 
fibrillation and aggregation states at different experimental conditions, in particular in the 
presence of hydrophobic environment [Grudzielanek 2007; Liu 2002; Perez-Lopez 2011; 
Sefton 1984]. Electrostatic and hydrophobic interactions are considered to be the primary 
interactions for the non-specific insulin/membrane interactions. Additionally, phase 
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behavior of phospholipid membranes can also affect the conformational behavior, 
aggregation and fibrillation state of insulin upon interactions [Birdi 1976; Nosrati 2009; 
Perez-Lopez 2011]. Few studies have also documented a partial unfolding of several 
proteins upon non specific interactions with the membranes. These proteins include 
insulin, cytochrome c, phospholipase A2, and pheromone-binding protein [Gobrenko 
2006; Grudzielanek 2007; Wojtasek 1999]. Hence, the affect of non-specific interactions 
of insulin with PEGylated phosphocholine membrane on the insulin folding/unfolding as 
well as conformational changes, in terms of α-helcial content, is essential. In this study, 
CD spectroscopy has been utilized to analyze the changes in the conformational behavior 
of insulin upon non-specific interactions with PEGylated phosphocholine vesicle 
membrane models. 
 
 
6.2. RESULTS. 
 
6.2.1. In-Situ Imaging of Insulin/GUV Interactions. 
 
 The first part of this chapter will focus on the effect of insulin interactions on the 
phase behavior of the DPPC/DPPE-PEG2000 GUV membrane containing 1 mol% PEG 
content. A procedure to label insulin with the FITC fluorophore to study the 
insulin/membrane interactions will be described. Furthermore, the insulin binding on the 
GUV as a membrane model has been visualized using two channel EFM and discussed in 
detail. 
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6.2.1.1. Methodology for In-Situ Insulin/GUV Imaging. 
 
The effect of insulin binding on the morphology of DPPC/DPPE-PEG2000 GUVs 
was performed by two-channel EFM (TRITC and FITC channels). DPPC/DPPE-
PEG2000 GUVs were prepared using the protocol described in Chapter 5. In this study, 
DOPE-Rh was used to image the GUV morphology whereas FITC-insulin was used to 
monitor the insulin binding on to the GUV membrane upon interactions. For this purpose, 
FITC labeled insulin was injected in the GUV imaging chamber slightly away from the 
vesicle of interest. The imaging was done by switching between TRITC and FITC 
channel. In the TRITC channel, the contrast was derived from differences in partitioning 
of DOPE-Rh into ordered (liquid condensed) and disordered (liquid expanded) 
phospholipid phases [Tsoukanova 2008; Tanwir 2012]. The areas appeared red in the 
TRITC channel due to the fluorescence from the DOPE-Rh fluorophore. Conversely, in 
the FITC channel, areas were stained green due the fluorescence of FITC fluorophore of 
FITC-insulin. The green stain thus corresponds to the binding of insulin on to the vesicle. 
Both channels were equipped with Nikon CFI infinity optics combining a medium width 
excitation filter attaching to a bandpass barrier filter. This filter has the ability to detect 
the detection of fluorescence from one of the fluorophores and cutting off that from the 
other fluorophore. To visualize the DOPE-Rh molecule, a green excitation filter set (the 
Nikon TRITC HYQ filter combination, 545CWL excitation filter, 570LP dichroic mirror 
and 620CWL barrier filter) was used. On the other hand, to observe the fluorescence 
from the fluorescein fluorophore of FITC-insulin, a blue excitation filter set (the Nikon 
B-1E filter combination, 480CWL excitation filter, 505LP dichroic mirror, and 540CWL 
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barrier filter) was used. The images were captured by a Hamamatsu CCD camera, ORCA 
ER(AG) (Hamamatsu, Japan) directly onto a computer screen using Simple PCI 6 
software (Compix Inc., PA). Image analysis in terms of the percentage of dark domains, 
% dark domains, was performed with the Quantify package of Simple PCI 6. In the 
Quantify package, the value of % dark domains is found by relating the area occupied by 
domains to the area of the image. 
 
6.2.1.2. Protocol to Label Insulin with FITC Fluorophore. 
 
 To better comprehend the insulin interactions with the vesicle membrane, insulin 
was labeled with the FITC fluorophore by covalent binding of fluorophore to the amino 
group of protein using Molecular Probes protocol with slight modifications [Haugland 
2005]. About 6 mg/mL of insulin was treated with FITC (molar ratio dye : insulin as 3:1) 
at room temperature with stirring in the dark for about an hour in 20 μL of 1M NaHCO3 
buffer (adjusted to pH 9). FITC of concentration ~10 mg/mL was prepared by dissolving 
FITC dye in 24 μL of DMSO and immediately added to the insulin solution. The insulin-
FITC solution was then purified using dialysis against PBS for ~ 48 hours, at 4 
o
C, to 
remove the free FITC molecules. The fluorescence intensity of the labeled insulin was 
measured using UV-Visible spectrophotometer (Nano Drop ND1000, Thermo). The 
absorbance of labeled insulin was measured at 280 nm whereas absorbance of FITC was 
measured at 494 nm to determine the molar ratio of FITC to insulin. The molar ratio of 
FITC to insulin was estimated to be 1.46:1. The solution was always covered with 
aluminum foil for light-sensitive components and stored at 4 
o
C. 
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6.2.1.3. In-Situ EFM Imaging of Insulin Interactions with DPPC/DPPE-PEG2000 
GUVs. 
 
 
 
 The imaging of insulin interactions with DPPC/DPPE-PEG2000 GUVs were 
performed using visible light microscopy as well as by switching between FITC and 
TRITC channels in EFM. Visible light microscopy was used to examine the size, shape 
and lamellarity of vesicles. FITC channel allowed monitoring the insulin binding on the 
vesicle membrane whereas TRITC channel provided information about the changes 
occurred in the membrane morphology due to insulin binding. Figure 6.1 exhibits the 
images of DPPC/DPPE-PEG2000 GUV containing 1 mol% PEG captured before and 
after insulin injection. Before insulin interactions, the vesicle seen in the visible light 
image appeared unilamellar with the diameter of ~83 μm (Figure 6.1D). The vesicle also 
comprised of 73% of the Lo phase, as can be seen from the TRITC image (Figure 6.1A). 
Interestingly, insulin injection caused a fast movement and rearrangement of the Lβ’ 
phase domains during the first 5 min of interaction time. Vesicle size also increased from 
83 to 90 μm in diameter after insulin injection, as can be seen from visible light image 
(cf. Figure 6.1D and E). Moreover, the Lβ’ phase of the vesicle increased from 73% to 
90% after the insulin penetration as observed by TRITC channel (Figure 6.1B). Identical 
patterns in FITC and TRITC images clearly indicate that insulin binds to the 
expanded/disordered phase of the vesicle (cf. Figure 6.1B & C). After ~1 h interaction 
time, monitoring the insulin/vesicle interactions became almost impossible due to image 
blurriness and contrast over time.  
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Figure 6.1.: Insulin interaction with the DPPC/DPPE-PEG2000 vesicle containing 1 
mol% PEG content by EFM. [A] TRITC channel and [D] visible light show images of 
GUV before insulin injection. [B] TRITC channel, [C] FITC channel, [E] visible light 
depict images of vesicle after insulin injection.  
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6.2.2. Examining Insulin/Membrane Interactions by Circular Dichroism (CD) 
Spectroscopy. 
 
 
This section of the report will elaborate on the use of CD spectroscopy to study 
the effect of insulin/membrane interactions on the secondary structure of insulin. 
Procedure to prepare and image SUVs as well as methodology for CD measurements will 
be explained in detail. Most importantly, the effect of insulin/membrane interactions on 
the insulin secondary structure and its folded/unfolded conformations will also be 
determined using CD data analysis.  
 
 
  
6.2.2.1. CD Spectroscopy to Study Insulin/Membrane Interactions. 
 
 
 
Circular Dichroism (CD) spectroscopy is being extensively used to gain 
complimentary structural and conformational information of proteins in solution 
[Greenfield 1996; Greenfield 2006; Kelly 2005; Sreerama 2004; Sreerama 2004a; Woody 
1995]. CD refers to the differential absorption of left- and right-handed circularly 
polarized light by an optically active chiral molecule (protein) at a selective wavelength 
[Kelly 2005; Shahid 2013; Sreerama 2004]. The unequal absorption of left- and right-
handed light of a sample gives rise to a CD spectrum which provides specific structural 
information of the molecule. CD spectrum may exhibit positive and negative peaks 
depending on the structure of the molecule. The CD measurements of proteins are usually 
carried out in the visible and ultraviolet (UV) region based on the electronic excitations 
[Sreerama 2004; Woody 1995]. However, measurement in the infrared spectral region 
has also been progressively gaining interest to obtain information about the vibrational 
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excitations of the molecules [Autschbach 2011; Sreerama 2004; Woody 1995; Yang 
2011]. This type of CD is known as vibrational circular dichroism (VCD). This report 
will only cover the UV-vis region of the CD spectrum to gain the structural information 
about proteins. The CD spectrum of a protein, in the UV region, is generally divided in to 
three distinctive wavelength ranges [Shahid 2013; Sreerama 2004; Woody 1995]. This 
includes (i) the far UV, which ranges between 190 – 250 nm, where peptide contributes, 
(ii) the near UV, which lies between 250 – 300 nm, where contribution from aromatic 
side chains is observed, and (iii) the near UV-visible, which ranges from 300 – 700 nm, 
where contributions from extrinsic chromophores dominate [Kelly 2005; Shahid 2013; 
Sreerama 2004; Woody 1995; Greenfield 2006]. The absorption peak in the far UV 
region is primarily due to the weak but broad n  π * and π  π * transitions in the 
peptide bond, which occur around 220, 208 and 190 nm, respectively [Kelly 2005; 
Sreerama 2004]. Hence, different types of proteins secondary structures give rise to 
distinctive CD spectra in this range, which can be used to obtain the structural 
information of proteins. For instance, proteins containing β-sheets will exhibit a CD 
spectrum with a positive band around 198 nm and a negative band around 215 nm 
[Greenfield 1996; Greenfield 2006; Kelly 2005; Sreerama 2004]. The CD spectrum of 
proteins with α-helical content can be characterized by one positive band at 192 nm and 
two negative bands of 208 and 222 nm. The two CD signals at 208 and 222 nm can also 
be further used in estimating the α-helical content of the protein [Greefield 1969; Kelly 
2005; Seelig 2000]. In fact, CD spectroscopy has been used in several studies to monitor 
the changes in the protein secondary structure, by estimating the α-helical content, upon 
interactions with membranes and various other molecules [Mollmann 2006; Nosrati 
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2009; Pal 2011; Seelig 2000; Shahid 2011; Tah 2014]. Hence, the goal of this study is to 
assess the folding/unfolding states as well as conformational changes in the insulin’s 
secondary structure, in terms of α-helical content, upon interactions with small 
unilamellar vesicles as membrane models using far-UV CD spectroscopy. 
 
6.2.2.2. Preparation of Small Unilamellar Vesicles (SUV) for CD Measurements. 
 
 
CD experiments were performed with DPPC/DPPE-PEG2000 small unilamellar 
vesicles (SUVs) with varying PEG content from 1 – 6 mol%. A procedure to prepare 
SUVs was relatively similar to that described for GUVs in Chapter 5 with few variations. 
First, the phospholipid stock solutions of DPPC and DPPE-PEG2000 were prepared in 
chloroform/methanol (60:40 v/v) solvent at a concentration of 20 mg/mL and 2 mg/mL, 
respectively. The binary mixtures of DPPC and DPPE-PEG2000 containing 1, 3, 6, and 9 
mol% PEG were obtained by calculating and mixing appropriate molar ratios. Each 
appropriate mixture was then transferred to a 6 ml glass vial with the flat bottom surface. 
The organic solvent was evaporated on a hotplate at 60 – 70 ˚C for ~30 min and then left 
in a desiccator overnight. Next day, the dried film was hydrated with PBS solution, pH 
~7.4, to achieve a final concentration of 0.4 mM. The solution was stirred for 30 min at 
70 ˚C followed by sonication process for 30 min at 50 ˚C in a water bath-type sonicator 
to produce a dispersion of SUVs ≤ 10 μm in diameter. The size was confirmed by 
visualizing SUVs before and after sonication by EFM. The CD measurements were 
performed within 5 hours of the SUVs preparation. 
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6.2.2.3. Methodology for CD Measurements. 
 
Far-UV CD spectra of the SUVs and insulin at a concentration of ~0.7 μM in PBS 
were obtained by using a Jasco J-810 spectropolarimeter equipped with a temperature 
controlled sample holder. A rectangular cell with a path length of 1 cm was used for all 
the measurements. Each spectrum was recorded from 260 to 200 nm with a scan rate of 
10 nm/min and a bandwidth of 1 nm at 20 ˚C. The spectra were obtained every hour after 
the insulin injection into SUVs dispersions over 3 h interaction time. All spectra were 
collected by averaging the signal at every 0.5 nm for 2 s. Each plot shows the average of 
three spectra. The PBS baseline was also measured to be used to subtract from all the 
average CD scans. Moreover, the spectra of insulin interacting with SUVs were corrected 
by subtracting the spectra of vesicles alone in PBS. Every measurement was performed 
three times. 
 
6.2.2.4. Far-UV-CD Spectrum of Native Insulin. 
 
 Figure 6.2 exhibits the far-UV CD spectrum of native insulin in PBS at 20 °C. 
The CD spectrum is shown from 200 – 250 nm for the simplicity of the results as well as 
for comparative analysis discussed later in the chapter. Figure 6.2 displays the CD 
spectrum of insulin in the range of 200 – 250 nm exhibiting two negative bands at ~209 
and ~222 nm. This is considered as a typical characteristic of a native insulin monomer 
with α-helix conformation [Ahmad 2004; Ahmad 2005; Ettinger 1971; Shahid 2013; Tah 
2014]. The two minima in the CD spectrum stated above correspond to two different 
transitions in the peptide. The negative band at ~222 nm is attributed to the n  π* 
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transition due to the large magnetic dipole moment alongside the carbonyl bond whereas 
the π  π* transition adjacent to the peptide bond gives rise to a negative band in the CD 
spectrum at ~208 nm [Beychok 1964; Ettinger 1971; Kelly 2005; Shahid 2013; Sreerama 
2004]. Moreover, both negative bands around 208 and 222 nm in the CD spectrum have 
also been associated to the strong contributions originating from cysteine and tyrosine 
amino acid residues in the protein, respectively [Ettinger 1971; Shahid 2013; Nosrati 
2009; Beychok 1964]. Hence, any conformational change in the insulin secondary 
structure upon interactions with the membrane model (SUV) will be detected as the 
intensity change in the CD spectra between the wavelength range of 200 – 250 nm. 
Furthermore, changes in the CD spectra can also aid in determining the folded/unfolded 
state of insulin upon interactions with SUV membrane models. 
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Figure 6.2.: Far-UV CD spectrum of native insulin in PBS, pH~7.4 at 20 ˚C. The 
negative bands at ~209 nm and ~222 nm depict an α- helical configuration in the insulin 
monomer. 
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6.2.2.5. Conformational and Structural Changes of Insulin upon Interactions with 
DPPC/DPPE-PEG2000 SUV Membranes. 
 
 
Small unilamellar vesicles (SUVs) were prepared to examine the changes in the 
secondary structure of insulin upon interaction with DPPC/DPPE-PEG2000 membrane 
by circular dichroism spectroscopy (CD). The primary reason for selecting SUVs instead 
of GUVs was due to the increased light scattering, which could interfere with the insulin 
spectra and yield poor results. Figure 6.3 shows the images of well-dispersed 
DPPC/DPPE-PEG2000 SUVs membrane morphology in PBS with various PEG content 
from 1 to 6 mol%. The size of SUVs decreased with increasing PEG2000 content (Figure 
6.3 A – C). As can be seen in the figure, the size of the SUVs containing 1 mol% PEG 
lies in the range of 2 – 8 μm, which decreased to 1 – 2 μm in diameter with increasing 
PEG content to 6 mol%. This trend is in well agreement with the DPPC/DPPE-PEG2000 
membrane GUVs upon varying PEG content (cf. Figure 5.1, 5.2 with Figure 6.3). After 
performing the EFM imaging, all the remaining SUV solutions were further used to study 
the insulin/membrane interactions by CD spectroscopy as discussed below.  
 
The far-UV CD spectra of insulin upon interactions with DPPC/DPPE-EPG2000 
SUVs with varying PEG content were collected in PBS at 20 °C (Figure 6.4). The red 
dashed line in Figure 6.4 represents the native insulin CD spectrum as a reference while 
all the other ones represent the CD spectra of insulin upon interactions with SUVs 
containing 1 to 6 mol% PEG. Interactions of insulin with DPPC/DPPE-PEG2000 SUVs, 
in two hours of interaction time, caused significant changes in the CD spectra. All the 
features of insulin’s CD spectra remain the same with respect to the native insulin 
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spectrum. However, the mean residue ellipticity, [θ], at both negative bands (209 and 222 
nm), changed with increasing PEG2000 content from 1 – 6 mol% PEG2000 in the SUVs. 
The intensity of the insulin CD spectrum showed a great effect at 209 nm where it 
decreased significantly in the presence of vesicles containing 6 mol% PEG-phospholipid. 
This effect is not much seen at 222 nm since all the bands are close to that of the native 
insulin. The CD spectrum of insulin in the presence of all kind of vesicles shows a 
considerable secondary structure (Figure 6.4). This emphasizes that the protein has not 
unfolded but endured a slight change in the conformation during the interactions. This 
correlates well with several reported data where insulin changes its conformation but 
does not unfold [Ahmad 2004; Ahmad 2005; Tah 2014]. This might points towards the 
insulin molecule to conform to a more compact conformation in order to interact with the 
SUVs with increasing PEG content. Hence, further analysis of insulin CD spectra in 
terms of α-helical content can be really helpful in understanding the changes in insulin 
secondary structure in the presence of DPPC/DPPE-PEG2000 SUVs with varying PEG 
content [Kelly 2005; Seelig 2000; Tah 2014]. 
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Figure 6.3.: EFM images of DPPC/DPPE-PEG2000 small unilamellar vesicles (SUV) 
bearing (A) 1, (B) 3, and (C) 6 mol% of PEG content. These images were captured before 
CD measurements were performed in order to verify the dispersion of SUVs in PBS. T = 
23 ºC. 
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Figure 6.4.: Far-UV CD spectra beginning from (A) the native insulin to insulin 
interacting with DPPC/DPPE-PEG2000 vesicles  containing (B) 1 mol%, (C) 3 mol%, 
and (D) 6 mol% PEG content, in PBS. Negative bands at 222 nm and 209 nm show 
typical feature of α-helical structure. T = 20 ˚C. 
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6.3. DISCUSSION. 
 
Phospholipid membrane models have become efficient tools to investigate various 
aspects of cellular membranes [Bagatolli 2006; Bagatolli 2000; Korlach 1999; Sun 2005; 
Sezgin 2012; Veatch 2003; Walde 2001]. Unilamellar vesicles and liposomes have also 
been widely used as platforms to study the protein/membrane interactions for various 
biological processes including cell division, cell-cell communication, transportation, as 
well as protein Lo/Ld preferential studies in membrane [Bagatolli 2006; Gobrenko 2006; 
Jalmar 2010; Kalvodova 2005; Kim 1998; Krishnan 2009; Mathivet 1996; Netz 1996; 
Sezgin 2012; Vermette 2003; Vogel 2013]. Several studies have also aimed to understand 
the encapsulation efficiency of PEGylated membrane models to deliver small proteins, 
peptides, DNA, and other biomolecules both in vitro and in vivo [Chan 2012; Kim 1999; 
Iwanga 1999; Swaminathan 2012]. However, the effect of protein binding, in particular 
small protein, on the morphology and phase behavior of PEGylated membrane models 
still needs to be explored extensively [Kozarac 1987; Rahmati 2008; Nosrati 2009; 
Shahid 2013]. Therefore, Chapter 4 of this dissertation was entirely devoted to 
comprehend the changes induced by insulin binding on the PEG-grafted phosphocholine 
monolayers. Importantly, this chapter has encompassed the effect of insulin binding on 
the size, morphology, and phase state of DPPC/DPPE-PEG2000 GUVs using visible light 
and two channel EFM. Moreover, this chapter has also aimed at elucidating the effect of 
protein/membrane interactions on the conformational behavior of small protein e.g. 
insulin, which still requires great attention [Ahmad 2004; Gobrenko 2006; Grudzielanek 
2007].  
   
193 
 
6.3.1. Imaging the Non-Specific Interactions of Insulin with Model Membrane. 
 
The effect of non-specific insulin interactions on the size of the DPPC-DPPE-
PEG2000 GUVs containing 1 mol% PEG was investigated using EFM. Interestingly, the 
vesicles appeared considerably larger in diameter upon insulin binding, as seen in the 
visible image in Figure 6.1 D and E. Based on the reported data, expansion of vesicles 
can certainly be attributed to the insulin insertion in to the hydrophobic moiety of 
phosphocholine membrane, which eventually made the vesicles appear larger in diameter 
[Hanakem 1996; Li 2013; Shahid 2013; Wiessner 1982]. In fact, several studies on 
protein/membrane interactions have reported on the area expansion of PEGylated and 
non-PEGylated membrane models upon binding of protein [Hanakem 1996; Nosrati 
2010; Shahid 2013; Seelig 2000]. This appears to be in good correlation with our 
insulin/monolayer studies as well where insulin binding induced the area expansion of 
both DPPC/DPPE-PEG2000 and DSPC/DSPE-PEG2000 monolayers [Chapter 4]. For 
instance, the mean molecular area of DPPC/DPPE-PEG2000 monolayer containing 1 
mol% PEG increased up to ~4.5 nm
2
 upon interactions with insulin at π ~ 15 mN/m (a π 
value that is considered to lie in the range relevant to typical membrane pressure 
[Konttila 1988]). Hence, this indicates that membrane area expansion is indeed the result 
of insulin insertion in to the membrane.  
 
The effect of insulin binding on the phase behavior of GUVs containing varying 
PEG content of 1, 3 and 6 mol% was also visualized using two channel EFM. However, 
direct imaging of changes in GUVs phase coexistence with higher PEG content was very 
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challenging due to the existence of high Ld phase even prior to insulin injection (images 
not shown). Hence, for the clarity of presentation, this discussion will only be limited to 
the DPPC/DPPE-PEG2000 GUVs containing 1 mol% PEG. The binding of insulin 
seemed to partition in to the Ld phase of the DPPC/DPPE-PEG2000 GUV membrane 
containing 1 mol% PEG content, which can be verified by identical patterns in the 
TRTIC and FITC images of GUV in Figure 6.1 B and C. Furthermore, an increased Lβ’ 
phase from 73% to 90% upon insulin binding to the Ld phase of the membrane has also 
found to be a very distinct observation (Figure 6.1 A and B). This suggests that insulin 
preferably partitions into the Ld phase of the membrane while forcing phospholipids to 
stay in a more closely packed configuration. The orderliness of the vesicles can also be 
somewhat associated to the steric repulsion and redistribution of the PEG chains upon the 
compression exerted by insulin [Halperin 2007; Vermette 2003]. This might result in an 
increased Lβ’ phase in the membrane, as can be seen in Figure 6.1B. Similar types of 
results have also been reported by several studies [Farias 1986; Sanchez 2002; Theumer 
2012]. Farias et al. has indicated that insulin decreases the fluidity (Lo phase) of a 
phospholipid vesicle membrane [Farias 1986]. A study performed by Theumer et al. 
reported that the LC (Lβ’) phase of the DPPC monolayer increased when the FB1 
molecule, a mycotoxin, partitioned in to the LE (Ld) phase of the membrane [Theumer 
2012]. The effect of PLA2s protein binding in to the LE phase on the packing behavior of 
GUV’s LC (Lβ’) phase has also been demonstrated in detail by Sanchez et al. [Sanchez 
2002]. In contrast, several studies have also associated the (i) protein insertion, (ii) 
competitive interactions of PEG-grafted phospholipid and protein molecules as well as 
(iii) entrapment of insulin in the polymer chains with the disruption of phospholipid 
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packing in the membrane [Allen 2002; Shahid 2013; Wang 2002]. Nevertheless, an 
increased Lβ’ phase in the vesicle due to insulin insertion is indeed an unique 
phenomenon seen in this study. These findings, hence, can have significant implications 
to understand the mechanisms governing the morphological changes of membrane 
mimetic surfaces in the presence of different types of dissolved biomolecules. 
 
6.3.2. Changes in Insulin α-Helical Content upon Interactions with DPPC/DPPE-
PEG2000 SUVs. 
 
The percentage of α-helix can be calculated using various methods which can 
provide valuable information about the structural changes of protein upon exposure to 
different experimental conditions [Greenfield 1969; Kelly 2005; Mollmann 2006; Seelig 
2000; Tah 2014]. In this report, we have used the equation described by Seelig et al. to 
calculate the α-helical content in insulin as follows [Seelig 2000], 
 
   100
][ 222 
n
h
hf


     6.1 
 
where [θ] depicts the molar mean residue ellipticity at 222 nm, in deg cm2 dmol-1, which 
can be calculated by the equation specified by Sreerama et al. as shown below [Sreerama 
2004], 
     
Cl
 100][       6.2 
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Where θ is the residue ellipticity (mdeg) obtained from the CD spectrum at a given 
wavelength, C represents the molar concentration, and l represents the pathlength in (cm) 
of the sample [Sreerama 2004]. Molar ellipticity can either be defined as deg.M
-1
.m
-1
 or 
as deg.cm
2
.dmole
-1 
since these units are equivalent. nh  in equation 6.1 is expressed as the 
maximum absorption of an α-helix in the protein with number of (n) amino acid residues 
and can be calculated as described by Seelig et al. shown below, 
 
     h
n
h nk  )/1(     6.3 
 
In equation 6.3, k represents the wavelength-dependent constant, which is found to be  
2.57 at a wavelength of 222 nm [Seelig 2000]. h is considered to be the maximum 
ellipticity of an α-helix in the molecule with infinite length of -39,000 deg cm2 dmol-1 
whereas n represents the number of amino acid residues constitutes the α-helical portion 
of the protein [Seelig 2000]. There are three α-helices in the insulin secondary structure 
from (i) A2 – A8 residues, (ii) A13 – A20 residues, and (iii) B9 – B19 residues [Periard 
1984; Yan 2003]. The number of amino acid making up the entire α-helical portion of the 
insulin molecule is 23. Table 6.1 summarizes the percentage of α-helix of insulin after 2 h 
of interactions with the DPPC/DPPE-PEG2000 SUVs. The percentage of α-helical 
content in insulin monomer is about 25.4% in PBS. This value is in well correlation with 
the previous literature values [Ettinger 1971; Rawitch 1980; Sadhale 1999]. Increasing 
the PEG content from 1 to 6 mol% in the SUVs increases the α-helical content from 
26.2% to 29.2% in insulin, respectively. The change in the insulin helical content is not 
very significant but it indicates that the insulin is slightly changing its conformation for 
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non-specific interactions with the PEGylated phosphocholine. These findings further 
imply that insulin does not unfold upon interactions with the PEG-grafted vesicle 
membrane [Ahmad 2004; Ahmad 2005; Tah 2014].  
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Table 6.1. 
 
Changes in the α-helical structure content of insulin due to PEG increment in 
DPPC/DPPE-PEG2000 SUVs 
 
        Mixtures                         Helix insulin (%) 
 
      Native Insulin         25 ± 1 
      Insulin/SUV with 1 mol% PEG       26 ± 1 
      Insulin/SUV with 3 mol% PEG       27 ± 2       
      Insulin/SUV with 6 mol% PEG       29 ± 1 
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6.3.3. CD Phase Diagram. 
 
CD data analysis has been used as a conventional method to obtain 
complementary information about the folded/unfolded conformation of proteins. In fact, 
CD phase diagrams derived from the CD data can also be very useful in resolving 
complex structural transition of proteins [Ahmad 2004; Ahmad 2005; Kuznetsova 2002]. 
To determine different types of conformational species of insulin present in the solution, 
the CD phase diagram of the insulin was obtained by plotting the mean residue ellipticity 
at 222 nm as a function of mean residue ellipticity at 209 nm, calculated using equation 
7.2, and is shown in Figure 6.5 [Ahmad 2004; Ahmad 2005; Kuznetsova 2002; Sreerama 
2004]. The linearity of the plot will reflect the all-or-none transition in the insulin 
whereas non-linearity of the diagram will point towards the structural transformations of 
the insulin molecule. As can be seen from the CD Phase diagram in Figure 6.5, there is 
only one linear segment for insulin in the presence of vesicles with increasing PEG 
content, which implies the existence of two species of insulin with a little change in the 
secondary structure. These monomeric conformations are known as the native monomer 
(M) and a compact monomer with increased α-helical structure (MC) [Ahmad 2004]. 
Thus, it is observed that the α-helical content of insulin increases as the PEG 
concentration increases in the DPPC/DPPE-PEG2000 vesicles, which may suggest that 
insulin molecule slightly conforms into a compact state in order to get through the PEG 
chains and penetrate the membrane. It can further be speculated that the primary domain 
penetrating the membrane can be insulin’s α-helical structure since insulin sequence 
contains ~17 hydrophobic amino acid residues out of which 10 are found in the α-helix 
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portion of insulin, as estimated using Yan et al. and Stretton et al. studies [Stretton 2002; 
Yan 2003]. Hence, it can be concluded that insulin changes its conformation, to some 
extent, upon interactions with the DPPC/DPPE-PEG2000 membrane vesicles with 
increasing PEG content but does not unfold. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
201 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  Native 
         1 mol% 
               3 mol% 
 
 
 
    
   6 mol% 
    
 
 
Figure 6.5.: CD phase diagram obtained by plotting 222 nm mean residue ellipticity, [θ], 
as a function of 209 nm mean residue ellipticity, [θ], for far-UV CD to show changes in 
insulin conformation state due to interactions with DPPC/DPPE-PEG2000 vesicles with 
various PEG content from 1, 3, and 6 mol% PEG. The values beside each point in the 
plot correspond to the PEG concentration incorporated in the vesicles for 
insulin/membrane interactions. 
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6.4.CONCLUSIONS. 
 
 Examining the insulin/membrane interactions has revealed a quite intricate effect 
on the phase behavior of DPPC/DPPE-PEG2000 GUVs. In-situ analysis of insulin 
interactions with DPPC/DPPE-PEG2000 membrane containing 1 mol% PEG vesicle has 
shown that membrane expanded as well as became more ordered. The expansion and 
orderliness of the vesicles is considered to be due to the steric repulsion and redistribution 
of the PEG chains upon the compression exerted by insulin. Furthermore, the effect of 
insulin/membrane interactions with varying PEG content shows a modest change in the 
insulin conformation. Circular dichroism data analysis illustrated that the α–helical 
content of insulin increased upon increasing the PEG content in the DPPC/DPPE-
PEG2000 vesicles. This implies that insulin turns into slightly more compact 
conformation in order to avoid PEG chains and binds the phospholipid membranes. 
However, the change in the helical content is minimal which further reveals that insulin 
does not unfold or denature upon interactions with DPPC/DPPE-PEG2000 SUVs.  
Hence, these findings may aid gaining more insight to further comprehend the 
mechanisms involved in membrane interactions with small biomolecules. 
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Chapter 7: Conclusions. 
 
PEGylated phosphocholine membrane models were examined in terms of phase behavior, 
morphology, composition, aliphatic chain length, as well as PEG content in aqueous medium of 
physiological relevance (PBS) at 20 
o
C. Two types of membrane models including monolayer 
and unilamellar vesicles were used to accomplish the aim of this study.  
 
7.1. KEY FINDINGS.  
 
In the first study, monolayers were used to assess the phase behavior of binary mixtures, 
DPPC/DPPE-PEG2000 and DSPC/DSPE-PEG20000, in terms of phase state, miscibility, 
compressibility, as well as PEG lateral distribution. Two-channel EFM imaging was used to 
monitor the phase state and PEG distribution in the monolayers simultaneously. This has enabled 
us to gain detailed information about the effect of varying PEG content and its distribution on the 
phase behavior of monolayers. These findings were summarized in phase diagrams to 
demonstrate distinct phase states on PBS. A comprehensive analysis of phosphocholine and 
PEG-phospholipids binary mixtures has given a new insight on the mixing behavior of 
PEGylated phosphocholine membranes on PBS in a range of 1 – 9 mol% PEG. Depending on the 
composition, both homogeneous mixing and completely immiscible phases have been observed 
in the mixtures. For instance, remarkable changes in the phase behavior of DSPC/DSPE-
PEG2000 mixtures have been observed upon increasing PEG content from 1 – 9 mol%. 
DSPC/DSPE-PEG2000 mixture containing 1 mol% PEG predominantly forms immiscible LC 
phase which turns to the coexistence of mixed LE and LC phases in mixture containing 9 mol%. 
In fact, there is a unique mixture composition seen at 3 mol% PEG, which features a single 
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homogenously mixed phase in the LC state. This unique mixture exists in a very small range of 
PEG content and hence was not identified in previous studies. These findings thus imply that the 
phase behavior of PEGylated phosphocholine membranes may significantly change in response 
to slight changes in composition which can be used for rational design of PEGylated membranes 
in the stealth technology to maintain a balance between the retention and release of therapeutic 
as well as diagnostic agents. These results have been successfully published in the Langmuir 
Journal in 2008 and 2012 [Tanwir 2008; Tanwir 2012]. The key findings from the study above 
have been successfully presented in the CSC conference in 2011. Some of the results from this 
investigation have also been exhibited at the Canadian Society for Chemistry (CSC) and Surface 
Canada conferences in 2009. 
 
In the second study, a comprehensive analysis of insulin interactions with PEGylated 
phosphocholine monolayers has indeed demonstrated an intricate phenomenon through area 
expansion measurement studies. Insulin penetration area, Ains, decreases with an increase of PEG 
content in both DPPC/DPPE-PEG2000 and DSPC/DSPE-PEG2000 mixtures. However, the 
degree of insulin binding, χins, increases upon increasing the PEG content in both types of binary 
mixtures. Interestingly, surface (lateral) pressure significantly reduced the degree of insulin 
binding, χins, as compared to the PEG content in both type of binary mixtures. Among both 
mixtures, DSPC/DSPE-PEG2000 mixtures had an overall reduced binding degree of insulin 
upon increasing PEG content from that of DPPC/DPPE-PEG2000 mixtures. Further analysis of 
mixtures revealed that the fluidity of monolayers (LE phase) increases with increasing PEG 
content, which may consequently increase the χins in the PEGylated phosphocholine membrane 
models. Hence, the knowledge gained herein can provide fundamental knowledge about the 
209 
 
mechanisms involved in the non-specific interactions of small proteins with the PEGylated 
phosphocholine membrane in order to improve the performance of various biomedical devices as 
well as therapeutic/diagnostic agents carriers with reduced protein adsorption. These findings 
have also been successfully presented in the CSC conference in 2010.  
 
The third study entailed visualizing the morphology of PEGylated phosphocholine GUVs 
using EFM. A comparative analysis has revealed that coexisting phases were present in GUVs 
bearing 1 – 6 mol% of PEG content. Increasing the PEG2000 content resulted in an overall 
increase in Ld phase in the vesicles. Furthermore, a reduction in the amount and size of GUVs 
was also observed with an increase in PEG-phospholipid content. In particular, GUVs with 9 
mol% PEG2000-phospholipid were unable to form giant vesicles that might be associated to 
high concentration of PEG-phospholipid. Formation of vesicle tubes has also been observed in 
DPPC/DPPE-PEG2000 GUVs containing 3 and 6 mol% PEG2000, which can have great 
implications for applications with controlled release. Most importantly, the membrane 
morphology of DPPC/DPPE-PEG2000 GUVs containing 1, 3 and 6 mol% PEG2000 has shown 
a great resemblance with the monolayer membrane models of the same binary mixtures at a 
surface (lateral) pressure of ~15 mN/m. This indeed is one of the key findings in this work 
illustrating a direct comparison between vesicle membrane and a monolayer as membrane 
models. Hence, it can be proposed that PEG content somewhere between 1 – 6 mol% can be 
useful in order to develop efficient drug delivery system with controlled bio-non-fouling 
properties. Results from this investigation have been successfully presented at the CSC and 
Pacifichem conferences in 2010.  
 
210 
 
 In this study, the insulin/membrane interactions were carried out using vesicle as a 
membrane model. This study revealed quite an intricate effect on the phase behavior of 
DPPC/DPPE-PEG2000 GUVs. In-situ analysis of insulin interactions with DPPC/DPPE-
PEG2000 membrane containing 1 mol% PEG vesicle has shown that membrane expanded as 
well as became more ordered. The expansion and orderliness of the vesicles is considered to be 
due to the steric repulsion and redistribution of the PEG chains upon the compression exerted by 
insulin. Furthermore, the effect of insulin/membrane interactions with varying PEG content 
showed a modest change in the insulin conformation. Findings from this study have been 
successfully presented at the CSC conference in 2010. 
 
 In the final investigation, the structural changes of insulin, in terms of α–helical content, 
were determined upon interactions with DPPC/DPPE-PEG2000 vesicles using circular dichroism 
spectroscopy. The data analysis illustrated that the α–helical content of insulin increased upon 
increasing the PEG content in the DPPC/DPPE-PEG2000 vesicles. This implies that insulin turns 
into slightly more compact conformation in order to avoid PEG chains and binds the 
phospholipid membranes. This further reveals that insulin does not unfold or denature upon 
interactions with DPPC/DPPE-PEG2000 SUVs as the CD spectra of insulin did not change upon 
interactions of PEGylated phosphocholine vesicles. This study further demonstrated the 
existence of two species of insulin molecule with a little change in the secondary structure 
known as a native monomer (M) and a compact monomer with increased α-helical structure 
(MC). Results of this study have been successfully exhibited at the CSC conference in 2010. 
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